var title_f20_16_20736="Echocardiogram of inlet VSD";
var content_f20_16_20736=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F79923&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F79923&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 498px\">",
"   <div class=\"ttl\">",
"    Echocardiogram of inlet VSD",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 478px; height: 322px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Apical four-chamber view demonstrating a large inlet VSD underneath the mitral and tricuspid valves.",
"    <div class=\"footnotes\">",
"     RA: right atrium; LA: left atrium; RV: right ventricle; LV: left ventricle.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Naser Ammash.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_16_20736=[""].join("\n");
var outline_f20_16_20736=null;
var title_f20_16_20737="Breastfeed preterm infant";
var content_f20_16_20737=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F61447&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F61447&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Breastfeeding the preterm infant",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 363px; height: 396px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Wolters Kluwer. Copyright &copy;2009.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_16_20737=[""].join("\n");
var outline_f20_16_20737=null;
var title_f20_16_20738="Fusarium hyphae";
var content_f20_16_20738=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F69801&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F69801&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Fusarium hyphae",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 445px; height: 337px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The septate hyaline hyphae of Fusarium spp are 3 to 8 microns in diameter and typically branch at acute angles.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_16_20738=[""].join("\n");
var outline_f20_16_20738=null;
var title_f20_16_20739="Difluprednate: Drug information";
var content_f20_16_20739=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Difluprednate: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?9/60/10180?source=see_link\">",
"    see \"Difluprednate: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F6741203\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Durezol&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F6741206\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Corticosteroid, Ophthalmic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F6741235\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Endogenous anterior uveitis:",
"     </b>",
"     Ophthalmic: Instill 1 drop into conjunctival sac of the affected eye(s) 4 times/day for 14 days then taper as clinically indicated",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Inflammation associated with ocular surgery:",
"     </b>",
"     Ophthalmic: Instill 1 drop in conjunctival sac of the affected eye(s) 4 times/day beginning 24 hours after surgery, continue for 2 weeks, then decrease to 2 times/day for 1 week, then taper based on response",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F6741236\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F6741238\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Emulsion, ophthalmic [drops]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Durezol&reg;: 0.05% (5 mL) [contains sorbic acid]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F6741204\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F14614211\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Wash hands prior to use and avoid touching tip of dropper. Remove contact lenses prior to use. Do not reinsert contact lenses within 10 minutes of difluprednate eye drops. The use of the same bottle for both eyes is not recommended in surgical patients.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F6741208\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of inflammation and pain following ocular surgery; treatment of endogenous anterior uveitis",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F9606264\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Durezol&reg; may be confused with Durasal&trade;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F6741216\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Adverse reactions following ocular surgery:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     5% to 15%: Ocular: Anterior chamber cells/flare, blepharitis, ciliary and conjunctival hyperemia, conjunctival/corneal edema, pain, photophobia, posterior capsule opacification",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 5%: Ocular: Inflammation, iritis, punctuate keratitis, visual acuity reduced",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Application site discomfort/irritation, cataracts, corneal pigmentation and striae, episcleritis, eyelid crusting/irritation, foreign body sensation, intraocular pressure increased, lacrimation increased, macular edema, ocular pruritus, optic nerve damage, perforation of globe, sclera hyperemia, secondary ocular infection, uveitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Adverse reactions associated with treatment of endogenous anterior uveitis:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     5% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Ocular: Blurred vision, hyperemia (conjunctival and limbal), intraocular pressure increased, irritation, pain, punctate keratitis, uveitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     2% to 5%: Ocular: Anterior chamber flare, corneal edema, dry eye, iridocyclitis, photophobia, visual acuity decreased",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F6741211\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Active viral (including herpes simplex keratitis, vaccinia, varicella) infections of the cornea or conjunctiva, fungal infection of ocular structures, or mycobacterial ocular infections",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F6741212\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Infection: Steroids may mask infection or enhance existing ocular infection; prolonged use may result in secondary infections due to immunosuppression. Fungal infections should be considered with persistent corneal ulceration during therapy. Use caution in patients with a history of herpes simplex infection. If signs and symptoms of infection do not improve after 2 days, patient should be re-evaluated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Ocular effects: Prolonged use may result in glaucoma and injury to the optic nerve, as well as, visual defects in acuity and field of vision. Posterior subcapsular cataracts may form after long-term use. Use with caution in presence of glaucoma (steroids increase intraocular pressure). Perforation may occur with topical steroids in diseases which thin the cornea or sclera. Steroid use may delay healing after cataract surgery. Intraocular pressure should be monitored if this product is used &ge;10 days.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Contact lens wearers: Contains sorbic acid which may be absorbed by contact lenses; contact lenses should be removed prior to use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Appropriate use: For ophthalmic use only; not for intraocular administration. Initial prescription and renewal of medication for &gt;28 days should be made by healthcare provider only after examination with the aid of magnification such as slit lamp biomicroscopy or fluorescein staining (if appropriate).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299195\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6741223\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F6741209\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13375041\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Difluprednate was shown to be teratogenic in animal reproduction studies when administered subcutaneously. The amount of difluprednate absorbed systemically following ophthalmic administration is below the limit of quantification (&lt;50 ng/mL).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F6741210\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F6741237\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Intraocular pressure and periodic examination of lens (with prolonged use &gt;28 days)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6875352\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Epitopic (FR);",
"     </li>",
"     <li>",
"      Ribeca (KP)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F6741229\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Corticosteroids inhibit the inflammatory response including edema, capillary dilation, leukocyte migration, and scar formation. Difluprednate penetrates cells readily to induce the production of lipocortins. These proteins modulate the activity of prostaglandins and leukotrienes.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F6741231\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Systemic: Exposure to active metabolite is negligible with ocular administration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Undergoes deacetylation to an active metabolite (DFB)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Korenfeld MS, Silverstein SM, Cooke DL, et al, \"Difluprednate Ophthalmic Emulsion 0.05% for Postoperative Inflammation and Pain,\"",
"      <i>",
"       J Cataract Refract Surg",
"      </i>",
"      , 2009, 35(1):26-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/16/20739/abstract-text/19101421/pubmed\" id=\"19101421\" target=\"_blank\">",
"        19101421",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9018 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-210.101.131.232-9BEAA163C5-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_16_20739=[""].join("\n");
var outline_f20_16_20739=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6741203\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6741206\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6741235\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6741236\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6741238\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6741204\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14614211\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6741208\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9606264\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6741216\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6741211\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6741212\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299195\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6741223\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6741209\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13375041\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6741210\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6741237\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6875352\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6741229\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6741231\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9018\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9018|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_international\" href=\"UTD.htm?7/34/7713?source=related_link\">",
"      Difluprednate: International drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?9/60/10180?source=related_link\">",
"      Difluprednate: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_16_20740="Fallopian tube carcinoma";
var content_f20_16_20740=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F60557&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F60557&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Fallopian tube carcinoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 376px; height: 245px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Surgical specimen of a left fallopian tube carcinoma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Mitchel Hoffman MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_16_20740=[""].join("\n");
var outline_f20_16_20740=null;
var title_f20_16_20741="Pacemakers";
var content_f20_16_20741=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Pacemakers (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?20/16/20741/contributors\">",
"       Authors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/16/20741/contributors\" id=\"au5282\">",
"       Brian Olshansky, MD",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/16/20741/contributors\" id=\"au4515\">",
"       David L Hayes, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?20/16/20741/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/16/20741/contributors\" id=\"se4322\">",
"       Leonard I Ganz, MD, FHRS, FACC",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?20/16/20741/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/16/20741/contributors\" id=\"de7537\">",
"       Brian C Downey, MD, FACC",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?20/16/20741?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      INTRODUCTION",
"     </span>",
"    </p>",
"    <p>",
"     Pacemakers are electronic devices that stimulate the heart with electrical impulses to maintain or restore a normal heartbeat. This topic review will discuss pacemakers, when they may be necessary or appropriate, the types of pacemakers that are available, and the precautions patients need to take after having a pacemaker placed.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      THE HEART'S CONDUCTION SYSTEM AND \"NATURAL PACEMAKER\"",
"     </span>",
"    </p>",
"    <p>",
"     The heart has its own built-in electrical system, called the conduction system (",
"     <a class=\"graphic graphic_figure graphicRef71235 \" href=\"UTD.htm?4/20/4420\">",
"      figure 1",
"     </a>",
"     ). The conduction system sends electrical signals throughout the heart that determine the timing of the heartbeat and cause the heart to beat in a coordinated, rhythmic pattern. The conduction system stimulates precise contractions of the heart's chambers to ensure that blood is pumped effectively.",
"    </p>",
"    <p>",
"     The electrical signals, or impulses, of the heart are generated by specialized tissue called the sinoatrial (SA) or sinus node (",
"     <a class=\"graphic graphic_figure graphicRef71235 \" href=\"UTD.htm?4/20/4420\">",
"      figure 1",
"     </a>",
"     ). The sinus node is sometimes called the heart's \"natural pacemaker.\" Each time the sinus node generates a new electrical impulse; that impulse spreads out through the heart's upper chambers, called the right atrium and the left atrium (",
"     <a class=\"graphic graphic_figure graphicRef77576 \" href=\"UTD.htm?11/14/11495\">",
"      figure 2",
"     </a>",
"     ). This electrical impulse stimulates the atria to contract, pumping blood into the lower chambers of the heart (the right and left ventricles).",
"    </p>",
"    <p>",
"     The electrical impulse then spreads to another area of specialized tissue located between the atria and the ventricles, the atrioventricular (AV) node. The AV node momentarily slows down the spread of the electrical impulse, to allow the left and right atria to finish contracting.",
"    </p>",
"    <p>",
"     From the AV node, the impulse spreads into a system of specialized fibers called the bundle of His and the right and left bundle branches (",
"     <a class=\"graphic graphic_figure graphicRef71235 \" href=\"UTD.htm?4/20/4420\">",
"      figure 1",
"     </a>",
"     ). These fibers distribute the electrical impulse rapidly to all areas of the right and left ventricles, stimulating them to contract in a coordinated way. With this contraction, blood is pumped from the right ventricle to the lungs, and from the left ventricle throughout the body.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      ARRHYTHMIAS",
"     </span>",
"    </p>",
"    <p>",
"     The heart's conduction system must function normally for the heart to beat properly and to pump blood effectively to meet the body's needs. Problems with the flow of electrical impulses in the heart are called arrhythmias, which is a general term meaning that there is an abnormality in the pattern of electrical conduction or electrical rhythm.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Bradyarrhythmias",
"     </span>",
"     &nbsp;&mdash;&nbsp;Bradyarrhythmias are heart rhythm abnormalities that cause an abnormally slow heartbeat. Most bradyarrhythmias are due to one of two kinds of problems: sinus bradycardia or heart block.",
"    </p>",
"    <p>",
"     Sinus bradycardia occurs when the heartbeat is too slow because the heart's \"natural pacemaker\" is operating too slowly. Although some people (for example, competitive athletes) may have a slow heartbeat as a result of good health, in others sinus bradycardia is an abnormal condition that requires treatment.",
"    </p>",
"    <p>",
"     Heart block is a term for a delay or interruption in the heart's conduction system, causing the electrical impulses to travel too slowly or to be stopped. There are several kinds of heart block, classified according to location (where in the conduction system the block occurs) and degree (whether the block is mild, causing delayed conduction, or severe, causing conduction to stop).",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       In first-degree atrioventricular (AV) block, all electrical impulses reach the ventricles from the atria, but are abnormally slowed as they pass through the AV node.",
"      </li>",
"      <li>",
"       In second-degree AV block, some atrial impulses fail to reach the ventricles (\"dropped beats\"), resulting in a slow or an irregular heart rate.",
"      </li>",
"      <li>",
"       In third-degree AV block, the most serious form, no atrial impulses are conducted to the ventricles. This condition is sometimes called complete heart block. For the heart to continue to beat, a separate electrical impulse (called an escape rhythm) may be generated in the ventricles. Without an escape rhythm, the ventricles (the chambers that pump blood throughout the body) stop beating.",
"      </li>",
"      <li>",
"       In right bundle branch block (RBBB), impulses are not conducted by the right bundle branch. Electrical impulses reach the right ventricle only by traveling through the heart muscle from the left ventricle. As a result, activation of the right ventricle is delayed.",
"      </li>",
"      <li>",
"       In left bundle branch block (LBBB), impulses are not conducted by the left bundle branch. Electrical impulses reach the left ventricle only by traveling through the heart muscle from the right ventricle. As a result, activation of the left ventricle is delayed.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Tachyarrhythmias",
"     </span>",
"     &nbsp;&mdash;&nbsp;Tachyarrhythmias are heart rhythm abnormalities that cause an abnormally fast heartbeat. Two tachyarrhythmias that are sometimes treated with a pacemaker are atrial fibrillation and ventricular tachycardia.",
"    </p>",
"    <p>",
"     Atrial fibrillation (AF) is a tachyarrhythmia originating in the atria. Electrical impulses appear at random in the atria and spread through the atrial muscle in an irregular, uncoordinated way. The atria \"quiver\" rather than contract normally. As a result, blood is not pumped effectively or regularly into the ventricles. Impulses to the ventricles may be conducted very rapidly, resulting in a rapid and irregular heart rate. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?0/16/261?source=see_link\">",
"      \"Patient information: Atrial fibrillation (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Ventricular tachycardia (VT) is a tachyarrhythmia originating in the ventricles. A repetitive electrical impulse appears somewhere in the ventricles and spreads through the ventricular muscle. Usually, VT produces some effective ventricular contractions, but at a rapid rate. With very rapid VT, blood may not be pumped effectively, and cardiac arrest may result. Therefore, VT is a potentially dangerous tachyarrhythmia.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Arrhythmia symptoms",
"     </span>",
"     &nbsp;&mdash;&nbsp;The symptoms of arrhythmias vary, depending upon the specific arrhythmia and other factors, especially if there is underlying heart disease. While some people may have no symptoms, others may have various symptoms and signs. Symptoms may include:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Fainting episodes (syncope) (see",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?4/9/4245?source=see_link\">",
"        \"Patient information: Syncope (fainting) (Beyond the Basics)\"",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       Dizziness or lightheadedness (presyncope)",
"      </li>",
"      <li>",
"       Palpitations (a sensation of the heart pounding)",
"      </li>",
"      <li>",
"       Confusion",
"      </li>",
"      <li>",
"       Extreme fatigue",
"      </li>",
"      <li>",
"       Shortness of breath",
"      </li>",
"      <li>",
"       Impaired ability of the heart to pump enough blood to meet the body's needs (heart failure)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     The decision to treat an arrhythmia with a pacemaker (or any other treatment) depends in part upon whether the person has symptoms or not as well as the severity of the symptoms.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Underlying causes",
"     </span>",
"     &nbsp;&mdash;&nbsp;A variety of conditions can lead to the development of cardiac arrhythmias. Some of the more common causes include:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Coronary artery disease, where there is a malfunction or damage of the heart due to narrowing or blockage of arteries supplying blood to heart muscle.",
"      </li>",
"      <li>",
"       Damage from a heart attack and the development of scar tissue in the muscle of the heart.",
"      </li>",
"      <li>",
"       Certain structural heart malformations present at birth (congenital heart defects)",
"      </li>",
"      <li>",
"       Inherited genetic abnormalities that are not necessarily associated with a structural problem of the heart, but may result in an arrhythmia (such as the long QT syndrome)",
"      </li>",
"      <li>",
"       Abnormalities in the control and regulation of the heartbeat by the nervous system, leading to fainting (called neurocardiogenic syncope)",
"      </li>",
"      <li>",
"       Diseases of heart muscle tissue, called cardiomyopathies. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?43/17/44305?source=see_link\">",
"        \"Patient information: Dilated cardiomyopathy (Beyond the Basics)\"",
"       </a>",
"       and",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?17/49/18197?source=see_link\">",
"        \"Patient information: Hypertrophic cardiomyopathy (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Therapy with certain medications that may alter the heart's normal rhythm.",
"      </li>",
"      <li>",
"       Normal aging of heart muscle.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H8\">",
"     <span class=\"h1\">",
"      TEMPORARY AND PERMANENT PACEMAKERS",
"     </span>",
"    </p>",
"    <p>",
"     Artificial pacemakers are electronic devices that stimulate the heart with electrical impulses to maintain or restore a normal rhythm in people with slow heart rhythms. There are many situations in which an artificial pacemaker may be recommended.",
"    </p>",
"    <p>",
"     Most commonly, a pacemaker is used for a slow heart rate (bradyarrhythmia) as described above. The decision to use such a device, as well as which specific type, will depend upon multiple factors, including:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       The exact nature and underlying cause of the arrhythmia",
"      </li>",
"      <li>",
"       Whether the condition is temporary or permanent",
"      </li>",
"      <li>",
"       The presence or absence of symptoms as described above",
"      </li>",
"      <li>",
"       The potential risk of complications from a pacemaker",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      How they work",
"     </span>",
"     &nbsp;&mdash;&nbsp;An artificial pacemaker provides an electrical impulse (or \"discharge\") that can stimulate the heart, thus restoring or maintaining a regular heartbeat. Although various types of artificial pacemaker devices are available, they generally include the following components:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       A thin metal box or case called a pulse generator (",
"       <a class=\"graphic graphic_picture graphicRef67059 \" href=\"UTD.htm?26/61/27602\">",
"        picture 1",
"       </a>",
"       ). The pulse generator contains the power source producing the electrical impulses of the pacemaker. In addition, the pulse generator contains a small computer processor that can be programmed to set the rate of the pacemaker, the pattern of pacing (see",
"       <a class=\"local\" href=\"#H10\">",
"        'Types of pacemakers'",
"       </a>",
"       below), the energy output, and various other parameters. The pulse generator for most modern permanent pacemakers weighs one to two ounces.",
"      </li>",
"      <li>",
"       Flexible insulated wires or leads carry electrical impulses from the generator to the heart muscle and relay information concerning the heart's natural activities back to the pacemaker. There may be several such wires, or leads, placed within the heart, most commonly in the right atrium and right ventricle.",
"      </li>",
"      <li>",
"       One or more electrodes at the tips of the leads transmit electrical impulses to the heart muscle and also sense the heart's own electrical activity.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Types of pacemakers",
"     </span>",
"     &nbsp;&mdash;&nbsp;A variety of types of pacemakers have been developed to restore or sustain a regular heartbeat in different ways.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Demand pacemakers monitor the heart's natural electrical activity and discharge only when the heart's own rate is too slow or the heart misses a beat.",
"      </li>",
"      <li>",
"       Fixed-rate pacemakers discharge impulses at a single, steady rate, regardless of the heart's own electrical activity.",
"      </li>",
"      <li>",
"       Rate-responsive pacemakers are designed to raise or lower the heart rate to help meet the body's needs during physical activity or rest. These devices also work on &ldquo;demand.&rdquo;",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Pacemakers may also be single, dual, or triple chambered:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Single-chamber pacemakers have one lead to carry impulses to and from either the right atrium or right ventricle.",
"      </li>",
"      <li>",
"       A dual-chamber pacemaker usually has two leads, one to the right atrium and one to the right ventricle, which can allow a heart rhythm that more naturally resembles the normal activities of the heart.",
"      </li>",
"      <li>",
"       Triple-chambered pacemakers typically have one lead in the right atrium, one to stimulate the right ventricle, and one to stimulate the left ventricle. These pacemakers are inserted in patients who have weakened heart muscle (which results in heart failure). These pacemakers \"resynchronize\" the ventricles and may improve the efficiency of the contraction of the heart, improving its blood flow.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Temporary pacemakers",
"     </span>",
"     &nbsp;&mdash;&nbsp;Temporary pacemakers are intended for short-term use during hospitalization. They are used because the arrhythmia is expected to be temporary and eventually resolve, or because the person requires temporary treatment until a permanent pacemaker can be placed.",
"    </p>",
"    <p>",
"     The pulse generator of a temporary pacemaker is located outside the body, and may be taped to the skin or attached to a belt or to the patient's bed.",
"    </p>",
"    <p>",
"     Patients with temporary pacemakers are hospitalized and continuously monitored. Members of the healthcare team will perform regular examinations to monitor for any possible complications.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Permanent pacemakers",
"     </span>",
"     &nbsp;&mdash;&nbsp;Permanent pacemakers are pacemakers that are intended for long-term use.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h3\">",
"      Indications",
"     </span>",
"     &nbsp;&mdash;&nbsp;Specific guidelines have been established concerning the conditions when a permanent pacemaker is (1) definitely beneficial, useful, and effective, (2) may be indicated, or (3) is not useful or effective and, in some cases, may be harmful [",
"     <a class=\"abstract\" href=\"UTD.htm?20/16/20741/abstract/1\">",
"      1",
"     </a>",
"     ]. Patients should speak with their healthcare provider concerning these guidelines and how they apply to their specific case.",
"    </p>",
"    <p>",
"     As a general rule, permanent pacing is recommended for certain conditions that are chronic or recurrent and not due to a transient cause. Permanent pacing may be considered necessary or appropriate for certain people with symptomatic bradyarrhythmia or, less commonly, to help prevent or terminate tachyarrhythmia.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h3\">",
"      Implantation",
"     </span>",
"     &nbsp;&mdash;&nbsp;The pulse generator of a permanent pacemaker is implanted into soft tissue beneath the skin, which is known as prepectoral implantation; this is located under the skin and fat tissue but above the pectoral or breast muscle. The pacemaker leads are typically inserted into a major vein (transvenously) and advanced until the electrodes are secured within the proper region(s) of heart muscle. The other ends of the leads are attached to the pulse generator (",
"     <a class=\"graphic graphic_figure graphicRef67053 \" href=\"UTD.htm?16/32/16899\">",
"      figure 3",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     Less commonly, the pulse generator is placed under the skin of the upper abdomen.",
"    </p>",
"    <p>",
"     Generally the pacemaker is implanted in a sterile laboratory or operating room by a specialist (cardiologist, surgeon, or cardiac electrophysiologist) with experience in this procedure. Local anesthesia is used to make the procedure as pain-free as possible. In some cases, sedation or even general anesthesia may be used. The position of the pacemaker leads is usually checked using X-ray imaging (called fluoroscopy). The length of the procedure depends upon the type of device being placed.",
"    </p>",
"    <p>",
"     Recovery from the procedure is rapid, but there may be some restrictions on arm movement and activities for the first few weeks. Lead dislodgement is more common in the first few weeks after implantation. The hospital stay is usually brief, and in some cases the procedure can be done as a day surgery. Uncommon but possible risks associated with permanent pacemaker implantation include collapsed lung (pneumothorax), infection, and bleeding.",
"    </p>",
"    <p>",
"     Once implanted, pacemakers can be programmed to change the baseline heart rate, the upper heart rate at which the pacemaker will pace, and heart rate changes that should occur with exercise.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h3\">",
"      Follow-up care",
"     </span>",
"     &nbsp;&mdash;&nbsp;People who have a permanent pacemaker will require periodic clinical check-ups, including certain tests such as ECGs, which record the electrical activity of the heart. In addition, the status of the pacemaker will be regularly checked or \"interrogated\" (often be done remotely using a telephone or the internet) to provide information regarding the type of heart rhythm, the functioning of the pacemaker leads, the frequency of utilization of the pacemaker, the battery life, and the presence of any abnormal heart rhythms.",
"    </p>",
"    <p>",
"     All contemporary devices are programmable with information and settings that can be altered and stored. Information is obtained by transmitting data from the pulse generator to a programmer, usually done during a follow-up office visit. However, with newer pulse generators it may be possible to obtain information about the pacemaker's performance by downloading data from the patient's device to the internet and then to the caregiver's office. Pacemaker activity can also be checked routinely via the telephone, using a telephone-transmitting device.",
"    </p>",
"    <p>",
"     The pulse generators are usually powered by lithium batteries that function for an average of five to eight years before they need to be replaced. When the batteries start to wear out, they do so in a very slow and predictable fashion, allowing sufficient time to be detected and pulse-generator replacement planned. Replacing the pulse generator usually requires a simple procedure in which a skin incision is made over the old incision, the old generator is removed, and a new generator is implanted and joined with the existing leads.",
"    </p>",
"    <p>",
"     The pacemaker leads are usually used indefinitely, unless a specific problem occurs (eg, the lead loses contact with the heart, the lead breaks, or the lead is not functioning properly). In such circumstances, the lead may require replacement. Typically, the old lead is left in place but disconnected from the pulse generator, and a new lead is inserted. Removal of an old lead is feasible but difficult in most cases, because of the formation of scar tissue binding the lead to the blood vessels and heart muscle. Rarely, lead removal is necessary if the system becomes infected.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H16\">",
"     <span class=\"h1\">",
"      AVOIDING ELECTROMAGNETIC INTERFERENCE",
"     </span>",
"    </p>",
"    <p>",
"     Although modern pacemakers are less susceptible to interference than older models, electromagnetic energy can interfere in some cases. Thus, experts advise that people with pacemakers be aware of the following:",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h2\">",
"      Household appliances",
"     </span>",
"     &nbsp;&mdash;&nbsp;Pacemaker manufacturers do not recommend any special precautions when using normally functioning common household appliances such as microwave ovens, televisions, radios, toasters, and electric blankets.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h2\">",
"      Cellular phones",
"     </span>",
"     &nbsp;&mdash;&nbsp;Due to the growing use of hand-held cellular phones, patients must be aware of their potential adverse effects. As examples:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Evidence suggests that cellular phones do not cause interference with permanent pacemakers. While some older generation pacemakers and implantable cardioverter-defibrillators (ICDs) did occasionally experience interference from cellular telephones, clinical experience suggests that there is no significant interference between pacemakers or ICDs and modern wireless communication devices or portable media players.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H19\">",
"     <span class=\"h2\">",
"      Anti-theft systems",
"     </span>",
"     &nbsp;&mdash;&nbsp;Electromagnetic anti-theft security systems are often found in or near the workplace, at airports, in stores, at courthouses, or in other high-security areas. Although interference with a pacemaker is possible, it is unlikely that any clinically significant interference would occur with the transient exposure associated with walking through such a field. Based upon several studies and observations, experts advise that patients with pacemakers should:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Be aware of the location of anti-theft systems and move through them at a normal pace.",
"      </li>",
"      <li>",
"       Avoid sitting or standing close to an anti-theft system.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9851569\">",
"     <span class=\"h2\">",
"      Metal detectors at airports",
"     </span>",
"     &nbsp;&mdash;&nbsp;Similar to antitheft systems, metal detectors at airports can potentially interfere with pacemakers, although this is unlikely. Such exposure has been shown to cause interference in some cases and may be related to the duration of exposure",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     distance between the security system and the pacemaker. Metal detectors will likely be triggered by the presence of a pacemaker and therefore at places such as airports, it will be important for individuals with pacemakers to carry an identification card for their pacemaker, and airport personnel will likely prefer to do a manual search.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H20\">",
"     <span class=\"h2\">",
"      External electrical equipment",
"     </span>",
"     &nbsp;&mdash;&nbsp;External electrical fields do not seem to cause a problem for most people with a pacemaker. However, in workplaces that contain welding equipment or strong motor-generator systems, because interference can inhibit pacing, it is recommended that a person with an implanted cardiac device remain at least two feet from external electrical equipment, verify that the equipment is properly grounded, and leave the immediate locale if lightheadedness or other symptoms develop.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H21\">",
"     <span class=\"h2\">",
"      Diagnostic or therapeutic procedures",
"     </span>",
"     &nbsp;&mdash;&nbsp;Certain types of surgery and procedures may interfere with pacemakers. Most importantly, the use of electrocautery can inhibit pacemaker function. It is not uncommon therefore that a pulse generator may require specific reprogramming before the procedure and programming back to its baseline condition after the procedure. In some instances, a magnet is all that is required on the device to make sure that there is no problem with the device during the procedure. Such procedures include:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Magnetic resonance imaging (MRI), which uses a strong magnetic field that is pulsed on and off at a rapid rate. For most patients with a pacemaker, this procedure is contraindicated.",
"      </li>",
"      <li>",
"       Transcutaneous electrical",
"       <span class=\"nowrap\">",
"        nerve/muscle",
"       </span>",
"       stimulators (TENS), a method of pain control",
"      </li>",
"      <li>",
"       Diathermy, which heats body tissues with high-frequency electromagnetic radiation or microwaves",
"      </li>",
"      <li>",
"       Extracorporeal shock wave lithotripsy, the use of sound waves to break up gallstones and kidney stones",
"      </li>",
"      <li>",
"       Therapeutic radiation for cancer or tumors, which can cause permanent pacemaker damage",
"      </li>",
"      <li>",
"       Any surgery in which electrocautery is being used. The risks are greatest when the electrocautery is being performed close to the pulse generator.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Thus, doctors, dentists, and other healthcare providers should be informed about a person's pacemaker. If a procedure associated with pacemaker interference is contemplated, the possible benefits, risks, and alternatives should be considered and discussed, as appropriate. People with pacemakers should carry a medical identification card for emergencies.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H22\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem. The manufacturer of your device likely also has a patient call line, and the number would be listed on your identification card.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1785028213\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11169775\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/49/6931?source=see_link\">",
"      Patient information: Pacemakers (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/60/38850?source=see_link\">",
"      Patient information: Implantable cardioverter-defibrillators (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?12/54/13154?source=see_link\">",
"      Patient information: Radiofrequency catheter ablation for the heart (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/34/37410?source=see_link\">",
"      Patient information: Cardiac resynchronization therapy (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?8/46/8931?source=see_link\">",
"      Patient information: Bradycardia (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/40/19075?source=see_link\">",
"      Patient information: Sick sinus syndrome (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?19/25/19859?source=see_link\">",
"      Patient information: Long QT syndrome (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11169783\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?0/16/261?source=see_link\">",
"      Patient information: Atrial fibrillation (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?4/9/4245?source=see_link\">",
"      Patient information: Syncope (fainting) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?43/17/44305?source=see_link\">",
"      Patient information: Dilated cardiomyopathy (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?17/49/18197?source=see_link\">",
"      Patient information: Hypertrophic cardiomyopathy (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H23\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/56/11142?source=see_link\">",
"      Cardiac device interactions with electromagnetic fields",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/17/11545?source=see_link\">",
"      Cardiac resynchronization therapy in heart failure: Implantation and other considerations",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/56/18314?source=see_link\">",
"      Cardiac resynchronization therapy in heart failure: Indications",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/36/31302?source=see_link\">",
"      Dual chamber pacing system malfunction: Evaluation and management",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/52/27463?source=see_link\">",
"      Indications for permanent cardiac pacing",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/19/44345?source=see_link\">",
"      Infections involving cardiac implantable electronic devices",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/51/1849?source=see_link\">",
"      Modes of cardiac pacing: Nomenclature and selection",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/14/21737?source=see_link\">",
"      Pacing system malfunction: Evaluation and management",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/61/21465?source=see_link\">",
"      Temporary cardiac pacing",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/44/37576?source=see_link\">",
"      Treatment of the sick sinus syndrome",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/pacemakersandimplantabledefibrillators.html\">",
"      www.nlm.nih.gov/medlineplus/pacemakersandimplantabledefibrillators.html",
"     </a>",
"     , available in Spanish)",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Heart, Lung &amp; Blood Institute (NHLBI)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nhlbi.nih.gov/health/dci/Diseases/pace/pace_whatis.html\">",
"      www.nhlbi.nih.gov/health/dci/Diseases/pace/pace_whatis.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American College of Cardiology (ACC)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.acc.org/\">",
"      www.acc.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Heart Association",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.americanheart.org\">",
"      www.americanheart.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Heart Rhythm Society",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.hrspatients.org/patients/treatments/pacemakers.asp\">",
"      www.hrspatients.org/patients/treatments/pacemakers.asp",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?20/16/20741/abstract/1-6\">",
"      1-6",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 1, 2011.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?20/16/20741?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20741/abstract/1\">",
"      Gregoratos G, Abrams J, Epstein AE, et al. ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/NASPE Committee to Update the 1998 Pacemaker Guidelines). Circulation 2002; 106:2145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20741/abstract/2\">",
"      Hayes DL, Barold SS, Camm AJ, Goldschlager NF. Evolving indications for permanent cardiac pacing: an appraisal of the 1998 American College of Cardiology/American Heart Association Guidelines. Am J Cardiol 1998; 82:1082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20741/abstract/3\">",
"      Gimbel JR, Cox JW Jr. Electronic article surveillance systems and interactions with implantable cardiac devices: risk of adverse interactions in public and commercial spaces. Mayo Clin Proc 2007; 82:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20741/abstract/4\">",
"      Groh WJ, Boschee SA, Engelstein ED, et al. Interactions between electronic article surveillance systems and implantable cardioverter-defibrillators. Circulation 1999; 100:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20741/abstract/5\">",
"      Martin ET, Coman JA, Shellock FG, et al. Magnetic resonance imaging and cardiac pacemaker safety at 1.5-Tesla. J Am Coll Cardiol 2004; 43:1315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20741/abstract/6\">",
"      Solan AN, Solan MJ, Bednarz G, Goodkin MB. Treatment of patients with cardiac pacemakers and implantable cardioverter-defibrillators during radiotherapy. Int J Radiat Oncol Biol Phys 2004; 59:897.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f20_16_20741=[""].join("\n");
var outline_f20_16_20741=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           INTRODUCTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           THE HEART'S CONDUCTION SYSTEM AND \"NATURAL PACEMAKER\"",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           ARRHYTHMIAS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H8\">",
"           TEMPORARY AND PERMANENT PACEMAKERS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H16\">",
"           AVOIDING ELECTROMAGNETIC INTERFERENCE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H22\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/20/4420\" title=\"figure 1\">",
"           Heart conduction system PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?11/14/11495\" title=\"figure 2\">",
"           Cardiac anatomy PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/32/16899\" title=\"figure 3\">",
"           ICD PI",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          PICTURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/61/27602\" title=\"picture 1\">",
"           Pacemaker photo PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f20_16_20742="Fenofibric acid: Drug information";
var content_f20_16_20742=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Fenofibric acid: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?30/3/30772?source=see_link\">",
"    see \"Fenofibric acid: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F6838326\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Fibricor&reg;;",
"     </li>",
"     <li>",
"      TriLipix&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F6838330\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antilipemic Agent, Fibric Acid",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F6838385\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Mixed dyslipidemia (coadministered with a statin):",
"     </b>",
"     Oral: TriLipix&trade;: 135 mg once daily (maximum: 135 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Hypertriglyceridemia:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Fibricor&reg;: Initial: 35-105 mg once daily; Maintenance:  Individualize according to patient response (maximum: 105 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     TriLipix&trade;: Initial: 45-135 mg once daily; Maintenance: Individualize according to patient response (maximum: 135 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Primary hypercholesterolemia or mixed dyslipidemia:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Fibricor&reg;: 105 mg once daily (maximum: 105 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     TriLipix&trade;: 135 mg once daily (maximum: 135 mg/day)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F6838386\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Dosage based on renal function",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F6838387\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Normal renal function:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Fibricor&reg;: Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;80 mL/minute: No dosage adjustment necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     TriLipix&trade;: eGFR &ge;60 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Mild-to-moderate renal impairment",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Fibricor&reg;: Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30-80 mL/minute: Initial: 35 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     TriLipix&trade;: eGFR 30-59 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : Initial: 45 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Severe renal impairment (with or without dialysis):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Fibricor&reg;: Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute: Use is contraindicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     TriLipix&trade;: eGFR &lt;30 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : Use is contraindicated.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F14223992\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use is contraindicated in active liver disease, including primary biliary cirrhosis and unexplained persistent liver function abnormalities.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F6838394\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, delayed release, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     TriLipix&reg;: 45 mg, 135 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 35 mg, 105 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fibricor&reg;: 35 mg, 105 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F6838328\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874686\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     TriLipix&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089806.pdf%20\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089806.pdf",
"     </a>",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F6838390\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered with or without food. Capsule: Swallow whole; do not open, break, chew, crush, or dissolve. When coadministered with a statin for mixed lipidemia, for convenience, may administer at the same time of day as the statin.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F6838332\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjunct to dietary therapy for the treatment of severely elevated serum triglyceride levels; adjunct to dietary therapy for the reduction of low density lipoprotein cholesterol (LDL-C), total cholesterol (total-C), triglycerides, and apolipoprotein B (apo B) and to increase high density lipoprotein cholesterol (HDL-C) in patients with primary hypercholesterolemia or mixed dyslipidemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     TriLipix&trade;  is also indicated as adjunct to dietary therapy concomitantly with a statin to reduce triglyceride levels and increase HDL-C levels in patients with mixed dyslipidemia and coronary heart disease (CHD) or at  risk for CHD",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F6838324\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Fibricor&reg; may be confused with Tricor&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       TriLipix&reg; may be confused with Trileptal&reg;, TriLyte&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F6838341\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse reactions and frequency reported as observed during monotherapy and concurrent administration with a statin (HMG-CoA reductase inhibitor).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%: Central nervous system: Headache (12% to 13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Dizziness (3% to 4%), pain (1% to 4%), fatigue (2% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Nausea (4% to 6%), dyspepsia (3% to 5%), diarrhea (3% to 4%), constipation (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hepatic: ALT increased (monotherapy: 1%; coadministered with statin: 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Back pain (4% to 6%), pain in extremities (3% to 5%), arthralgia (4%), myalgia (3% to 4%), muscle spasm (2% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Nasopharyngitis (4% to 5%), upper respiratory infection (4% to 5%), sinusitis (3% to 4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Additional adverse reactions when fenofibric acid coadministered with a statin (frequency not defined): AST increased, bronchitis, cough, CPK increased, hepatic enzymes increased, hypertension, influenza, insomnia, musculoskeletal pain, pharyngolaryngeal pain, urinary tract infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Postmarketing and/or case reports (seen with fenofibrate) (limited to important or life-threatening): Abdominal pain, agranulocytosis, anemia, cholesystitis, cirrhosis, CPK increased, creatinine increased, DVT, HDL-C decreased, hematocrit/hemoglobin decreased, hepatitis (including hepatocellular, chronic active, and cholestatic hepatitis), homocysteine increased, pancreatitis, pulmonary embolism, rash, renal failure, rhabdomyolysis, Stevens-Johnson syndrome, thrombocytopenia, toxic epidermal necrolysis, weakness, white blood cell count decreased",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F6838336\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to fenofibric acid, fenofibrate, or any component of the formulation; hepatic dysfunction including primary biliary cirrhosis and unexplained persistent liver function abnormalities; severe renal impairment (including patients on dialysis); pre-existing gallbladder disease; breast-feeding",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F6838337\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cholelithiasis: May cause cholelithiasis; discontinue if gallstones found upon gallbladder studies.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; HDL cholesterol (HDL-C): A paradoxical, severe, and reversible decrease in HDL-C (as low as 2 mg/dL) with a simultaneous decrease in apolipoprotein A1 has been reported within 2 weeks to years after initiation of fibrate therapy. Monitor HDL-C within a few months of initiation of therapy and discontinue if HDL-C becomes severely depressed; do not restart therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hemogloblin/hematocrit/WBC effects: May cause mild-to-moderate decreases in hemoglobin, hematocrit and WBC upon initiation of therapy, which usually stabilizes with long-term therapy. Agranulocytosis and thrombocytopenia have rarely been reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic effects: Hepatic transaminases can become significantly elevated (dose-related); hepatocellular, chronic active, and cholestatic hepatitis have been reported. Regular monitoring of liver function tests is required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Rarely hypersensitivity reactions (eg, severe skin rash, Stevens-Johnson syndrome, toxic epidermal necrolysis) may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myopathy/rhabdomyolysis: Has been associated with rare myositis or rhabdomyolysis; patients should be monitored closely. Risk increased in the elderly, those receiving concomitant HMG-CoA reductase inhibitors or colchicine, and patients with diabetes mellitus, renal failure, or hypothyroidism. Patients should be instructed to report unexplained muscle pain, tenderness, weakness, or brown urine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal effects: Reversible increases in serum creatinine (&gt;2 mg/dL) have been observed with use; no adverse effects on clinical outcomes (ie, adverse renal or cardiovascular outcomes) seen in one analysis (Bonds, 2012). Fenofibrate has been shown to increase creatinine production (unknown mechanism) resulting in an equal increase of creatinuria demonstrating that the increase does not reflect a reduction in creatinine clearance (Hottelart, 2002). Monitor renal function in patients with renal impairment and consider monitoring patients with increased risk for developing renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Venous thromboembolism (VTE): Use has been associated with pulmonary embolism (PE) and deep vein thrombosis (DVT). Use with caution in patients with risk factors for VTE.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with mild-to-moderate renal impairment; dosage adjustment required. Contraindicated with severe renal impairment including those receiving dialysis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anticoagulants: Use with caution in patient taking oral anticoagulants (eg, warfarin); adjustments in therapy may be required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; HMG-CoA reductase inhibitors: Use caution with HMG-CoA reductase inhibitors; may lead to myopathy, rhabdomyolysis. No incremental benefit of combination therapy on cardiovascular morbidity and mortality over statin monotherapy has been established. In combination with HMG-CoA reductase inhibitors, fenofibric acid derivatives are generally regarded as safer than gemfibrozil due to limited pharmacokinetic interaction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Due to a higher incidence of renal impairment, use with caution in the elderly; dosage adjustment based on renal function may be required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Type 2 diabetes mellitus: In two large randomized controlled clinical trials, neither fenofibrate monotherapy (Keech, 2005) nor the addition of fenofibrate to simvastatin (ACCORD Study Group, 2010) compared to placebo has been shown to reduce cardiovascular disease morbidity and mortality in patients with type 2 diabetes. The implications of these trials are thought to apply to fenofibric acid as well.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperlipidemia: Secondary causes of hyperlipidemia should be ruled out prior to therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Optimal response: Therapy should be withdrawn if an adequate response is not obtained after 2-3 months of therapy at the maximal daily dose. In patients with severe hypertriglyceridemia, the occurrence of pancreatitis may represent a failure of efficacy.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299315\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2A6 (weak), CYP2C8 (weak), CYP2C9 (moderate)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6839969\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Fibric Acid Derivatives. Management: Separate doses by at least 2 hours to minimize this interaction; fenofibric acid labeling recommends administration one hour prior to or 4-6 hours after a bile acid sequestrant.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Colesevelam.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carvedilol: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Carvedilol. Specifically, concentrations of the S-carvedilol enantiomer may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chenodiol: Fibric Acid Derivatives may diminish the therapeutic effect of Chenodiol.  Management: Monitor clinical response to chenodiol closely when used together with any fibric acid derivative.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: Fibric Acid Derivatives may enhance the myopathic (rhabdomyolysis) effect of Colchicine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): May enhance the nephrotoxic effect of Fibric Acid Derivatives. Fibric Acid Derivatives may decrease the serum concentration of CycloSPORINE (Systemic). Management: Careful consideration of the risks and benefits should be undertaken prior to use of this combination; extra monitoring of renal function and cyclosporine concentrations will likely be required.  Adjustment of cyclosporine dose may be necessary.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Substrates: CYP2C9 Inhibitors (Moderate) may decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ezetimibe: Fibric Acid Derivatives may increase the serum concentration of Ezetimibe.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HMG-CoA Reductase Inhibitors: Fenofibric Acid may enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonylureas: Fibric Acid Derivatives may enhance the hypoglycemic effect of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): May enhance the nephrotoxic effect of Fenofibric Acid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ursodiol: Fibric Acid Derivatives may diminish the therapeutic effect of Ursodiol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Fibric Acid Derivatives may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Warfarin: Fenofibric Acid may enhance the anticoagulant effect of Warfarin. Fenofibric Acid may increase the serum concentration of Warfarin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F6838333\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F6838334\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in animal reproduction studies. When treatment is required during pregnancy, other agents are preferred (NCEP, 2002).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F6838335\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/contraindicated",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F6838389\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken with or without food. Patients should follow appropriate lipid-lowering diet.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F7281363\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsule, delayed release",
"     </b>",
"     (Trilipix Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     45 mg (90): $200.06",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     135 mg (90): $600.19",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Fenofibric Acid Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     35 mg (30): $30.03",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     105 mg (30): $90.10",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Fibricor Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     35 mg (30): $41.18",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     105 mg (30): $123.56",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F6838392\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Periodic blood counts during first year of therapy; total cholesterol, LDL-C, triglycerides, and HDL-C should be measured periodically; LFTs (including ALT) (baseline and regularly during therapy) and discontinue therapy if levels remain &gt;3 times normal limits; serum creatinine (in patients with or at risk for renal impairment)",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F6838365\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Fenofibric acid, an agonist for the nuclear transcription factor peroxisome proliferator-activated receptor-alpha (PPAR-alpha), downregulates apoprotein C-III (an inhibitor of lipoprotein lipase) and upregulates the synthesis of apolipoprotein A-I, fatty acid transport protein, and lipoprotein lipase resulting in an increase in VLDL catabolism, fatty acid oxidation, and elimination of triglyceride-rich particles; as a result of a decrease in VLDL levels, total plasma triglycerides are reduced by 30% to 60%; modest increased in HDL occurs in some hypertriglyceridemia patients.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F6838367\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Well absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: ~99%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Fenofibric acid (active form) undergoes inactivation by glucuronidation. The choline salt dissociates in the GI tract to form fenofibric acid (free acid)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bioavailability: TriLipix&trade;: ~81%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: ~20 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak, plasma: Fibricor&reg;: ~2.5 hours; TriLipix&trade;: 4-5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Urine (as fenofibric acid and fenofibric acid glucuronide)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      ACCORD Study Group, Ginsberg HN, Elam MB, et al, &ldquo;Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2010, 362(17):1563-74.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/16/20742/abstract-text/20228404/pubmed\" id=\"20228404\" target=\"_blank\">",
"        20228404",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Berglund L, Brunzell JD, Goldberg AC, et al, &ldquo;Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline,&rdquo;",
"      <i>",
"       J Clin Endocrinol Metab",
"      </i>",
"      , 2012, 97(9):2969-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/16/20742/abstract-text/22962670/pubmed\" id=\"22962670\" target=\"_blank\">",
"        22962670",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bonds DE, Craven TE, Buse J, et al, \"Fenofibrate-Associated Changes in Renal Function and Relationship to Clinical Outcomes Among Individuals With Type 2 Diabetes: The Action to Control Cardiovascular Risk in Diabetes (ACCORD) Experience,\"",
"      <i>",
"       Diabetologia",
"      </i>",
"      , 2012, 55(6):1641-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/16/20742/abstract-text/22450889/pubmed\" id=\"22450889\" target=\"_blank\">",
"        22450889",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III),&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2001, 285(19):2486-97.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/16/20742/abstract-text/11368702/pubmed\" id=\"11368702\" target=\"_blank\">",
"        11368702",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Grundy SM, Cleeman JI, Merz CN, et al, &ldquo;Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2004, 44(3):720-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/16/20742/abstract-text/15358046/pubmed\" id=\"15358046\" target=\"_blank\">",
"        15358046",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hottelart C, El Esper N, Rose F, et al, \"Fenofibrate Increases Creatininemia by Increasing Metabolic Production of Creatinine,\"",
"      <i>",
"       Nephron",
"      </i>",
"      , 2002, 92(3):536-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/16/20742/abstract-text/12372935/pubmed\" id=\"12372935\" target=\"_blank\">",
"        12372935",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Keech A, Simes RJ, Barter P, et al, &ldquo;Effects of Long-term Fenofibrate Therapy on Cardiovascular Events in 9795 People With Type 2 Diabetes Mellitus (The FIELD Study): Randomised Controlled Trial,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2005, 366(9500):1849-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/16/20742/abstract-text/16310551/pubmed\" id=\"16310551\" target=\"_blank\">",
"        16310551",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mohiuddin SM, Pepine CJ, Kelly MT, et al, &ldquo;Efficacy and Safety of ABT-335 (Fenofibric Acid) in Combination With Simvastatin In Patients With Mixed Dyslipidemia: A Phase 3, Randomized, Controlled Study,&rdquo;",
"      <i>",
"       Am Heart J",
"      </i>",
"      , 2009, 157(1):195-203.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/16/20742/abstract-text/19081418/pubmed\" id=\"19081418\" target=\"_blank\">",
"        19081418",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mychaleckyj JC, Craven T, Nayak U, et al, \"Reversibility of Fenofibrate Therapy-Induced Renal Function Impairment in ACCORD Type 2 Diabetic Participants,\"",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2012, 35(5):1008-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/16/20742/abstract-text/22432114/pubmed\" id=\"22432114\" target=\"_blank\">",
"        22432114",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smith SC Jr, Benjamin EJ, Bonow RO, et al, &ldquo;AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update: A Guideline From the American Heart Association and American College of Cardiology Foundation,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(22):2458-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/16/20742/abstract-text/22052934/pubmed\" id=\"22052934\" target=\"_blank\">",
"        22052934",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Taskinen M, Sullivan DR, Ehnholm, et al, &ldquo;Relationships of HDL Cholesterol, ApoA-I, and ApoA-II With Homocysteine and Creatinine in Patients With Type 2 Diabetes Treated With Fenofibrate,&rdquo;",
"      <i>",
"       Arterioscler Thromb Vasc Biol",
"      </i>",
"      , 2009, 29(6):950-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/16/20742/abstract-text/19325138/pubmed\" id=\"19325138\" target=\"_blank\">",
"        19325138",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9060 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-D3C9B8B2AC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_16_20742=[""].join("\n");
var outline_f20_16_20742=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6838326\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6838330\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6838385\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6838386\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6838387\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14223992\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6838394\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6838328\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874686\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6838390\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6838332\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6838324\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6838341\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6838336\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6838337\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299315\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6839969\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6838333\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6838334\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6838335\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6838389\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7281363\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6838392\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6838365\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6838367\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9060\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9060|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?30/3/30772?source=related_link\">",
"      Fenofibric acid: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_16_20743="Prothrombin gene mutation";
var content_f20_16_20743=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Prothrombin gene mutation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/16/20743/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/16/20743/contributors\">",
"     Kenneth A Bauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/16/20743/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/16/20743/contributors\">",
"     Lawrence LK Leung, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/16/20743/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/16/20743/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/16/20743/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inherited thrombophilia is a genetic tendency to venous thromboembolism. The Factor V Leiden and prothrombin G20210A mutations are the most common defects, accounting for more than 50 percent of cases. Deficiencies in protein S, protein C, and antithrombin account for most of the remaining cases, while rare causes include the dysfibrinogenemias [",
"    <a class=\"abstract\" href=\"UTD.htm?20/16/20743/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The total incidence of an inherited thrombophilia in subjects with a deep vein thrombosis ranges from 24 to 37 percent overall compared with about 10 percent in controls. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43786?source=see_link&amp;anchor=H4#H4\">",
"     \"Overview of the causes of venous thrombosis\", section on 'Inherited thrombophilia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic review will discuss the genetics, prevalence, clinical presentation and diagnosis of the prothrombin G2010A mutation. Issues related to screening for and the general treatment of the inherited thrombophilias are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/41/11930?source=see_link\">",
"     \"Evaluation of the patient with established venous thrombosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/26/20903?source=see_link\">",
"     \"Screening for inherited thrombophilia in asymptomatic populations\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/12/23752?source=see_link\">",
"     \"Management of inherited thrombophilia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/57/14234?source=see_link\">",
"     \"Diagnosis and treatment of venous thrombosis and thromboembolism in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PROTHROMBIN GENE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prothrombin (factor II) is the precursor of thrombin, the end-product of the coagulation cascade. It is a vitamin K-dependent protein which is synthesized in the liver and circulates with a half-life of approximately three to five days. Vitamin K acts as a cofactor for posttranslational gamma-carboxylation of prothrombin which is required for functional activity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/32/20999?source=see_link\">",
"     \"Vitamin K, gamma carboxyglutamic acid, and the function of coagulation and other proteins\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Prothrombin G20210A",
"    </span>",
"    &nbsp;&mdash;&nbsp;The human prothrombin gene spans 21 kb on chromosome 11p11-q12 and consists of 14 exons and 13 introns, which account for 90 percent of the sequence. A report published in 1996 identified a transition (guanine to adenine) at nucleotide 20210 in the 3' untranslated region of the prothrombin gene as a risk factor for thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/16/20743/abstract/3\">",
"     3",
"    </a>",
"    ]. Heterozygous carriers have 30 percent higher plasma prothrombin levels than normals [",
"    <a class=\"abstract\" href=\"UTD.htm?20/16/20743/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Linkage studies performed in 397 individuals from 21 Spanish families corroborated that G20210A is a functional polymorphism as well as the association of this polymorphism with an increased susceptibility to thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/16/20743/abstract/4\">",
"     4",
"    </a>",
"    ]. The molecular mechanism by which the nucleotide G20210A transition raises plasma prothrombin levels may result from altering the efficiency of mRNA processing",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the decay rate of prothrombin mRNA [",
"    <a class=\"abstract\" href=\"UTD.htm?20/16/20743/abstract/5-7\">",
"     5-7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PREVALENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is wide variability in geographic distribution of the prothrombin G20210A mutation. The proportion of the white population heterozygous for the allele varies from 0.7 percent to 6.5 percent, with the highest prevalence rates reported in Spain [",
"    <a class=\"abstract\" href=\"UTD.htm?20/16/20743/abstract/2,3,8-13\">",
"     2,3,8-13",
"    </a>",
"    ]. A study of data from 11 centers in Europe found a range of 0.7 to 4.0 percent, with the prevalence in southern Europe being almost twice as high as northern Europe (3.0 versus 1.7 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/16/20743/abstract/13\">",
"     13",
"    </a>",
"    ]. The prothrombin gene mutation is extremely rare in the nonwhite (black or Asian) population [",
"    <a class=\"abstract\" href=\"UTD.htm?20/16/20743/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies of allele frequencies of four dimorphisms of the G20210A prothrombin gene indicated strong linkage disequilibrium, suggesting a founder effect [",
"    <a class=\"abstract\" href=\"UTD.htm?20/16/20743/abstract/15\">",
"     15",
"    </a>",
"    ]. It has been suggested that the mutation probably occurred after the divergence of Africans from non-Africans and of Caucasoid from Mongoloid subpopulations [",
"    <a class=\"abstract\" href=\"UTD.htm?20/16/20743/abstract/15\">",
"     15",
"    </a>",
"    ]. Similar data, indicating a single genetic origin in the same time period, have been found in studies of individuals with the factor V Leiden mutation, which occurs in the same ethnic groups [",
"    <a class=\"abstract\" href=\"UTD.htm?20/16/20743/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/35/28218?source=see_link\">",
"     \"Activated protein C resistance and factor V Leiden\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     RISK OF THROMBOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Heterozygous carriers of the G20210A prothrombin gene mutation have an increased risk of deep vein and cerebral vein thrombosis.",
"   </p>",
"   <p>",
"    There is insufficient information in the literature to evaluate the degree of thrombotic risk in those homozygous for the G20210A prothrombin gene mutation, but it is undoubtedly substantially higher than that in heterozygotes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Deep vein thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The G20210A prothrombin gene mutation has been found with greater frequency in patients with venous thrombosis than controls in a number of studies from Europe, the United States, and Brazil [",
"    <a class=\"abstract\" href=\"UTD.htm?20/16/20743/abstract/2,3,8,10-12,17\">",
"     2,3,8,10-12,17",
"    </a>",
"    ]. In the Leiden Thrombophilia Study, for example, 6.2 percent of venous thrombosis patients and 2.3 percent of healthy matched controls had the prothrombin gene mutation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/16/20743/abstract/3\">",
"     3",
"    </a>",
"    ]. The mutation independently conferred a 2.8-fold increased risk of venous thrombosis, an effect that was seen in both sexes and all age groups (",
"    <a class=\"graphic graphic_table graphicRef56252 \" href=\"UTD.htm?21/4/21579\">",
"     table 1",
"    </a>",
"    ). Similar results were noted in a report of 281 consecutive Italian patients with venous thrombosis; the frequency of the prothrombin gene mutation was more than three times higher in the patients than in 850 controls (8.0 versus 2.3 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/16/20743/abstract/2\">",
"     2",
"    </a>",
"    ]. The mutation was present in 40 percent of patients (compared with 5 percent of controls) in a series of 10 patients with idiopathic portal vein thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/16/20743/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There appears to be an increased incidence of a second thrombotic defect among symptomatic patients with any of the causes of familial thrombophilia, particularly with factor V Leiden. Furthermore, patients with two defects are at increased risk for venous thrombosis. These relationships were originally described in patients with heterozygous antithrombin, protein C, or protein S deficiency and also apply to those with the prothrombin gene mutation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/16/20743/abstract/19-23\">",
"     19-23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A pooled analysis of eight case-control studies evaluated these risks in patients bearing factor V Leiden",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the prothrombin gene mutation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/16/20743/abstract/19\">",
"     19",
"    </a>",
"    ]. The following odds ratios for the risk of VTE were found:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Prothrombin gene mutation heterozygotes &mdash; 3.8",
"     </li>",
"     <li>",
"      Factor V Leiden heterozygotes &mdash; 4.9",
"     </li>",
"     <li>",
"      Both mutations (ie, double heterozygotes) &mdash; 20.0",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Double heterozygotes occurred in 2.2 percent of patients with VTE overall, in 12 percent of patients who were heterozygous for factor V Leiden and in 23 percent of patients heterozygous for the prothrombin gene mutation.",
"   </p>",
"   <p>",
"    In one study of 115 symptomatic patients with factor V Leiden, for example, 12 percent also had the prothrombin gene mutation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/16/20743/abstract/23\">",
"     23",
"    </a>",
"    ]. In this and another study, the presence of both defects increased the thrombotic risk three to fivefold above the risk of a single defect [",
"    <a class=\"abstract\" href=\"UTD.htm?20/16/20743/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It remains to be determined whether the prothrombin gene mutation increases the risk of thrombosis in patients with heterozygous antithrombin, protein C or protein S deficiency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Risk of recurrent DVT",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is controversial whether heterozygous carriers have an increase in the rate of",
"    <strong>",
"     recurrent",
"    </strong>",
"    venous thromboembolism [",
"    <a class=\"abstract\" href=\"UTD.htm?20/16/20743/abstract/24-27\">",
"     24-27",
"    </a>",
"    ]. Two meta-analyses have come to differing conclusions concerning whether the presence of the prothrombin gene mutation is (odds ratio 1.72; 95% CI 1.27-2.31) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/16/20743/abstract/28\">",
"     28",
"    </a>",
"    ], or is not (odds ratio 1.4; 95% CI 0.90-2.0) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/16/20743/abstract/29\">",
"     29",
"    </a>",
"    ], associated with an increased risk for DVT recurrence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prothrombin gene mutation may also increase the risk of venous thrombosis in patients with acquired risk factors, such as pregnancy. In a case-control study of 42 women with venous thromboembolism during pregnancy or the postpartum period and 213 controls without a history of thrombosis, 31 percent of the women with thrombosis had the prothrombin gene mutation, an odds ratio of 10.2 compared with controls [",
"    <a class=\"abstract\" href=\"UTD.htm?20/16/20743/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/5/26714?source=see_link\">",
"     \"Inherited thrombophilias in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Cerebral vein thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prothrombin gene mutation is a risk factor for cerebral venous thrombosis particularly in the presence of exposure to oral contraceptives [",
"    <a class=\"abstract\" href=\"UTD.htm?20/16/20743/abstract/31,32\">",
"     31,32",
"    </a>",
"    ], similar to data obtained for other genetic prothrombotic conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?20/16/20743/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. In one report, for example, the prevalence of the prothrombin gene mutation was significantly higher in 40 patients with cerebral vein thrombosis than in 120 healthy controls (20 versus 3 percent, odds ratio [OR] 10.2) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/16/20743/abstract/32\">",
"     32",
"    </a>",
"    ]. The odds ratio for cerebral vein thrombosis also was higher in women using oral contraceptives (OR 22.1) and much higher in users of oral contraceptives who also had the prothrombin gene mutation (7 of 40 patients versus 1 of 120 controls, OR 149).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Arterial thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prothrombin gene mutation is not a risk factor for cerebrovascular ischemic disease in older patients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/16/20743/abstract/35\">",
"     35",
"    </a>",
"    ]. A study of 131 unselected patients with ischemic stroke and transient ischemic attacks found that the prevalence of the prothrombin gene mutation was similar to that found in a control population [",
"    <a class=\"abstract\" href=\"UTD.htm?20/16/20743/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, a relation to stroke in younger patients has been suggested:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, patients with no other risk factors who had a documented ischemic stroke before 50 years of age were more likely to have the G20210A prothrombin gene mutation than 198 controls (7.6 versus 1.2 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/16/20743/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a second report in patients with a documented",
"      <span class=\"nowrap\">",
"       stroke/transient",
"      </span>",
"      ischemic attack before 60 years of age, the prevalence of the prothrombin gene mutation was significantly higher than controls only in males (6 versus 1 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/16/20743/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Evaluation of the role of the prothrombin gene mutation in acute myocardial infarction has produced conflicting results [",
"    <a class=\"abstract\" href=\"UTD.htm?20/16/20743/abstract/35,38-40\">",
"     35,38-40",
"    </a>",
"    ]. In one series of 560 men with a first infarct, the G20210A allele was more common in the patients than in age-matched controls (1.8 versus 1.2 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/16/20743/abstract/38\">",
"     38",
"    </a>",
"    ]. The risk was substantially increased when one of the major cardiovascular risk factors was also present with odds ratios varying between 3 and 6; these odds ratios exceeded the single effects of the known risk factors in the absence of the prothrombin gene mutation. Similar findings were noted in another study in which the prevalence of the mutant allele was higher in 220 survivors of myocardial infarction than in controls (3.0 versus 0.7 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/16/20743/abstract/39\">",
"     39",
"    </a>",
"    ]. However, in a third series of 644 patients with premature coronary disease (402 of whom had previously had a myocardial infarction) and 879 controls, no association was noted between the prothrombin gene mutation and coronary disease or any conventional cardiovascular risk factor [",
"    <a class=\"abstract\" href=\"UTD.htm?20/16/20743/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polymerase chain reaction (PCR) methods have been used to detect the G20210A prothrombin gene mutation in genomic DNA [",
"    <a class=\"abstract\" href=\"UTD.htm?20/16/20743/abstract/3\">",
"     3",
"    </a>",
"    ]. In addition, methods are available to detect both the G20210A mutation and factor V Leiden in the same reaction [",
"    <a class=\"abstract\" href=\"UTD.htm?20/16/20743/abstract/41\">",
"     41",
"    </a>",
"    ]. This is achieved by multiplex PCR amplification of the involved region of both genes using whole blood as a DNA source, followed by combined restriction digestion and agarose gel electrophoresis. This method has been further simplified by following duplex PCR-mediated site-directed mutagenesis with restriction analysis using an inexpensive endonuclease [",
"    <a class=\"abstract\" href=\"UTD.htm?20/16/20743/abstract/42\">",
"     42",
"    </a>",
"    ]. Individual PCR assays for the two mutations are most widely used at present.",
"   </p>",
"   <p>",
"    Plasma prothrombin concentrations cannot be used to screen for the prothrombin gene mutation. Although 87 percent of patients with the mutation have values for plasma prothrombin in the upper quartile [",
"    <a class=\"abstract\" href=\"UTD.htm?20/16/20743/abstract/3\">",
"     3",
"    </a>",
"    ], the presence of significant overlap prevents the use of this measurement for diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     OTHER PROTHROMBIN GENE MUTATIONS AND POLYMORPHISMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polymorphisms of the prothrombin gene other than G20210A have been described.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Prothrombin C20209T",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial reports differ as to whether this polymorphism is [",
"    <a class=\"abstract\" href=\"UTD.htm?20/16/20743/abstract/43,44\">",
"     43,44",
"    </a>",
"    ] or is not [",
"    <a class=\"abstract\" href=\"UTD.htm?20/16/20743/abstract/45\">",
"     45",
"    </a>",
"    ] associated with an increased risk for development of VTE.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Prothrombin A19911G",
"    </span>",
"    &nbsp;&mdash;&nbsp;The intronic A19911G prothrombin gene polymorphism appears to raise prothrombin levels by increasing splicing efficiency at the nearby 20210 splice site [",
"    <a class=\"abstract\" href=\"UTD.htm?20/16/20743/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one study this polymorphism slightly increased the risk of VTE in carriers of the G20210A genotype [",
"    <a class=\"abstract\" href=\"UTD.htm?20/16/20743/abstract/47\">",
"     47",
"    </a>",
"    ], while in a second study it increased the risk of VTE in carriers of factor V Leiden as well as in those without thrombophilia [",
"    <a class=\"abstract\" href=\"UTD.htm?20/16/20743/abstract/48\">",
"     48",
"    </a>",
"    ]. This latter study was underpowered to detect a slightly increased risk in carriers of the G20210A genotype (odds ratio 1.2; 95% CI 0.8-1.8).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28420302\">",
"    <span class=\"h2\">",
"     Prothrombin Yukuhashi",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prothrombin Yukuhashi (Arg596Leu) was found in a Japanese thrombophilic family. The mutant prothrombin had moderately lower, but adequate, activity than wild-type prothrombin, but formation of the thrombin-antithrombin complex was substantially impaired in the presence and absence of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/16/20743/abstract/49\">",
"     49",
"    </a>",
"    ]. It was postulated that prothrombin Arg596Leu mutation leads to generation of a thrombin molecule with prolonged procoagulant activity in vivo as a consequence of being resistant to inactivation by antithrombin, thereby conferring an increased susceptibility to thrombosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17203351\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prothrombin gene mutation is a guanine to adenine transition at nucleotide 20210 in the 3' untranslated region of prothrombin. Heterozygous carriers have 30 percent higher plasma prothrombin levels than normals. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Prothrombin gene'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Prevalence",
"      </strong>",
"      &mdash; The proportion of the white population heterozygous for the allele varies from 0.7 percent to 6.5 percent, with the highest prevalence rates reported in Spain. The mutation is extremely rare in the nonwhite (black or Asian) population. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Prevalence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Thrombotic risk",
"      </strong>",
"      &mdash; In the Leiden Thrombophilia Study, the prothrombin gene mutation independently conferred a 2.8-fold increased risk of venous thrombosis (",
"      <a class=\"graphic graphic_table graphicRef56252 \" href=\"UTD.htm?21/4/21579\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Risk of thrombosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The common presence of two thrombophilic defects (eg, factor V Leiden and the prothrombin gene mutation) increases the thrombotic risk three- to fivefold above the risk of a single defect.",
"     </li>",
"     <li>",
"      The prothrombin gene mutation may be a risk factor for deep vein thrombosis in pregnant women and for cerebral vein thrombosis, especially in those taking oral contraceptives.",
"     </li>",
"     <li>",
"      It is controversial whether heterozygous carriers have an increase in the rate of",
"      <strong>",
"       recurrent",
"      </strong>",
"      venous thromboembolism. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Risk of recurrent DVT'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The prothrombin gene mutation is not a risk factor for cerebrovascular ischemic disease in older patients, but may be a risk factor in younger patients. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Arterial thrombosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Diagnosis",
"      </strong>",
"      &mdash; Polymerase chain reaction methods have been used to detect the G20210A prothrombin gene mutation in genomic DNA. Plasma prothrombin concentrations cannot be used to screen for the prothrombin gene mutation, due to significant overlap with the normal population. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20743/abstract/1\">",
"      Mateo J, Oliver A, Borrell M, et al. Laboratory evaluation and clinical characteristics of 2,132 consecutive unselected patients with venous thromboembolism--results of the Spanish Multicentric Study on Thrombophilia (EMET-Study). Thromb Haemost 1997; 77:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20743/abstract/2\">",
"      Margaglione M, Brancaccio V, Giuliani N, et al. Increased risk for venous thrombosis in carriers of the prothrombin G--&gt;A20210 gene variant. Ann Intern Med 1998; 129:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20743/abstract/3\">",
"      Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88:3698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20743/abstract/4\">",
"      Soria JM, Almasy L, Souto JC, et al. Linkage analysis demonstrates that the prothrombin G20210A mutation jointly influences plasma prothrombin levels and risk of thrombosis. Blood 2000; 95:2780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20743/abstract/5\">",
"      Carter AM, Sachchithananthan M, Stasinopoulos S, et al. Prothrombin G20210A is a bifunctional gene polymorphism. Thromb Haemost 2002; 87:846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20743/abstract/6\">",
"      Pollak ES, Lam HS, Russell JE. The G20210A mutation does not affect the stability of prothrombin mRNA in vivo. Blood 2002; 100:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20743/abstract/7\">",
"      Gehring NH, Frede U, Neu-Yilik G, et al. Increased efficiency of mRNA 3' end formation: a new genetic mechanism contributing to hereditary thrombophilia. Nat Genet 2001; 28:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20743/abstract/8\">",
"      Leroyer C, Mercier B, Oger E, et al. Prevalence of 20210 A allele of the prothrombin gene in venous thromboembolism patients. Thromb Haemost 1998; 80:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20743/abstract/9\">",
"      Bowen DJ, Bowley S, John M, Collins PW. Factor V Leiden (G1691A), the prothrombin 3'-untranslated region variant (G20210A) and thermolabile methylenetetrahydrofolate reductase (C677T): a single genetic test genotypes all three loci--determination of frequencies in the S. Wales population of the UK. Thromb Haemost 1998; 79:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20743/abstract/10\">",
"      Kapur RK, Mills LA, Spitzer SG, Hultin MB. A prothrombin gene mutation is significantly associated with venous thrombosis. Arterioscler Thromb Vasc Biol 1997; 17:2875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20743/abstract/11\">",
"      Hillarp A, Z&ouml;ller B, Svensson PJ, Dahlb&auml;ck B. The 20210 A allele of the prothrombin gene is a common risk factor among Swedish outpatients with verified deep venous thrombosis. Thromb Haemost 1997; 78:990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20743/abstract/12\">",
"      Souto JC, Coll I, Llobet D, et al. The prothrombin 20210A allele is the most prevalent genetic risk factor for venous thromboembolism in the Spanish population. Thromb Haemost 1998; 80:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20743/abstract/13\">",
"      Rosendaal FR, Doggen CJ, Zivelin A, et al. Geographic distribution of the 20210 G to A prothrombin variant. Thromb Haemost 1998; 79:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20743/abstract/14\">",
"      Miyata T, Kawasaki T, Fujimura H, et al. The prothrombin gene G20210A mutation is not found among Japanese patients with deep vein thrombosis and healthy individuals. Blood Coagul Fibrinolysis 1998; 9:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20743/abstract/15\">",
"      Zivelin A, Rosenberg N, Faier S, et al. A single genetic origin for the common prothrombotic G20210A polymorphism in the prothrombin gene. Blood 1998; 92:1119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20743/abstract/16\">",
"      Zivelin A, Griffin JH, Xu X, et al. A single genetic origin for a common Caucasian risk factor for venous thrombosis. Blood 1997; 89:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20743/abstract/17\">",
"      Arruda VR, Annichino-Bizzacchi JM, Gon&ccedil;alves MS, Costa FF. Prevalence of the prothrombin gene variant (nt20210A) in venous thrombosis and arterial disease. Thromb Haemost 1997; 78:1430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20743/abstract/18\">",
"      Chamouard P, Pencreach E, Maloisel F, et al. Frequent factor II G20210A mutation in idiopathic portal vein thrombosis. Gastroenterology 1999; 116:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20743/abstract/19\">",
"      Emmerich J, Rosendaal FR, Cattaneo M, et al. Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism--pooled analysis of 8 case-control studies including 2310 cases and 3204 controls. Study Group for Pooled-Analysis in Venous Thromboembolism. Thromb Haemost 2001; 86:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20743/abstract/20\">",
"      Zoller B, Svensson PJ, Dahlback B, Hillarp A. The A20210 allele of the prothrombin gene is frequently associated with the factor V Arg 506 to Gln mutation but not with protein S deficiency in thrombophilic families. Blood 1998; 91:2210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20743/abstract/21\">",
"      Makris M, Preston FE, Beauchamp NJ, et al. Co-inheritance of the 20210A allele of the prothrombin gene increases the risk of thrombosis in subjects with familial thrombophilia. Thromb Haemost 1997; 78:1426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20743/abstract/22\">",
"      De Stefano V, Martinelli I, Mannucci PM, et al. The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation. N Engl J Med 1999; 341:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20743/abstract/23\">",
"      Ehrenforth S, Ludwig G, Klinke S, et al. The prothrombin 20210 A allele is frequently coinherited in young carriers of the factor V Arg 506 to Gln mutation with venous thrombophilia. Blood 1998; 91:2209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20743/abstract/24\">",
"      Simioni P, Prandoni P, Lensing AW, et al. Risk for subsequent venous thromboembolic complications in carriers of the prothrombin or the factor V gene mutation with a first episode of deep-vein thrombosis. Blood 2000; 96:3329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20743/abstract/25\">",
"      Lindmarker P, Schulman S, Sten-Linder M, et al. The risk of recurrent venous thromboembolism in carriers and non-carriers of the G1691A allele in the coagulation factor V gene and the G20210A allele in the prothrombin gene. DURAC Trial Study Group. Duration of Anticoagulation. Thromb Haemost 1999; 81:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20743/abstract/26\">",
"      Eichinger S, Minar E, Hirschl M, et al. The risk of early recurrent venous thromboembolism after oral anticoagulant therapy in patients with the G20210A transition in the prothrombin gene. Thromb Haemost 1999; 81:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20743/abstract/27\">",
"      De Stefano V, Martinelli I, Mannucci PM, et al. The risk of recurrent venous thromboembolism among heterozygous carriers of the G20210A prothrombin gene mutation. Br J Haematol 2001; 113:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20743/abstract/28\">",
"      Ho WK, Hankey GJ, Quinlan DJ, Eikelboom JW. Risk of recurrent venous thromboembolism in patients with common thrombophilia: a systematic review. Arch Intern Med 2006; 166:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20743/abstract/29\">",
"      Vink R, Kraaijenhagen RA, Levi M, B&uuml;ller HR. Individualized duration of oral anticoagulant therapy for deep vein thrombosis based on a decision model. J Thromb Haemost 2003; 1:2523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20743/abstract/30\">",
"      Grandone E, Margaglione M, Colaizzo D, et al. Genetic susceptibility to pregnancy-related venous thromboembolism: roles of factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations. Am J Obstet Gynecol 1998; 179:1324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20743/abstract/31\">",
"      Reuner KH, Ruf A, Grau A, et al. Prothrombin gene G20210--&gt;A transition is a risk factor for cerebral venous thrombosis. Stroke 1998; 29:1765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20743/abstract/32\">",
"      Martinelli I, Sacchi E, Landi G, et al. High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives. N Engl J Med 1998; 338:1793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20743/abstract/33\">",
"      de Bruijn SF, Stam J, Koopman MM, Vandenbroucke JP. Case-control study of risk of cerebral sinus thrombosis in oral contraceptive users and in [correction of who are] carriers of hereditary prothrombotic conditions. The Cerebral Venous Sinus Thrombosis Study Group. BMJ 1998; 316:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20743/abstract/34\">",
"      Bertina RM, Rosendaal FR. Venous thrombosis--the interaction of genes and environment. N Engl J Med 1998; 338:1840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20743/abstract/35\">",
"      Smiles AM, Jenny NS, Tang Z, et al. No association of plasma prothrombin concentration or the G20210A mutation with incident cardiovascular disease: results from the Cardiovascular Health Study. Thromb Haemost 2002; 87:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20743/abstract/36\">",
"      De Stefano V, Chiusolo P, Paciaroni K, et al. Prothrombin G20210A mutant genotype is a risk factor for cerebrovascular ischemic disease in young patients. Blood 1998; 91:3562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20743/abstract/37\">",
"      Lalouschek W, Schillinger M, Hsieh K, et al. Matched case-control study on factor V Leiden and the prothrombin G20210A mutation in patients with ischemic stroke/transient ischemic attack up to the age of 60 years. Stroke 2005; 36:1405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20743/abstract/38\">",
"      Doggen CJ, Cats VM, Bertina RM, Rosendaal FR. Interaction of coagulation defects and cardiovascular risk factors: increased risk of myocardial infarction associated with factor V Leiden or prothrombin 20210A. Circulation 1998; 97:1037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20743/abstract/39\">",
"      Arruda VR, Siquiera LH, Chiaparini LC, et al. Prevalence of the prothrombin gene variant 20210 G --&gt; A among patients with myocardial infarction. Cardiovasc Res 1998; 37:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20743/abstract/40\">",
"      Eikelboom JW, Baker RI, Parsons R, et al. No association between the 20210 G/A prothrombin gene mutation and premature coronary artery disease. Thromb Haemost 1998; 80:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20743/abstract/41\">",
"      Gomez E, van der Poel SC, Jansen JH, et al. Rapid simultaneous screening of factor V Leiden and G20210A prothrombin variant by multiplex polymerase chain reaction on whole blood. Blood 1998; 91:2208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20743/abstract/42\">",
"      Muriel G, Christine B, Philippe J, et al. An even easier method for one-step detection of both FV Leiden and FII G20210A transition. Blood 1998; 92:3478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20743/abstract/43\">",
"      Dunn ST, Allen RA, Bates F, et al. Abnormal melt curve profile during prothrombin 20210G --&gt; A analysis due to the 20209C --&gt; T variant. Blood Coagul Fibrinolysis 2006; 17:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20743/abstract/44\">",
"      Warshawsky I, Makkar V, Rimmerman C, Kottke-Marchant K. Prothrombin 20209C&gt;T: 16 new cases, association with the 19911A&gt;G polymorphism, and literature review. J Thromb Haemost 2009; 7:1585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20743/abstract/45\">",
"      Hooper WC, Roberts S, Dowling N, et al. The prevalence of the prothrombin gene variant C20209T in African-Americans and Caucasians and lack of association with venous thromboembolism. Thromb Res 2006; 118:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20743/abstract/46\">",
"      von Ahsen N, Oellerich M. The intronic prothrombin 19911A&gt;G polymorphism influences splicing efficiency and modulates effects of the 20210G&gt;A polymorphism on mRNA amount and expression in a stable reporter gene assay system. Blood 2004; 103:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20743/abstract/47\">",
"      P&eacute;rez-Ceballos E, Corral J, Alberca I, et al. Prothrombin A19911G and G20210A polymorphisms' role in thrombosis. Br J Haematol 2002; 118:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20743/abstract/48\">",
"      Martinelli I, Battaglioli T, Tosetto A, et al. Prothrombin A19911G polymorphism and the risk of venous thromboembolism. J Thromb Haemost 2006; 4:2582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20743/abstract/49\">",
"      Miyawaki Y, Suzuki A, Fujita J, et al. Thrombosis from a prothrombin mutation conveying antithrombin resistance. N Engl J Med 2012; 366:2390.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1359 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.55.141.10-5088ACF45B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_16_20743=[""].join("\n");
var outline_f20_16_20743=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17203351\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PROTHROMBIN GENE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Prothrombin G20210A",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PREVALENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      RISK OF THROMBOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Deep vein thrombosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Risk of recurrent DVT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Cerebral vein thrombosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Arterial thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      OTHER PROTHROMBIN GENE MUTATIONS AND POLYMORPHISMS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Prothrombin C20209T",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Prothrombin A19911G",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28420302\">",
"      Prothrombin Yukuhashi",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17203351\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/1359\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/1359|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/4/21579\" title=\"table 1\">",
"      Risk factors VTE genetic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/35/28218?source=related_link\">",
"      Activated protein C resistance and factor V Leiden",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/57/14234?source=related_link\">",
"      Diagnosis and treatment of venous thrombosis and thromboembolism in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/41/11930?source=related_link\">",
"      Evaluation of the patient with established venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/5/26714?source=related_link\">",
"      Inherited thrombophilias in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/12/23752?source=related_link\">",
"      Management of inherited thrombophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43786?source=related_link\">",
"      Overview of the causes of venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/26/20903?source=related_link\">",
"      Screening for inherited thrombophilia in asymptomatic populations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/32/20999?source=related_link\">",
"      Vitamin K, gamma carboxyglutamic acid, and the function of coagulation and other proteins",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_16_20744="Left colectomy: Open technique";
var content_f20_16_20744=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Left colectomy: Open technique",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/16/20744/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/16/20744/contributors\">",
"     Anthony MacLean, MD, FRCSC, FACS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/16/20744/contributors\">",
"     W Donald Buie, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/16/20744/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/16/20744/contributors\">",
"     Martin Weiser, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/16/20744/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/16/20744/contributors\">",
"     Rosemary B Duda, MD, MPH, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/16/20744/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 22, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H95928380\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A left hemicolectomy includes resection of the transverse colon left of the middle colic vessels to the level of the upper rectum. A segmental left colectomy is performed when lesser resections are indicated (eg, trauma, polyp), providing the anastomosis is performed in well vascularized bowel.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H95928387\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The indications for a left hemicolectomy include benign conditions (eg, segmental Crohn&rsquo;s colitis, trauma, ischemia, polyps unresectable through a colonoscope) and malignant diseases (eg, distal transverse colon cancer, mid-descending colon cancers). Diverticular disease, typically treated with a sigmoid colon resection, may require a left hemicolectomy if the descending colon is unsuitable for an anastomosis due to active diverticulitis or muscular hypertrophy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H95928417\">",
"    <span class=\"h1\">",
"     PREOPERATIVE PREPARATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H95932770\">",
"    <span class=\"h2\">",
"     Bowel preparation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon the results of 14 randomized trials and 8 meta-analyses, the Canadian Society of Colon and Rectal Surgeons concluded that there is insufficient information to support or refute the omission of a mechanical bowel preparation for patients undergoing elective left-sided open colorectal surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?20/16/20744/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/23/16762?source=see_link&amp;anchor=H125365066#H125365066\">",
"     \"Surgical oncologic principles for the resection of colon cancer\", section on 'Bowel preparation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The authors&rsquo; typical preoperative instructions include a regular diet the day before surgery and a fleet enema one to two hours preoperatively to clear the rectum and lower sigmoid. The enema is omitted in emergency situations and when a mechanical bowel preparation is performed. We order a mechanical bowel preparation when we anticipate that an intraoperative colonoscopy may be required to identify an unmarked, nonpalpable lesion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H95932777\">",
"    <span class=\"h2\">",
"     Prophylactic antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is our practice to give a first generation cephalosporin (typically",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/2/4136?source=see_link\">",
"     cefazolin",
"    </a>",
"    ) as well as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    intravenously within one hour of incision for left colectomy (",
"    <a class=\"graphic graphic_table graphicRef65369 \" href=\"UTD.htm?23/52/24397\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef79097 \" href=\"UTD.htm?22/46/23275\">",
"     table 2",
"    </a>",
"    ). We do not use oral antibiotics or continue prophylaxis postoperatively.",
"   </p>",
"   <p>",
"    The use and timing of antimicrobial prophylaxis for prevention of surgical site infection following gastrointestinal procedures is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/23/18806?source=see_link\">",
"     \"Control measures to prevent surgical site infection following gastrointestinal procedures\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31290?source=see_link&amp;anchor=H10#H10\">",
"     \"Overview of control measures to prevent surgical site infection\", section on 'Timing of prophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H95932784\">",
"    <span class=\"h2\">",
"     Venous thromboembolism prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients undergoing intra-abdominal surgery are at a moderate to high risk for developing a deep venous thrombosis (DVT) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/16/20744/abstract/2\">",
"     2",
"    </a>",
"    ]. All patients scheduled for colonic resection should receive primary prophylaxis. Prevention of DVT is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41802?source=see_link\">",
"     \"Prevention of venous thromboembolic disease in surgical patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H95928440\">",
"    <span class=\"h2\">",
"     Preoperative vaccination",
"    </span>",
"    &nbsp;&mdash;&nbsp;For settings where the surgeon anticipates a splenectomy with the left hemicolectomy (eg, large splenic flexure cancers, local invasion of the spleen), vaccines to protect against Streptococcus pneumonia, Haemophilus influenza type B, and Neisseria meningitides should be administered at least 14 days before the operation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/9/1177?source=see_link&amp;anchor=H4#H4\">",
"     \"Prevention of sepsis in the asplenic patient\", section on 'Immunizations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H95928447\">",
"    <span class=\"h1\">",
"     ANATOMY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H95933378\">",
"    <span class=\"h2\">",
"     Arterial supply",
"    </span>",
"    &nbsp;&mdash;&nbsp;The arterial supply of the left colon has few profuse anastomoses and collateral circulations. The middle colic artery (MCA) and the inferior mesenteric artery (IMA) provide the principle blood supply to the left colon (",
"    <a class=\"graphic graphic_figure graphicRef73756 \" href=\"UTD.htm?40/32/41479\">",
"     figure 1",
"    </a>",
"    ). The marginal artery of Drummond and the arc of Riolan provide collateral blood vessels. Typically, the blood supply of the transverse colon is excellent provided the marginal artery is not damaged.",
"   </p>",
"   <p>",
"    Variability in the arterial anastomoses occurs, which is an important point when performing a segmental resection. The two most tenuous sites and the corresponding arterial supplies include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Splenic flexure &ndash; the ascending branch of the left colic artery (LCA) forms an anastomosis with the left branch of the middle colic artery (MCA), forming the marginal artery. The marginal artery is often very small, and in 11 percent of patients, it is devoid of vasa recta for a length of approximately 1 to 3 cm [",
"      <a class=\"abstract\" href=\"UTD.htm?20/16/20744/abstract/3\">",
"       3",
"      </a>",
"      ]. If used for anastomosis, the area should be examined closely for adequate pulsation (or perfusion) and bleeding prior to anastomosis.",
"     </li>",
"     <li>",
"      Distal descending colon &ndash; the descending branch of the LCA forms an anastomosis with the proximal branch of the upper sigmoid artery. The first sigmoid artery can also arise from the left colic artery. For this reason, when ligating the LCA in a limited resection, the upper sigmoid colon should be resected with the distal descending colon.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H95928469\">",
"    <span class=\"h2\">",
"     Venous and lymphatic drainage",
"    </span>",
"    &nbsp;&mdash;&nbsp;The venous drainage of the left colon is through the inferior mesenteric vein (",
"    <a class=\"graphic graphic_figure graphicRef81960 \" href=\"UTD.htm?3/3/3127\">",
"     figure 2",
"    </a>",
"    ). The lymphatic drainage flows along the left colic artery and the sigmoid vessels to the inferior mesenteric vessels (",
"    <a class=\"graphic graphic_figure graphicRef58219 \" href=\"UTD.htm?38/33/39448\">",
"     figure 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H95933007\">",
"    <span class=\"h1\">",
"     OPEN SURGICAL TECHNIQUE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H95933435\">",
"    <span class=\"h2\">",
"     Optional equipment",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is helpful to have a flexible colonoscope available in the operating room, as it may be needed to identify a cancer or other mucosal lesion if it cannot be palpated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H95928513\">",
"    <span class=\"h2\">",
"     Operative positioning",
"    </span>",
"    &nbsp;&mdash;&nbsp;We prefer that the patient is placed in lithotomy position, though the procedure can also be performed supine. The former allows simultaneous access to the abdomen and perineum for the colorectal anastomosis when using the circular stapler. It also provides additional space for the second assistant and an additional position for the operating surgeon when mobilizing the splenic flexure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H95933462\">",
"    <span class=\"h2\">",
"     Exploration for resectability",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to initiating the resection, the abdomen is thoroughly examined for resectability of the left colon.",
"   </p>",
"   <p>",
"    For patients with cancer, this evaluation includes an assessment of local, regional, and distant disease.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The abdomen is explored for evidence of anomalies",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      metastatic disease, including peritoneal implants, hepatic metastases, and distant nodal metastases.",
"     </li>",
"     <li>",
"      The primary tumor is palpated to confirm its location. Local and regional resectability is determined by assessing tumor invasion into the stomach, major vessels,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      duodenum (",
"      <a class=\"graphic graphic_figure graphicRef60998 \" href=\"UTD.htm?31/6/31846\">",
"       figure 4",
"      </a>",
"      ). The entire colon is palpated to identify synchronous colonic lesions.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H95933022\">",
"    <span class=\"h2\">",
"     Extent of resection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The selection of the operative procedure (eg, left hemicolectomy or segmental resection) is based upon the location of the lesion, malignant or benign indication, blood supply, and venous and lymphatic drainage of the colon [",
"    <a class=\"abstract\" href=\"UTD.htm?20/16/20744/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H921062\">",
"    <span class=\"h3\">",
"     Colectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malignant lesions of the left colon are typically resected with a left hemicolectomy, extending from the distal transverse colon to the upper rectum, 2 to 3 cm above the sacral promontory (",
"    <a class=\"graphic graphic_figure graphicRef53859 \" href=\"UTD.htm?12/46/13028\">",
"     figure 5",
"    </a>",
"    ). For malignant lesions of the splenic flexure, a limited resection extending from the transverse to the sigmoid colon can be performed, but the pedicle of the left colic artery and the first sigmoid branch must be included (",
"    <a class=\"graphic graphic_figure graphicRef75381 \" href=\"UTD.htm?40/51/41779\">",
"     figure 6",
"    </a>",
"    ). The proximal and distal colon segments are divided with a minimum of 5 cm margin of normal colon. The anastomosis is intraperitoneal between well-vascularized colon segments; the presacral plane posterior to the rectum is not entered.",
"   </p>",
"   <p>",
"    Benign lesions may be resected with a hemicolectomy or a segmental resection. For example, extensive benign lesions of the left colon (eg, inflammatory bowel disease, diverticular disease), can be resected with a resection of the colon less extensive than that for a cancer operation, providing the anastomosis is performed in well vascularized bowel (",
"    <a class=\"graphic graphic_figure graphicRef65664 \" href=\"UTD.htm?10/34/10788\">",
"     figure 7",
"    </a>",
"    ). For well-defined benign conditions of the left colon (eg, trauma, diverticular disease, inflammatory bowel disease), a segmental resection with a primary anastomosis in well-vascularized colon and a limited mesenteric resection can be performed (",
"    <a class=\"graphic graphic_figure graphicRef54427 \" href=\"UTD.htm?14/3/14387\">",
"     figure 8",
"    </a>",
"    ). Resection margins must be chosen to ensure adequate blood supply in the remaining colon. (See",
"    <a class=\"local\" href=\"#H95933378\">",
"     'Arterial supply'",
"    </a>",
"    above.) For large polyps that require a surgical resection because of a possible malignancy, the authors perform a formal cancer operation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H921070\">",
"    <span class=\"h3\">",
"     Mesenteric resection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The extent of the mesenteric resection also varies according to the indication for surgery. For example, when performing the resection for malignant lesions, the inferior mesenteric artery is ligated at its origin from the aorta, the inferior mesenteric vein is ligated at the level of the pancreas, and the mesentery and draining lymphatics are removed with the vascular pedicle.",
"   </p>",
"   <p>",
"    A less extensive resection of the mesentery is performed for benign conditions, with the mesenteric vessels ligated close to the colon (",
"    <a class=\"graphic graphic_figure graphicRef65664 \" href=\"UTD.htm?10/34/10788\">",
"     figure 7",
"    </a>",
"    ). However, for settings of severe mesenteric inflammation (eg, diverticulitis, inflammatory bowel disease) and thickening of the mesentery near the bowel wall, a more radical mesenteric dissection may be warranted [",
"    <a class=\"abstract\" href=\"UTD.htm?20/16/20744/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H921078\">",
"    <span class=\"h3\">",
"     Omental resection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The omentum is divided from the transverse colon for most resections. However, when the omentum is involved with a left transverse colon cancer, it must be resected en bloc. The omentum is divided between the colon and the gastroepiploic arcade along the greater curvature of the stomach tying off the epiploic branches (",
"    <a class=\"graphic graphic_figure graphicRef56689 \" href=\"UTD.htm?40/59/41907\">",
"     figure 9",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H920625\">",
"    <span class=\"h2\">",
"     Mobilization of the left colon",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two approaches to resecting the left colon, one begins laterally by mobilizing the colon and progresses medially, while the other begins medially by identifying the lymphovascular bundle and progresses laterally. The approach is at the discretion of the surgeon, although in most settings the lateral to medial approach is performed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H95928534\">",
"    <span class=\"h3\">",
"     Lateral to medial approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;The lateral to medial approach begins by mobilizing the left colon by dividing the lateral peritoneal attachment of the colon and developing the retromesenteric plane. This approach provides early identification and exposure of the ureter and gonadal vessels and is performed for resection of malignant and benign left colon diseases.",
"   </p>",
"   <p>",
"    The general principles for performing a left hemicolectomy, beginning with mobilizing the left colon, include [",
"    <a class=\"abstract\" href=\"UTD.htm?20/16/20744/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Retract the small bowel medially to expose the left colon.",
"     </li>",
"     <li>",
"      Retract the colon medially and incise the peritoneal attachments in the left paracolic gutter just medial to the line of Toldt at the level of the sigmoid colon (",
"      <a class=\"graphic graphic_figure graphicRef69062 \" href=\"UTD.htm?5/52/5953\">",
"       figure 10",
"      </a>",
"      ). A bloodless plane is entered as the mesocolon is lifted away from the investing retroperitoneal fascia, which is left intact.",
"     </li>",
"     <li>",
"      Identify and avoid injury to the left ureter and gonadal vessels in the retroperitoneum (",
"      <a class=\"graphic graphic_figure graphicRef54111 \" href=\"UTD.htm?1/27/1463\">",
"       figure 11",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef65876 \" href=\"UTD.htm?21/59/22454\">",
"       figure 12",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef77687 \" href=\"UTD.htm?40/12/41156\">",
"       figure 13",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef56743 \" href=\"UTD.htm?6/44/6853\">",
"       figure 14",
"      </a>",
"      ). If the ureter is not visible, the dissection may be too deep. Check medially under the reflected peritoneum, as the ureter may have been lifted with the investing retroperitoneal fascia.",
"     </li>",
"     <li>",
"      Incise the peritoneum to the level of the splenic flexure. The peritoneal incision now follows the curve of the colon, remains inferomedial to the spleen, and continues around the corner of the flexure. Divide splenocolic ligaments with scissors or electrocautery to prevent tearing of the splenic capsule.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An alternative approach for obese patients with a thick mesentery or in settings where it is technically difficult to mobilize the splenic flexure is to approach the splenic flexure medially from the midtransverse colon and the dissection continued laterally (",
"    <a class=\"graphic graphic_figure graphicRef81638 \" href=\"UTD.htm?38/22/39265\">",
"     figure 15",
"    </a>",
"    ). For patients with a high splenic flexure, the optimal approach is to mobilize the apex stepwise, alternating the mobilization from the distal transverse colon and proximal descending colon.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rotate the left colon medially to identify the renocolic ligament and divide with scissors or electrocautery to release the mesocolon from Gerota&rsquo;s fascia (",
"      <a class=\"graphic graphic_figure graphicRef56301 \" href=\"UTD.htm?37/16/38145\">",
"       figure 16",
"      </a>",
"      ). Elevating the ligaments over an index finger can facilitate the dissection. Small bleeding points can be cauterized or ligated.",
"     </li>",
"     <li>",
"      Lift and distract the omentum and left transverse colon to create tension on their fusion plane (",
"      <a class=\"graphic graphic_figure graphicRef66463 \" href=\"UTD.htm?27/62/28640\">",
"       figure 17",
"      </a>",
"      ). Use electrocautery to divide the omentum from the epiploica and the superior leaf of the transverse mesocolon. This maneuver permits entry into the lesser sac behind the stomach (",
"      <a class=\"graphic graphic_figure graphicRef75897 \" href=\"UTD.htm?25/62/26594\">",
"       figure 18",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef61843 \" href=\"UTD.htm?12/63/13303\">",
"       figure 19",
"      </a>",
"      ). Dissect medially, separating the omentum from the colon to the middle colic vessels. There should be minimal bleeding when the dissection is performed in the correct plane. Avoid placing the mesocolon under tension by dissecting the reflected edge of the mesocolon as it is lifted off the retroperitoneum.",
"     </li>",
"     <li>",
"      Continue mobilization of the left colon until it is completely free from its retroperitoneal attachments and suspended entirely on its mesentery near the midline.",
"     </li>",
"     <li>",
"      Incise the medial aspect of the mesocolon from the level of the duodenum to the sacral promontory.",
"     </li>",
"     <li>",
"      Identify and clear the inferior mesenteric artery (IMA) of local tissue at its origin from the aorta without injuring the preaortic sympathetic nerves. Doubly ligate the IMA with an absorbable (eg, 0 or 2-0 polyglycolic or polyglactin) or nonabsorbable suture (eg, 0 or 2-0 silk), depending on the surgeon&rsquo;s discretion.",
"     </li>",
"     <li>",
"      Identify and clear the inferior mesenteric vein (IMV) of local tissue as it passes behind the duodenal jejunal junction. Doubly ligate the IMV with an absorbable or nonabsorbable suture as done for the IMA.",
"     </li>",
"     <li>",
"      Divide the mesentery with energy devices (eg, LigaSure&trade;, Harmonic scalpel",
"      <sup>",
"       &reg;",
"      </sup>",
"      ) or sharply divide and ligate with suture ties, depending on surgeon&rsquo;s preference and availability of equipment. Energy devices are costly, faster, and can seal vessels up to 7 mm in diameter, including the pedicles. Avoid tension to ensure a complete vessel seal.",
"     </li>",
"     <li>",
"      Score the mesorectum with electrocautery, clamp and divide the tissue perpendicular to the axis of the bowel between clamps, and secure with 2-0 absorbable suture. Alternatives to the clamp and divide technique include the pinch-burn technique (grasp tissue with forceps and apply electrocautery until vessels are sealed and tissue divided), LigaSure technique, and harmonic scalpel. The mesocolon of the proximal bowel is prepared in a similar fashion. The remaining colon must be well vascularized, pulses must be palpated in the last arcade, and the cut bowel edges must bleed.",
"     </li>",
"     <li>",
"      Divide the proximal and distal bowel between two noncrushing bowel clamps (eg, Doyen intestinal clamp) if performing a hand-sewn anastomosis, or between a transverse bowel clamp and linear stapler if performing a stapled anastomosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H95928541\">",
"    <span class=\"h3\">",
"     Medial to lateral approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;The medial to lateral approach is ideal when the cancer is large",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    adherent to the lateral side wall. The advantages of this approach include maximal time for sharp demarcation between ischemic and well-perfused bowel, lymphovascular pedicle ligated prior to risk of injury by torsion during colon mobilization, and more efficient identification of the resection plane in the setting of severe mesenteric inflammation (eg, diverticulitis, inflammatory bowel disease).",
"   </p>",
"   <p>",
"    The general principles for performing a left hemicolectomy, beginning with the ligation of the inferior mesenteric vessels, include [",
"    <a class=\"abstract\" href=\"UTD.htm?20/16/20744/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Expose the root of the mesenteric vessels by lifting the small bowel medically and superiorly.",
"     </li>",
"     <li>",
"      Incise the peritoneum 1 to 2 cm distal to the origin of the inferior mesenteric artery while placing the sigmoid and descending colon under gentle tension (",
"      <a class=\"graphic graphic_figure graphicRef61892 \" href=\"UTD.htm?32/11/32947\">",
"       figure 20",
"      </a>",
"      ). Extend the peritoneal incision along the sulcus to the sacral promontory. A dissection plane between the retroperitoneum and the mesocolon is developed moving medial to lateral and posterior to the inferior mesenteric artery. The retroperitoneal investing fascia remains intact.",
"     </li>",
"     <li>",
"      Identify the ureter and gonadal vessels sweep structures posteriorly.",
"     </li>",
"     <li>",
"      Continue the dissection laterally behind the mesocolon and colon until the lateral peritoneum is the only remaining structure.",
"     </li>",
"     <li>",
"      Identify and ligate the IMA and IMV as described above (see",
"      <a class=\"local\" href=\"#H95928534\">",
"       'Lateral to medial approach'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Develop the dissection plane superiorly and posterior to the mesocolon, splenic flexure, and left transverse colon. The posterior attachments are divided with electrocautery or scissors.",
"     </li>",
"     <li>",
"      Retract the colon medially and incise the lateral peritoneum beginning at the level of the rectosigmoid colon and extending the incision to the splenic flexure. This dissection plane should meet the plane developed medially between the retroperitoneum and mesocolon.",
"     </li>",
"     <li>",
"      Divide the transverse colon from the omentum, resect the mesentery, and transect the bowel as described above.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H95928548\">",
"    <span class=\"h1\">",
"     RESTORING BOWEL CONTINUITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Options for restoring bowel continuity include an end-to-end or side-to-end colorectal or colocolic anastomosis, which can be either performed with a stapling device or hand-sewn. An alternative anastomosis that can be used between the proximal and distal colon (not rectum) is the functional end-to-end anastomosis, which is technically a side-to-side approach. There is insufficient evidence that any one configuration is better functionally or less likely to leak, or that a stapled colorectal anastomosis is superior to a hand-sewn one [",
"    <a class=\"abstract\" href=\"UTD.htm?20/16/20744/abstract/5\">",
"     5",
"    </a>",
"    ]. The decision is based upon surgeon experience, preference, and available equipment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/23/28024?source=see_link&amp;anchor=H186830037#H186830037\">",
"     \"Right and extended right colectomy: Open technique\", section on 'Restoring bowel continuity'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H95928578\">",
"    <span class=\"h2\">",
"     Hand-sewn anastomosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A single layer hand-sewn closure with absorbable (eg, polyglycolic acid) suture or nonabsorbable (eg, silk, polypropylene) suture is used to create a hand-sewn anastomosis. There is no evidence that a two-layer closure is preferable to a single-layer closure [",
"    <a class=\"abstract\" href=\"UTD.htm?20/16/20744/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. While two-layer closures were routinely performed in the past, a randomized trial of 132 patients undergoing an intestinal anastomosis found that the single-layer closure was associated with similar complication rates for anastomotic leaks (two [3.0 percent] versus one patient [1.5 percent]) and intra-abdominal abscesses (two patients each) compared with a two-layer closure [",
"    <a class=\"abstract\" href=\"UTD.htm?20/16/20744/abstract/8\">",
"     8",
"    </a>",
"    ]. However, the cost of materials and time to sew the anastomosis was significantly less for the single-layer anastomosis.",
"   </p>",
"   <p>",
"    There is no evidence of superiority of one type of suture material compared with another in anastomoses [",
"    <a class=\"abstract\" href=\"UTD.htm?20/16/20744/abstract/9\">",
"     9",
"    </a>",
"    ]. We prefer to use absorbable polyglycolic acid suture for its handling characteristics as well as for its absorption at an appropriate rate. Polyglycolic acid suture retains approximately 60 percent of its strength at day 14, but decreases to less than 3 percent by day 28 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/16/20744/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The technical steps include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Apply a noncrushing intestinal clamp (eg, Doyen) 5 cm proximal to the cut end on the colon side to control spillage. A distal clamp can also be applied. Lembert sutures are placed in the seromuscular tissue with 4-0 silk suture using a running or interrupted technique at the discretion of the surgeon.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If performing the anastomosis with an interrupted technique (",
"    <a class=\"graphic graphic_figure graphicRef70551 \" href=\"UTD.htm?39/4/40014\">",
"     figure 21",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Place the first sutures at the mesenteric and antimesenteric corners.",
"     </li>",
"     <li>",
"      Place sutures 3 to 4 mm apart and 3 to 4 mm back from the edge to invert the bowel.",
"     </li>",
"     <li>",
"      Gently tie sutures to approximate tissue without tension.",
"     </li>",
"     <li>",
"      Additional sutures can be used to buttress any gaps.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If performing the anastomosis with a running technique (",
"    <a class=\"graphic graphic_figure graphicRef80262 \" href=\"UTD.htm?39/41/40606\">",
"     figure 22",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Place one suture at the antimesenteric and another at the mesenteric border.",
"     </li>",
"     <li>",
"      Begin the anastomosis by starting at the antimesenteric border and progress to the mesenteric border, using the seromuscular technique.",
"     </li>",
"     <li>",
"      Turn the bowel over and use mesenteric border suture to complete running anastomosis.",
"     </li>",
"     <li>",
"      An interrupted suture can be used to buttress any gaps.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H173944628\">",
"    <span class=\"h2\">",
"     Stapled anastomosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;An alternative to the hand-sewn is the stapled anastomosis. While a stapled anastomosis is faster to perform, it requires specialized, costly equipment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H95928585\">",
"    <span class=\"h3\">",
"     End-to-end",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most frequently used stapled approach for a colorectal anastomosis is the end-to-end anastomosis. The general principles for performing an end-to-end colorectal anastomosis include (",
"    <a class=\"graphic graphic_figure graphicRef59240 \" href=\"UTD.htm?22/30/23008\">",
"     figure 23",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Place a pursestring suture at the proximal resection margin and insert the anvil of the circular stapler into the lumen. Secure the pursestring around the shaft.",
"     </li>",
"     <li>",
"      Staple the upper rectum transversely with a linear stapler.",
"     </li>",
"     <li>",
"      Insert the trocar of the circular stapler transanally into the rectal stump and advance to the staple line.",
"     </li>",
"     <li>",
"      Extrude the trocar just anterior to the staple line of the rectum under direct vision.",
"     </li>",
"     <li>",
"      Connect the anvil to the instrument, close and fire to create the anastomosis.",
"     </li>",
"     <li>",
"      Remove the stapler transanally and examine the circular margins (also called donuts). The margins must be intact and full thickness for the anastomosis to be constructed properly. The central section of the staple line on the rectum of the rectal stump is excised with the circular stapler. Leaving this staple line intact either anterior or posterior to the circular staple line will compromise the anastomosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H95928592\">",
"    <span class=\"h3\">",
"     Side-to-end",
"    </span>",
"    &nbsp;&mdash;&nbsp;A stapled side-to-end anastomosis is performed when there is a notable size discrepancy between the ends of the bowel, or based upon surgeon&rsquo;s preference. In this situation, the side of the proximal colon is stapled to the end of the distal bowel (eg, upper rectum).",
"   </p>",
"   <p>",
"    The general principles for performing a side-to-end colorectal anastomosis include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Make an enterotomy in the proximal colon, approximately 3 to 4 cm from the end on the antimesenteric border.",
"     </li>",
"     <li>",
"      Insert the anvil into the lumen of the proximal colon, with the stem protruding through the enterotomy and secure with a pursestring suture.",
"     </li>",
"     <li>",
"      Staple the lumen of the proximal bowel with a linear stapler.",
"     </li>",
"     <li>",
"      The trocar is inserted transanally and the procedure completed as described in the preceding section.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H95928599\">",
"    <span class=\"h3\">",
"     Functional end-to-end",
"    </span>",
"    &nbsp;&mdash;&nbsp;This anastomosis can be performed in the setting of a mobile distal colon and is not suitable for a colorectal anastomosis. The proximal and distal resection margins are divided with a linear stapling device in preparation for the anastomosis.",
"   </p>",
"   <p>",
"    The general principles for performing a functional end-to-end colocolic anastomosis include (",
"    <a class=\"graphic graphic_figure graphicRef72031 \" href=\"UTD.htm?37/7/38005\">",
"     figure 24",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Excise the antimesenteric corner of the staple line of the proximal and distal colon.",
"     </li>",
"     <li>",
"      Pass a limb of the linear stapler into each lumen along the antimesenteric border, close and fire to create the anastomosis.",
"     </li>",
"     <li>",
"      Close the remaining enterotomy with a linear stapler, a transverse stapler, or sutures.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H173946411\">",
"    <span class=\"h2\">",
"     Leak testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anastomoses should be tested for leaks. The colocolic anastomosis is submerged in saline to identify an air leak. The colorectal anastomosis is evaluated with rigid proctoscopy while submerging the anastomosis in saline. The staple line is inverted with nonabsorbable sutures if a leak is identified and the assessment process is repeated until no leak is identified.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H95928620\">",
"    <span class=\"h1\">",
"     INTRA-OPERATIVE CHALLENGES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H173946466\">",
"    <span class=\"h2\">",
"     Splenic injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Injury to the spleen can occur during the dissection of the splenic flexure. Management of a splenic injury is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/57/1946?source=see_link&amp;anchor=H12350972#H12350972\">",
"     \"Management of intra-abdominal, pelvic, and genitourinary complications of colorectal surgery\", section on 'Splenic injury'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H173946523\">",
"    <span class=\"h2\">",
"     Ureteral injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;The key to prevention of an injury to the ureter is identification. Management of intra-operative ureteral injuries is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/40/43655?source=see_link\">",
"     \"Surgical repair of an iatrogenic ureteral injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H95928643\">",
"    <span class=\"h2\">",
"     Anastomotic blood supply",
"    </span>",
"    &nbsp;&mdash;&nbsp;The proximal and distal margins should be well vascularized to reduce the risk of an anastomotic dehiscence or leak. If the ends do not bleed, or pulsatile vessels cannot be palpated near the lumens, further proximal",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    distal resection to viable bowel is performed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H95928657\">",
"    <span class=\"h2\">",
"     Synchronous colon cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the uncommon setting of the detection of an unsuspected synchronous colonic cancer, we perform a subtotal colectomy to remove both lesions, including adequate resection margins with high ligation of mesenteric vessels and complete nodal harvest. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/23/16762?source=see_link&amp;anchor=H125358729#H125358729\">",
"     \"Surgical oncologic principles for the resection of colon cancer\", section on 'Subtotal and total colectomy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H173946613\">",
"    <span class=\"h2\">",
"     Synchronous metastatic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical management of synchronous metastatic disease (stage IV) is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/29/19930?source=see_link\">",
"     \"Locoregional methods for management and palliation in patients who present with stage IV colorectal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H95928678\">",
"    <span class=\"h1\">",
"     POSTOPERATIVE MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postoperative management of colectomy patients has evolved, with contemporary emphasis on early postoperative feeding, early ambulation, reduction of perioperative fluid volume, pain management and avoidance of intra-abdominal drains [",
"    <a class=\"abstract\" href=\"UTD.htm?20/16/20744/abstract/10-17\">",
"     10-17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H95928686\">",
"    <span class=\"h2\">",
"     Fast track programs",
"    </span>",
"    &nbsp;&mdash;&nbsp;The components and results of fast-track protocols are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/3/25656?source=see_link\">",
"     \"Fast-track protocols in colorectal surgery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/23/28024?source=see_link&amp;anchor=H186830109#H186830109\">",
"     \"Right and extended right colectomy: Open technique\", section on '\"Fast track\" Postoperative management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H95928693\">",
"    <span class=\"h2\">",
"     Thromboprophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Venous thromboprophylaxis is continued postoperatively until discharge. For high-risk patients (eg, cancer), we continue prophylaxis for 30 days with low molecular weight",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    . The prevention of venous thromboembolism is reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41802?source=see_link&amp;anchor=H9#H9\">",
"     \"Prevention of venous thromboembolic disease in surgical patients\", section on 'Prevention of VTE'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41802?source=see_link&amp;anchor=H17#H17\">",
"     \"Prevention of venous thromboembolic disease in surgical patients\", section on 'Pharmacologic agents for VTE prevention'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H173946965\">",
"    <span class=\"h2\">",
"     Unanticipated splenectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;If a splenectomy is performed without prophylaxis, immunizations to avoid sepsis should be administered no sooner than 14 days after the procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?20/16/20744/abstract/18\">",
"     18",
"    </a>",
"    ]. Immunization and prevention of sepsis in the asplenic patient is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/9/1177?source=see_link\">",
"     \"Prevention of sepsis in the asplenic patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H95928714\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications of a left colectomy include anastomotic leak, intra-abdominal abscess, fistula, hemorrhage, bowel obstruction, and wound infection as well as complications of general anesthesia. The frequency and management of intra-abdominal complications, including anastomotic complications, of colorectal surgery are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/57/1946?source=see_link\">",
"     \"Management of intra-abdominal, pelvic, and genitourinary complications of colorectal surgery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/5/4186?source=see_link\">",
"     \"Management of anastomotic complications of colorectal surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H95932936\">",
"    <span class=\"h2\">",
"     Physiologic consequences",
"    </span>",
"    &nbsp;&mdash;&nbsp;The vast majority of patients tolerate a partial colon resection (eg, left colectomy, right colectomy, sigmoid colectomy) with only minor physiologic consequences related to fluid absorption, such as temporary loose stools and increased frequency of bowel movements [",
"    <a class=\"abstract\" href=\"UTD.htm?20/16/20744/abstract/19-21\">",
"     19-21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H95928742\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A left hemicolectomy includes the resection of the transverse colon left of the middle colic vessels to the level of the upper rectum.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The indications for a left colectomy include benign conditions (eg, segmental Crohn&rsquo;s colitis, trauma, ischemia, polyps unresectable through a colonoscope) and malignant diseases (eg, distal transverse colon cancer, mid-descending colon cancers). (See",
"      <a class=\"local\" href=\"#H95928387\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Intra-operative challenges include splenic injury, ureteral injury, inadequate blood supply to resection margins, and synchronous unanticipated colon cancers. (See",
"      <a class=\"local\" href=\"#H95928620\">",
"       'Intra-operative challenges'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The continuity of bowel is restored with a colocolic or colorectal anastomosis, depending on the length of the distal bowel available for an anastomosis. At the surgeon&rsquo;s discretion, the anastomosis can be performed hand-sewn or stapled, using an end-to-end or end-to-side approach. A functional side-to-side anastomosis is an alternative approach for a colocolic anastomosis with mobile distal bowel. (See",
"      <a class=\"local\" href=\"#H95928548\">",
"       'Restoring bowel continuity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We use a &ldquo;fast track&rdquo; protocol for postoperative management. This includes oral feedings on postoperative day one, solid foods on postoperative day two, early ambulation, and discharge as tolerated. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/3/25656?source=see_link\">",
"       \"Fast-track protocols in colorectal surgery\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20744/abstract/1\">",
"      Eskicioglu C, Forbes SS, Fenech DS, et al. Preoperative bowel preparation for patients undergoing elective colorectal surgery: a clinical practice guideline endorsed by the Canadian Society of Colon and Rectal Surgeons. Can J Surg 2010; 53:385.",
"     </a>",
"    </li>",
"    <li>",
"     Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, Colwell CW. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133:381S-453S.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20744/abstract/3\">",
"      Meyers MA. Griffiths' point: critical anastomosis at the splenic flexure. Significance in ischemia of the colon. AJR Am J Roentgenol 1976; 126:77.",
"     </a>",
"    </li>",
"    <li>",
"     Sonoda T, Milsom JW.  Section 5: Gastrointestinal tract and abdomen. Chapter 34: Segmental colon resection.ACS Surgery: Principles and Practice file://www.acssurgery.com/acs/chapters/ch0534.htm (Accessed on November 07, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20744/abstract/5\">",
"      Neutzling CB, Lustosa SA, Proenca IM, et al. Stapled versus handsewn methods for colorectal anastomosis surgery. Cochrane Database Syst Rev 2012; 2:CD003144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20744/abstract/6\">",
"      Everett WG. A comparison of one layer and two layer techniques for colorectal anastomosis. Br J Surg 1975; 62:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20744/abstract/7\">",
"      Goligher JC, Lee PW, Simpkins KC, Lintott DJ. A controlled comparison one- and two-layer techniques of suture for high and low colorectal anastomoses. Br J Surg 1977; 64:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20744/abstract/8\">",
"      Burch JM, Franciose RJ, Moore EE, et al. Single-layer continuous versus two-layer interrupted intestinal anastomosis: a prospective randomized trial. Ann Surg 2000; 231:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20744/abstract/9\">",
"      Outlaw KK, Vela AR, O'Leary JP. Breaking strength and diameter of absorbable sutures after in vivo exposure in the rat. Am Surg 1998; 64:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20744/abstract/10\">",
"      Delaney CP, Fazio VW, Senagore AJ, et al. 'Fast track' postoperative management protocol for patients with high co-morbidity undergoing complex abdominal and pelvic colorectal surgery. Br J Surg 2001; 88:1533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20744/abstract/11\">",
"      Basse L, Hjort Jakobsen D, Billesb&oslash;lle P, et al. A clinical pathway to accelerate recovery after colonic resection. Ann Surg 2000; 232:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20744/abstract/12\">",
"      Basse L, Thorb&oslash;l JE, L&oslash;ssl K, Kehlet H. Colonic surgery with accelerated rehabilitation or conventional care. Dis Colon Rectum 2004; 47:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20744/abstract/13\">",
"      Behrns KE, Kircher AP, Galanko JA, et al. Prospective randomized trial of early initiation and hospital discharge on a liquid diet following elective intestinal surgery. J Gastrointest Surg 2000; 4:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20744/abstract/14\">",
"      Di Fronzo LA, Cymerman J, O'Connell TX. Factors affecting early postoperative feeding following elective open colon resection. Arch Surg 1999; 134:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20744/abstract/15\">",
"      DiFronzo LA, Yamin N, Patel K, O'Connell TX. Benefits of early feeding and early hospital discharge in elderly patients undergoing open colon resection. J Am Coll Surg 2003; 197:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20744/abstract/16\">",
"      Delaney CP, Zutshi M, Senagore AJ, et al. Prospective, randomized, controlled trial between a pathway of controlled rehabilitation with early ambulation and diet and traditional postoperative care after laparotomy and intestinal resection. Dis Colon Rectum 2003; 46:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20744/abstract/17\">",
"      Khoo CK, Vickery CJ, Forsyth N, et al. A prospective randomized controlled trial of multimodal perioperative management protocol in patients undergoing elective colorectal resection for cancer. Ann Surg 2007; 245:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20744/abstract/18\">",
"      Harji DP, Jaunoo SS, Mistry P, Nesargikar PN. Immunoprophylaxis in asplenic patients. Int J Surg 2009; 7:421.",
"     </a>",
"    </li>",
"    <li>",
"     Pemberton JH PSF. Colonic absorption. Perspectiv Colon Rectal Surg 1, 89-103. 1988.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20744/abstract/20\">",
"      Warner BW. Short- and long-term complications of colectomy. J Pediatr Gastroenterol Nutr 2009; 48 Suppl 2:S72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20744/abstract/21\">",
"      Wright HK. The functional consequences of colectomy. Am J Surg 1975; 130:532.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15008 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-219.243.220.100-C38B34FA94-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_16_20744=[""].join("\n");
var outline_f20_16_20744=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H95928742\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H95928380\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H95928387\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H95928417\">",
"      PREOPERATIVE PREPARATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H95932770\">",
"      Bowel preparation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H95932777\">",
"      Prophylactic antibiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H95932784\">",
"      Venous thromboembolism prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H95928440\">",
"      Preoperative vaccination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H95928447\">",
"      ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H95933378\">",
"      Arterial supply",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H95928469\">",
"      Venous and lymphatic drainage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H95933007\">",
"      OPEN SURGICAL TECHNIQUE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H95933435\">",
"      Optional equipment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H95928513\">",
"      Operative positioning",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H95933462\">",
"      Exploration for resectability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H95933022\">",
"      Extent of resection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H921062\">",
"      - Colectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H921070\">",
"      - Mesenteric resection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H921078\">",
"      - Omental resection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H920625\">",
"      Mobilization of the left colon",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H95928534\">",
"      - Lateral to medial approach",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H95928541\">",
"      - Medial to lateral approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H95928548\">",
"      RESTORING BOWEL CONTINUITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H95928578\">",
"      Hand-sewn anastomosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H173944628\">",
"      Stapled anastomosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H95928585\">",
"      - End-to-end",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H95928592\">",
"      - Side-to-end",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H95928599\">",
"      - Functional end-to-end",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H173946411\">",
"      Leak testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H95928620\">",
"      INTRA-OPERATIVE CHALLENGES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H173946466\">",
"      Splenic injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H173946523\">",
"      Ureteral injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H95928643\">",
"      Anastomotic blood supply",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H95928657\">",
"      Synchronous colon cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H173946613\">",
"      Synchronous metastatic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H95928678\">",
"      POSTOPERATIVE MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H95928686\">",
"      Fast track programs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H95928693\">",
"      Thromboprophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H173946965\">",
"      Unanticipated splenectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H95928714\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H95932936\">",
"      Physiologic consequences",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H95928742\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/15008\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15008|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/32/41479\" title=\"figure 1\">",
"      Blood supply to the colon and rectum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?3/3/3127\" title=\"figure 2\">",
"      Venous drainage of the colon and rectum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/33/39448\" title=\"figure 3\">",
"      Lymphatic drainage of the colon and rectum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/6/31846\" title=\"figure 4\">",
"      Anatomic relationship of colon to surrounding structures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/46/13028\" title=\"figure 5\">",
"      Left colectomy for malignancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/51/41779\" title=\"figure 6\">",
"      Left colon resection for a splenic flexure lesion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/34/10788\" title=\"figure 7\">",
"      Left hemicolectomy for a benign process",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/3/14387\" title=\"figure 8\">",
"      Segmental resection of a benign left colon lesion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/59/41907\" title=\"figure 9\">",
"      Anatomy of the stomach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?5/52/5953\" title=\"figure 10\">",
"      Mobilization of left colon from lateral peritoneal attachments",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/27/1463\" title=\"figure 11\">",
"      Anatomy of the kidney and ureter - male",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/59/22454\" title=\"figure 12\">",
"      Anatomy of the male ureter - lateral view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/12/41156\" title=\"figure 13\">",
"      Anatomy of the ureters - female pelvis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/44/6853\" title=\"figure 14\">",
"      Anatomy of ureters - male pelvis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/22/39265\" title=\"figure 15\">",
"      Mobilization of the splenic flexure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/16/38145\" title=\"figure 16\">",
"      Dissection of the left mesocolon from Gerota fascia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/62/28640\" title=\"figure 17\">",
"      Resection of omentum from transverse colon",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?25/62/26594\" title=\"figure 18\">",
"      Gastrocolic ligament and the lesser sac",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/63/13303\" title=\"figure 19\">",
"      Lesser sac - Sagittal section",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/11/32947\" title=\"figure 20\">",
"      Mobilization of left colon - Medial approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?39/4/40014\" title=\"figure 21\">",
"      Hand-sewn colorectal anastomosis with interrupted sutures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?39/41/40606\" title=\"figure 22\">",
"      Hand-sewn colorectal anastomosis with running sutures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?22/30/23008\" title=\"figure 23\">",
"      Stapled circular colorectal anastomosis - End-to-end",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/7/38005\" title=\"figure 24\">",
"      Functional end to end colocolic stapled anastomosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15008|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/52/24397\" title=\"table 1\">",
"      Antimicrobial prophylaxis for gastrointestinal surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/46/23275\" title=\"table 2\">",
"      Timing of surgical prophylaxis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/23/18806?source=related_link\">",
"      Control measures to prevent surgical site infection following gastrointestinal procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/3/25656?source=related_link\">",
"      Fast-track protocols in colorectal surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/29/19930?source=related_link\">",
"      Locoregional methods for management and palliation in patients who present with stage IV colorectal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/5/4186?source=related_link\">",
"      Management of anastomotic complications of colorectal surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/57/1946?source=related_link\">",
"      Management of intra-abdominal, pelvic, and genitourinary complications of colorectal surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31290?source=related_link\">",
"      Overview of control measures to prevent surgical site infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/9/1177?source=related_link\">",
"      Prevention of sepsis in the asplenic patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41802?source=related_link\">",
"      Prevention of venous thromboembolic disease in surgical patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/23/28024?source=related_link\">",
"      Right and extended right colectomy: Open technique",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/23/16762?source=related_link\">",
"      Surgical oncologic principles for the resection of colon cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/40/43655?source=related_link\">",
"      Surgical repair of an iatrogenic ureteral injury",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_16_20745="High albuminuria (microalbuminuria) and cardiovascular disease";
var content_f20_16_20745=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   High albuminuria (microalbuminuria) and cardiovascular disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/16/20745/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/16/20745/contributors\">",
"     George L Bakris, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/16/20745/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/16/20745/contributors\">",
"     Bernard J Gersh, MB, ChB, DPhil, FRCP, MACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/16/20745/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/16/20745/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/16/20745/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 4, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION, TERMINOLOGY, AND DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The urine dipstick is a relatively insensitive marker for proteinuria, not becoming positive until protein excretion exceeds 300 to 500",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    (upper limit of normal equals less than 150 mg, with most subjects being under 100 mg). Using a specific assay for albumin is a more sensitive technique. The normal rate of albumin excretion is less than 30",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    (20",
"    <span class=\"nowrap\">",
"     &micro;g/min);",
"    </span>",
"    persistent albumin excretion between 30 and 300",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    (20 to 200",
"    <span class=\"nowrap\">",
"     &micro;g/min)",
"    </span>",
"    is called high albuminuria (formerly called &ldquo;microalbuminuria&rdquo;). Albumin excretion above 300",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    (200",
"    <span class=\"nowrap\">",
"     &micro;g/min)",
"    </span>",
"    is considered to represent overt or dipstick positive proteinuria (also called very high albuminuria [formerly called &ldquo;macroalbuminuria&rdquo;]). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/29/5594?source=see_link\">",
"     \"Definition and staging of chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Initial studies demonstrated that high albuminuria (formerly, microalbuminuria) may be the earliest clinical manifestation of diabetic nephropathy in patients with type 1 diabetes, and first begins to appear five years after diagnosis. In comparison, high albuminuria is often present at diagnosis in patients with type 2 diabetes and may reflect underlying cardiovascular disease rather than diabetic nephropathy. Yearly screening for high albuminuria is recommended in patients with both type 1 diabetes (starting five years after disease onset) and type 2 diabetes (starting at disease onset). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42777?source=see_link\">",
"     \"Microalbuminuria in type 1 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/33/39449?source=see_link\">",
"     \"Microalbuminuria in type 2 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to being associated with diabetic nephropathy, high albuminuria has also been associated with cardiovascular disease in both nondiabetic and diabetic patients. These studies will be reviewed here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DETECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Establishing the diagnosis of high albuminuria (formerly, microalbuminuria) requires the demonstration of a",
"    <strong>",
"     persistent",
"    </strong>",
"    elevation in albumin excretion.",
"    <strong>",
"     Transient",
"    </strong>",
"    elevations in the excretion of albumin can be seen in the following settings [",
"    <a class=\"abstract\" href=\"UTD.htm?20/16/20745/abstract/1\">",
"     1",
"    </a>",
"    ] (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/37/13914?source=see_link\">",
"     \"Assessment of urinary protein excretion and evaluation of isolated non-nephrotic proteinuria in adults\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fever",
"     </li>",
"     <li>",
"      Infection",
"     </li>",
"     <li>",
"      Exercise",
"     </li>",
"     <li>",
"      Heart failure",
"     </li>",
"     <li>",
"      Nonspecific joint inflammation",
"     </li>",
"     <li>",
"      Poor glycemic control (hemoglobin A1c greater than 8 percent)",
"     </li>",
"     <li>",
"      Elevation in blood pressure (greater than",
"      <span class=\"nowrap\">",
"       160/100",
"      </span>",
"      mmHg)",
"     </li>",
"     <li>",
"      Hyperlipidemia (LDL cholesterol greater than 120",
"      <span class=\"nowrap\">",
"       mg/dL)",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Urine albumin concentration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although 24-hour urine collection is the gold standard for the detection of high albuminuria (formerly, microalbuminuria) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/16/20745/abstract/1,2\">",
"     1,2",
"    </a>",
"    ], it has been suggested that screening can be more simply achieved by a timed urine collection or an early morning specimen to minimize changes in urine volume that occur during the day [",
"    <a class=\"abstract\" href=\"UTD.htm?20/16/20745/abstract/1\">",
"     1",
"    </a>",
"    ]. High albuminuria is unlikely if the albumin excretion rate is below 20",
"    <span class=\"nowrap\">",
"     &micro;g/min",
"    </span>",
"    in a timed collection or the urine albumin concentration is less than 20 to 30",
"    <span class=\"nowrap\">",
"     mg/L",
"    </span>",
"    in a random specimen. Higher values (particularly those just above this range) may represent false positive results, and should be confirmed by repeated measurements [",
"    <a class=\"abstract\" href=\"UTD.htm?20/16/20745/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are also a variety of semiquantitative dipsticks, such as Clinitek Microalbumin Dipsticks and Micral-Test II test strips, which can be used to test for high albuminuria if urine albumin excretion cannot be directly measured. The reported sensitivity and specificity of these tests range from 80 to 97 percent and 33 to 80 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?20/16/20745/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One problem with measuring the urine albumin concentration or estimating it with a sensitive dipstick is that false negative and false positive results can occur since the urine albumin concentration is determined by the urine volume as well as the amount of albuminuria [",
"    <a class=\"abstract\" href=\"UTD.htm?20/16/20745/abstract/4\">",
"     4",
"    </a>",
"    ]. Thus, at a particular rate of albumin excretion, a substantial increase or decrease in urine volume will respectively lower and raise the urine albumin concentration. The confounding effect of the urine volume can be minimized by repeated measurements on early morning specimens [",
"    <a class=\"abstract\" href=\"UTD.htm?20/16/20745/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Albumin-to-creatinine ratio",
"    </span>",
"    &nbsp;&mdash;&nbsp;The confounding effect of variations in urine volume on the urine albumin concentration can be avoided by calculation of the urine albumin-to-creatinine ratio in an untimed urine specimen. A value 30 to 300",
"    <span class=\"nowrap\">",
"     mg/g",
"    </span>",
"    of creatinine (or, using standard (SI) units, 3.4 to 34",
"    <span class=\"nowrap\">",
"     mg/mmol",
"    </span>",
"    of creatinine) suggests that albumin excretion is between 30 and 300",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    and therefore that high albuminuria (formerly, microalbuminuria) is probably present [",
"    <a class=\"abstract\" href=\"UTD.htm?20/16/20745/abstract/5\">",
"     5",
"    </a>",
"    ]. Values above 300",
"    <span class=\"nowrap\">",
"     mg/g",
"    </span>",
"    (or 34",
"    <span class=\"nowrap\">",
"     mg/mmol)",
"    </span>",
"    are indicative of very high albuminuria (formerly, macroalbuminuria). This classification system requires that at least two of three specimens fall within the high or very high albuminuric range [",
"    <a class=\"abstract\" href=\"UTD.htm?20/16/20745/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one report, 24-hour urine collections and random, single-void urine specimens for albumin and creatinine were obtained in 14 normal subjects, 13 with type 1 diabetes, and 12 with type 2 diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?20/16/20745/abstract/6\">",
"     6",
"    </a>",
"    ]. A close correlation was noted between the two measurements and the within-patient variability was small. A random albumin-to-creatinine ratio above 30",
"    <span class=\"nowrap\">",
"     mg/g",
"    </span>",
"    had a sensitivity of 100 percent for the detection of high albuminuria. Similar findings have been noted by others [",
"    <a class=\"abstract\" href=\"UTD.htm?20/16/20745/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Limitations",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are three important caveats that must be considered to maximize the reliability of the urine albumin-to-creatinine ratio.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vigorous exercise can cause a transient increase in albumin excretion [",
"      <a class=\"abstract\" href=\"UTD.htm?20/16/20745/abstract/8\">",
"       8",
"      </a>",
"      ]. As a result, patients should refrain from vigorous exercise in the 24 hours prior to the test.",
"     </li>",
"     <li>",
"      The optimal time to measure the urine albumin-to-creatinine ratio is uncertain. The best data come from reports that primarily evaluated patients without diabetes. In an initial study, the best correlation with a 24 hour urine collection occurred with samples obtained after the first morning void and before bedtime [",
"      <a class=\"abstract\" href=\"UTD.htm?20/16/20745/abstract/9\">",
"       9",
"      </a>",
"      ]. In contrast, a later and larger study found the best correlation with the first morning void although the difference with collections at other times was not significant [",
"      <a class=\"abstract\" href=\"UTD.htm?20/16/20745/abstract/10\">",
"       10",
"      </a>",
"      ]. Given the uncertainty, we suggest that first morning void specimens are preferred and, if this cannot be done, serial specimens should always be obtained at the same time of day.",
"     </li>",
"     <li>",
"      The accuracy of the urine albumin-to-creatinine ratio will be diminished if creatinine excretion is substantially different from the expected value; this is particularly important in patients with borderline values. Albumin excretion will be underestimated in a muscular man with a high rate of creatinine excretion and overestimated in a cachectic patient in whom muscle mass and creatinine excretion are markedly reduced. The ratio also varies with",
"      <span class=\"nowrap\">",
"       race/ethnicity",
"      </span>",
"      in the United States, as creatinine excretion is significantly higher among non-Hispanic blacks and Mexican Americans than among non-Hispanic whites [",
"      <a class=\"abstract\" href=\"UTD.htm?20/16/20745/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measurement of the urine albumin-to-creatinine ratio in an untimed urinary sample is the preferred screening strategy for high albuminuria (formerly, microalbuminuria) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/16/20745/abstract/1,5,12\">",
"     1,5,12",
"    </a>",
"    ]. This test has the following advantages: it does not require early morning or timed collections, it gives a quantitative result that correlates with the 24-hour urine values over a wide range of protein excretion, it is simple to perform and inexpensive, and repeat values can be easily obtained to ascertain that high albuminuria, if present, is persistent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CORRELATION OF HIGH ALBUMINURIA (MICROALBUMINURIA) WITH CARDIOVASCULAR DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple studies in different patient populations have suggested that, in addition to its relation to renal disease, high albuminuria (formerly, microalbuminuria) is an important risk factor for cardiovascular disease and early cardiovascular mortality in patients with and without diabetes",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?20/16/20745/abstract/13-32\">",
"     13-32",
"    </a>",
"    ]. Among patients with chronic kidney disease, observational studies have suggested a graded increase in coronary risk with the presence of overt proteinuria as measured with a urinary dipstick. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34298?source=see_link\">",
"     \"Chronic kidney disease and coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following observations represent data from different groups of patients, ranging from those with cardiovascular disease to population-based cohorts:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Clinical trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among over 9000 participants at high risk for a cardiovascular event in the HOPE (Heart Outcomes Prevention Evaluation) trial, the presence of high albuminuria (formerly, microalbuminuria) was associated with an increased relative risk of the primary aggregate end point (myocardial infarction (MI), stroke, or cardiovascular death) in those with and without diabetes (1.97 and 1.61, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/16/20745/abstract/13\">",
"     13",
"    </a>",
"    ]. The risk of an adverse cardiovascular event increased progressively with increasing absolute levels of high albuminuria. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/2/29737?source=see_link&amp;anchor=H7#H7\">",
"     \"Blood pressure management in patients with atherosclerotic cardiovascular disease\", section on 'Trials demonstrating benefit'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An increase in risk was also noted a post hoc analysis from the LIFE trial of patients with hypertension and electrocardiographic evidence of left ventricular hypertrophy, the urine albumin-to-creatinine ratio was measured in 7143 nondiabetic subjects (median value 10.2",
"    <span class=\"nowrap\">",
"     mg/g",
"    </span>",
"    creatinine [1.16",
"    <span class=\"nowrap\">",
"     mg/mmol])",
"    </span>",
"    and 1063 subjects with diabetes (median value 26.9",
"    <span class=\"nowrap\">",
"     mg/g",
"    </span>",
"    creatinine [3.05",
"    <span class=\"nowrap\">",
"     mg/mmol])",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/16/20745/abstract/14\">",
"     14",
"    </a>",
"    ]. For every 10-fold increase in the albumin-to-creatinine ratio, the risk of the composite end-point of cardiovascular death, MI, or stroke increased by 57 percent and the risk of cardiovascular death by 98 percent among nondiabetics. The respective increases in risk for diabetics were 39 and 47 percent. A subsequent analysis of this trial showed that the risk of the composite end-point of cardiovascular death, MI, or stroke was reduced among participants who had a substantial reduction in high albuminuria at the one-year follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?20/16/20745/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Population-based studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of population-based studies have identified high albuminuria (formerly, microalbuminuria) as a significant predictor of cardiovascular risk [",
"    <a class=\"abstract\" href=\"UTD.htm?20/16/20745/abstract/15,16,34\">",
"     15,16,34",
"    </a>",
"    ]. In an analysis from the PREVEND study, urinary albumin excretion was measured in a general population sample of 40,548 participants who were followed for a median of 2.6 years [",
"    <a class=\"abstract\" href=\"UTD.htm?20/16/20745/abstract/15\">",
"     15",
"    </a>",
"    ]. There were 518 deaths (1.3 percent) of which 178 were cardiovascular deaths (0.4 percent). When adjusted for age and sex, there was a graded increase in the relative risk of cardiovascular mortality of 1.35 for each doubling of urinary albumin excretion. A potential limitation of this study is that the urine albumin concentration, rather than the albumin-to-creatinine ratio was used.",
"   </p>",
"   <p>",
"    The mortality risk in postmenopausal women was evaluated in a population-based cohort study of 12,239 postmenopausal women [",
"    <a class=\"abstract\" href=\"UTD.htm?20/16/20745/abstract/16\">",
"     16",
"    </a>",
"    ]. Cardiovascular mortality was increased in those in the highest quintile of urinary albumin excretion (&gt;21",
"    <span class=\"nowrap\">",
"     mg/g",
"    </span>",
"    creatinine [&gt;2.41",
"    <span class=\"nowrap\">",
"     mg/mmol])",
"    </span>",
"    compared to women without detectable albuminuria (13.2 versus 2.6 per 1000 years, age-adjusted rate ratio 4.4) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/16/20745/abstract/16\">",
"     16",
"    </a>",
"    ]. This relationship was independent of diabetes and hypertension.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     High normal albuminuria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Higher levels of albumin excretion within the normal range, well under the above definitions for high albuminuria (&ge;30",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    [20",
"    <span class=\"nowrap\">",
"     &micro;g/min]",
"    </span>",
"    or urine albumin-to-creatinine ratio &ge;30",
"    <span class=\"nowrap\">",
"     mg/g),",
"    </span>",
"    are associated with an increase in cardiovascular risk that is additive to conventional risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?20/16/20745/abstract/17,18,35-38\">",
"     17,18,35-38",
"    </a>",
"    ]. The following observations illustrated the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the Third Copenhagen Heart Study, 2726 patients underwent a urine collection for measurement of albumin and were followed for the development of coronary heart disease or death [",
"      <a class=\"abstract\" href=\"UTD.htm?20/16/20745/abstract/17\">",
"       17",
"      </a>",
"      ]. Patients in the top quartile of urinary albumin excretion (&gt;4.8",
"      <span class=\"nowrap\">",
"       &micro;g/min",
"      </span>",
"      [6.9",
"      <span class=\"nowrap\">",
"       mg/day])",
"      </span>",
"      had an adjusted relative risk of death of 1.9 and of coronary heart disease of 2.0. Among the hypertensive participants, the cumulative incidence of heart disease (11 versus 5 percent) and mortality (28 versus 13 percent) were significantly increased with urinary albumin excretion &ge;5",
"      <span class=\"nowrap\">",
"       &micro;g/min",
"      </span>",
"      (&gt;7.2",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      compared to values below 5",
"      <span class=\"nowrap\">",
"       &micro;g/min.",
"      </span>",
"      The adjusted relative risk for coronary heart disease and mortality were 2.0 and 1.9, after adjustment for other risk factors.",
"     </li>",
"     <li>",
"      Similar findings with very low levels of albuminuria were noted in a review from the Framingham Heart Study of 1568 nonhypertensive, nondiabetic men and women (mean age 55) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/16/20745/abstract/35\">",
"       35",
"      </a>",
"      ]. At a median follow-up of six years, 54 participants developed a first cardiovascular event and 49 died. Participants with a urine albumin-to-creatinine ratio above the median (&ge;3.9 and &ge;7.5",
"      <span class=\"nowrap\">",
"       mg/g",
"      </span>",
"      in men and women) had a significant increase in the risk of a first cardiovascular event (5.1 versus 1.8 percent, adjusted hazard ratio 2.92, 95% CI 1.57-5.44) and an almost significant increase in mortality (4.2 versus 2.0 percent, adjusted hazard ratio 1.75, 95% CI 0.95-3.22). The increase in risk remained significant in participants with a low or intermediate pretest probability of cardiovascular disease.",
"     </li>",
"     <li>",
"      Another report from the Framingham Heart Study demonstrated the association of high normal albumin excretion with the risks of hypertension and blood pressure progression in 1499 nonhypertensive, nondiabetic individuals [",
"      <a class=\"abstract\" href=\"UTD.htm?20/16/20745/abstract/18\">",
"       18",
"      </a>",
"      ]. At a mean follow-up of 2.9 years, 15 percent developed hypertension and 33 percent progressed to a higher blood pressure category. The odds ratio in the highest quartile of urine albumin-to-creatinine ratio (&gt;6.7 and 15.2",
"      <span class=\"nowrap\">",
"       mg/g",
"      </span>",
"      in men and women, respectively) compared with the lowest quartile was 1.93 and 1.45 for developing hypertension and progressive hypertension, respectively. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/4/4169?source=see_link&amp;anchor=H2#H2\">",
"       \"Hypertension: Who should be treated?\", section on 'Definitions'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a multivariable analysis adjusting for known risk factors, the adjusted odds ratio for developing hypertension was 1.20 for every 1 standard deviation in urine albumin-to-creatinine ratio. Compared to those in the lowest urine albumin-to-creatinine ratio quartile, individuals in the highest quintile (men 6.6",
"    <span class=\"nowrap\">",
"     mg/g,",
"    </span>",
"    women 15.4",
"    <span class=\"nowrap\">",
"     mg/g)",
"    </span>",
"    had an adjusted odds ratio of 1.93 for developing hypertension and 1.45 for blood pressure progression.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     ST and T wave changes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of high albuminuria (formerly, microalbuminuria) also enhances the predictive value of ST and T wave changes for cardiovascular disease. This was illustrated in another analysis from the population-based PREVEND study [",
"    <a class=\"abstract\" href=\"UTD.htm?20/16/20745/abstract/19\">",
"     19",
"    </a>",
"    ]. Among 7330 subjects, 1244 had ST-T changes; 885 had high albuminuria (mean albumin excretion 53",
"    <span class=\"nowrap\">",
"     mg/day);",
"    </span>",
"    and 223 had both. At a median follow-up of six years, the patients with both ST-T changes and high albuminuria compared to those with ST-T changes alone had marked increases in the incidence of all-cause mortality (7.2 versus 1.1 percent) and cardiovascular mortality (2.7 versus 0.5 percent). High albuminuria had a greater impact on the risk of all-cause mortality than hypertension, hypercholesterolemia, cigarette smoking, obesity, or diabetes mellitus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Possible mechanisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;How high albuminuria (formerly, microalbuminuria) is associated with cardiovascular disease is not well understood. High albuminuria in nondiabetic patients appears to be a signal from the kidney that the vasculature, particularly the endothelium, is not functioning normally. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vasodilation in response to certain stimuli is relatively reduced in older \"normal individuals\" with high albuminuria compared to those with lower levels of albumin excretion [",
"      <a class=\"abstract\" href=\"UTD.htm?20/16/20745/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Among nondiabetic patients with essential hypertension, those with high albuminuria had higher plasma levels of von Willebrand factor (vWf) antigen than patients with normal albumin excretion [",
"      <a class=\"abstract\" href=\"UTD.htm?20/16/20745/abstract/40\">",
"       40",
"      </a>",
"      ]; furthermore, individual vWf and albumin excretion values were significantly correlated. vWf has been associated with occlusive thrombosis; thus, the increased plasma vWf levels might directly contribute to the enhanced cardiovascular risk.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Endothelial dysfunction is also present in diabetic patients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/16/20745/abstract/21\">",
"     21",
"    </a>",
"    ] and the degree of coronary endothelial dysfunction appears to be greater in patients with high albuminuria [",
"    <a class=\"abstract\" href=\"UTD.htm?20/16/20745/abstract/41\">",
"     41",
"    </a>",
"    ]. One important factor may be hyperglycemia-induced alterations in extracellular matrix, such as decreased density of heparan sulfate proteoglycans. This abnormality can lead to increased microvascular permeability, resulting in high albuminuria at the glomerulus and perhaps increased lipoprotein deposition in peripheral vessels.",
"   </p>",
"   <p>",
"    The apparent association between high albuminuria and cardiovascular disease is in part related to an adverse risk factor profile in patients with and without diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?20/16/20745/abstract/25,42-45\">",
"     25,42-45",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the Cardiovascular Health Study of almost 1100 older adults who did not have diabetes mellitus or hypertension, high albuminuria was associated with increasing age, increasing systolic blood pressure, and inflammatory markers (such as C-reactive protein levels) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/16/20745/abstract/42\">",
"       42",
"      </a>",
"      ]. The importance of blood pressure was also noted in report of almost 8800 individuals without diabetes mellitus or hypertension in the Third National Health and Nutrition Examination Survey (NHANES) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/16/20745/abstract/43\">",
"       43",
"      </a>",
"      ]. Compared to optimal blood pressure",
"      <span class=\"nowrap\">",
"       (&lt;120/&lt;80",
"      </span>",
"      mmHg), high-normal blood pressure (130 to",
"      <span class=\"nowrap\">",
"       139/85",
"      </span>",
"      to 89 mmHg) was associated with a significant increase in the risk of high albuminuria (odds ratio 1.3 per 10 mmHg increase in systolic or diastolic pressure). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/0/27658?source=see_link\">",
"       \"C-reactive protein in cardiovascular disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In a cross-sectional analysis of 1160 patients with type 1 diabetes in the Diabetes Control and Complications Trial, as progressive increases in albuminuria were associated with elevations in proatherogenic intermediate-density lipoprotein and small dense LDL particles [",
"      <a class=\"abstract\" href=\"UTD.htm?20/16/20745/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a cross-sectional study of patients with type 2 diabetes with preserved kidney function (median GFR 87",
"      <span class=\"nowrap\">",
"       ml/min",
"      </span>",
"      per 1.73 m2), the urine albumin-to-creatinine ratio (ACR) was positively correlated with coronary and carotid artery calcification as defined by scores derived from computed tomography [",
"      <a class=\"abstract\" href=\"UTD.htm?20/16/20745/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     CORRELATION OF CARDIOVASCULAR DISEASE WITH HIGH ALBUMINURIA (MICROALBUMINURIA)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The association between high albuminuria (formerly, microalbuminuria) and cardiovascular disease also extends to the development of high albuminuria",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    progression to clinical proteinuria among patients at high cardiovascular risk. This was shown in a retrospective analysis of the HOPE trial, in which 1859 of 7674 patients either developed new high albuminuria (1542 patients) or new clinical proteinuria (317 participants) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/16/20745/abstract/46\">",
"     46",
"    </a>",
"    ]. Enrolled patients were at high risk for adverse cardiovascular outcomes, which was defined as either:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Evidence of vascular disease, including coronary heart disease (81 percent, with a prior history of MI in 53 percent), stroke, or peripheral vascular disease",
"      <strong>",
"       OR",
"      </strong>",
"     </li>",
"     <li>",
"      Diabetes and at least one other coronary risk factor (serum total cholesterol above 200",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [5.2",
"      <span class=\"nowrap\">",
"       mmol/L],",
"      </span>",
"      low serum HDL cholesterol, hypertension [present in 56 percent], high albuminuria, or current smoking).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/37/24152?source=see_link\">",
"     ramipril",
"    </a>",
"    , compared to placebo, decreased the risk for renal progression (odds ratio 0.87). It is not clear if the benefit was derived from angiotensin converting enzyme inhibition or from blood pressure lowering. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/2/29737?source=see_link&amp;anchor=H7#H7\">",
"     \"Blood pressure management in patients with atherosclerotic cardiovascular disease\", section on 'Trials demonstrating benefit'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SCREENING",
"    </span>",
"    &nbsp;&mdash;&nbsp;We test for high albuminuria (formerly, microalbuminuria) among diabetic patients to screen for cardiovascular risk and to look for changes over time that would indicate the presence of nephropathy. High albuminuria is often present at diagnosis in patients with type 2 diabetes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/33/39449?source=see_link\">",
"     \"Microalbuminuria in type 2 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We also screen for high albuminuria among nondiabetic patients at increased risk for chronic kidney disease and cardiovascular disease, such as those with hypertension and the metabolic syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?20/16/20745/abstract/47\">",
"     47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32954?source=see_link\">",
"     \"The metabolic syndrome (insulin resistance syndrome or syndrome X)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As described above, there is evidence of an increase in mortality risk with high albuminuria that is independent of diabetes and hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?20/16/20745/abstract/15,16,32\">",
"     15,16,32",
"    </a>",
"    ]. Nevertheless, we do",
"    <strong>",
"     NOT",
"    </strong>",
"    screen for high albuminuria in the general population of nondiabetic patients without any such risk factors, since the value of screening in these patients is unclear; the ability of any therapies to provide benefit in this setting is unknown, and it is not cost effective [",
"    <a class=\"abstract\" href=\"UTD.htm?20/16/20745/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is increasing evidence that even mild chronic kidney disease (serum creatinine &ge;1.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [133",
"    <span class=\"nowrap\">",
"     &micro;mol/L]",
"    </span>",
"    or estimated glomerular filtration rate &le;60",
"    <span class=\"nowrap\">",
"     mL/min)",
"    </span>",
"    is associated with an increased risk of cardiovascular disease. As a result, chronic kidney disease is considered by many to be a coronary equivalent that should be managed according to secondary prevention goals. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34298?source=see_link\">",
"     \"Chronic kidney disease and coronary heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40906?source=see_link\">",
"     \"Secondary prevention of cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The KDIGO guidelines suggest that high albuminuria (formerly, microalbuminuria) alone that persists for more than three months falls within the definition of chronic kidney disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/29/5594?source=see_link\">",
"     \"Definition and staging of chronic kidney disease\"",
"    </a>",
"    .) Some authorities disagree, suggesting that isolated high albuminuria (without a reduction in glomerular filtration rate) represents generalized endothelial dysfunction.",
"   </p>",
"   <p>",
"    Regardless of whether high albuminuria alone represents chronic kidney disease, it is clearly associated with an increase in cardiovascular risk as described above. Both high albuminuria and overt proteinuria (very high albuminuria) are treated in diabetic patients to slow the progression of diabetic nephropathy. In comparison, it is not certain that treatment specifically aimed at lowering albumin excretion in nondiabetics with high albuminuria would be beneficial. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42777?source=see_link\">",
"     \"Microalbuminuria in type 1 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/48/40714?source=see_link\">",
"     \"Treatment of diabetic nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Antihypertensive drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have examined the effects of antihypertensive therapy on high albuminuria (formerly, microalbuminuria) and clinical cardiovascular outcomes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the PREVEND IT trial, 846 normotensive patients with \"normal\" serum cholesterol (mean total cholesterol 223",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [5.8",
"      <span class=\"nowrap\">",
"       mmol/L]),",
"      </span>",
"      mean LDL cholesterol 154 [4.0",
"      <span class=\"nowrap\">",
"       mmol/L],",
"      </span>",
"      and high albuminuria [15 to 300",
"      <span class=\"nowrap\">",
"       mg/24",
"      </span>",
"      hours] were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/30/16872?source=see_link\">",
"       fosinopril",
"      </a>",
"      or placebo and to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/27/25016?source=see_link\">",
"       pravastatin",
"      </a>",
"      or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?20/16/20745/abstract/49\">",
"       49",
"      </a>",
"      ]. This was largely a primary prevention study since only 3.4 percent had a history of a prior cardiovascular event.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    At follow-up of almost four years,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/30/16872?source=see_link\">",
"     fosinopril",
"    </a>",
"    significantly lowered urinary protein excretion and was associated with a nonsignificant trend toward a lower rate of the primary end point of cardiovascular mortality or hospitalization for cardiovascular morbidity (hazard ratio 0.60, 95% CI of 0.33 to 1.10). Similar findings were noted in two post-hoc subset analyses of the LIFE trial, reductions in baseline albuminuria, which were more pronounced with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/35/26168?source=see_link\">",
"     losartan",
"    </a>",
"    than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"     atenolol",
"    </a>",
"    , were associated with enhanced cardiovascular benefits [",
"    <a class=\"abstract\" href=\"UTD.htm?20/16/20745/abstract/33,50\">",
"     33,50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Reduced protein excretion with angiotensin converting enzyme inhibitors is well described in nondiabetic patients, while the possible cardiovascular benefit in PREVEND IT may have resulted from a significantly lower blood pressure",
"    <span class=\"nowrap\">",
"     (129/76",
"    </span>",
"    versus",
"    <span class=\"nowrap\">",
"     132/78",
"    </span>",
"    mmHg for placebo), rather than a specific effect of angiotensin II inhibition. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41130?source=see_link\">",
"     \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although intriguing, further study is required to determine whether therapy specifically aimed at decreasing albuminuria in nondiabetic patients will improve cardiovascular outcomes.",
"   </p>",
"   <p>",
"    The IMPROVE trial was performed in an attempt order to determine the optimal strategy to reduce albuminuria [",
"    <a class=\"abstract\" href=\"UTD.htm?20/16/20745/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. In this multicenter, randomized trial, 405 hypertensive patients with high albuminuria and increased cardiovascular risk were assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/37/24152?source=see_link\">",
"     ramipril",
"    </a>",
"    alone or ramipril plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/37/21079?source=see_link\">",
"     irbesartan",
"    </a>",
"    . The primary end point was the reduction in albumin excretion rate by week 20; cardiovascular outcomes were not assessed in this trial.",
"   </p>",
"   <p>",
"    The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Combined therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/37/24152?source=see_link\">",
"       ramipril",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/37/21079?source=see_link\">",
"       irbesartan",
"      </a>",
"      was no more effective than ramipril alone in reducing albumin excretion in all patients with albuminuria.",
"     </li>",
"     <li>",
"      Subgroups analysis showed that combined therapy was more effective than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/37/24152?source=see_link\">",
"       ramipril",
"      </a>",
"      alone in reducing albumin excretion rate in patients with overt nephropathy (defined as albuminuria &gt;200",
"      <span class=\"nowrap\">",
"       micrograms/min).",
"      </span>",
"      The small number of patients and the large 95 percent confidence intervals in both groups suggest that these data be interpreted with caution.",
"     </li>",
"     <li>",
"      A greater reduction in both systolic and diastolic blood pressure was achieved in patients who received the combination of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/37/24152?source=see_link\">",
"       ramipril",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/37/21079?source=see_link\">",
"       irbesartan",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      The incidence of adverse effects was similar in both treatment groups.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Statin therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/27/25016?source=see_link\">",
"     pravastatin",
"    </a>",
"    arm of the PREVEND IT trial, pravastatin significantly lowered both total cholesterol (223 to 185",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [5.8 versus 4.8",
"    <span class=\"nowrap\">",
"     mmol/L])",
"    </span>",
"    and LDL cholesterol (158 to 119",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [4.1 versus 3.1",
"    <span class=\"nowrap\">",
"     mmol/L]),",
"    </span>",
"    while there was no change in the placebo group [",
"    <a class=\"abstract\" href=\"UTD.htm?20/16/20745/abstract/49\">",
"     49",
"    </a>",
"    ]. Pravastatin therapy did not reduce albumin excretion and was associated with a nonsignificant 13 percent reduction in the primary cardiovascular end point (5.0 versus 5.7 percent, hazard ratio 0.87, 95% CI 0.49-1.57) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/16/20745/abstract/49\">",
"     49",
"    </a>",
"    ]. However, this study was underpowered for the cardiovascular outcome, and other primary prevention trials in patients with similar baseline lipid levels have shown a significant cardiovascular benefit from statin therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/50/19240?source=see_link\">",
"     \"Clinical trials of cholesterol lowering for primary prevention of coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the absence of clear data, the following represents our usual approach in",
"    <strong>",
"     nondiabetic",
"    </strong>",
"    patients who are noted to have high albuminuria (formerly, microalbuminuria) (see",
"    <a class=\"local\" href=\"#H14\">",
"     'Screening'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Testing for high albuminuria should be repeated at least twice to make certain that it is a persistent abnormality. Possible inflammatory causes should be sought, such as periodontal disease.",
"     </li>",
"     <li>",
"      Among patients with persistent high albuminuria who are hypertensive, we would use an ACE inhibitor or angiotensin II receptor blocker (ARB) because of the greater ability of these drugs to reduce albuminuria compared to other antihypertensive drugs. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42777?source=see_link\">",
"       \"Microalbuminuria in type 1 diabetes mellitus\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41130?source=see_link\">",
"       \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The goal blood pressure is",
"    <span class=\"nowrap\">",
"     &lt;140/&lt;90",
"    </span>",
"    mmHg in the absence of diabetes, renal disease, or cardiovascular disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/40/33417?source=see_link\">",
"     \"What is goal blood pressure in the treatment of hypertension?\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although patients with high albuminuria are at increased coronary risk, there are not data to support a conclusion that the increase in risk is sufficient to call high albuminuria alone a coronary equivalent, as is diabetes and chronic kidney disease. We recommend",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      therapy and suggest consideration of a statin in patients who also have other risk factors for cardiovascular disease. The goal LDL-cholesterol concentration is less than 100",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (2.6",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/8/39048?source=see_link\">",
"       \"Estimation of cardiovascular risk in an individual patient without known cardiovascular disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Albumin excretion should be monitored at regular intervals. Issues related to blood pressure and LDL-cholesterol goals in patients with atherosclerotic cardiovascular disease are discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/2/29737?source=see_link&amp;anchor=H15#H15\">",
"       \"Blood pressure management in patients with atherosclerotic cardiovascular disease\", section on 'Goal blood pressure'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/59/3002?source=see_link\">",
"       \"Intensity of lipid lowering therapy in secondary prevention of coronary heart disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The management of diabetic patients with high albuminuria is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42777?source=see_link\">",
"     \"Microalbuminuria in type 1 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H220350\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      High albuminuria (formerly called &ldquo;microalbuminuria&rdquo;) is defined as persistent albumin excretion between 30 and 300",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      (20 to 200",
"      <span class=\"nowrap\">",
"       &micro;g/min).",
"      </span>",
"      High albuminuria, and even lower levels of albumin excretion (&ge;30",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      [20",
"      <span class=\"nowrap\">",
"       &micro;g/min]",
"      </span>",
"      or urine albumin-to-creatinine ratio &ge;30",
"      <span class=\"nowrap\">",
"       mg/g)",
"      </span>",
"      have been associated with cardiovascular disease that is additive to conventional risk factors in both nondiabetic and diabetic patients. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction, terminology, and definitions'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Correlation of high albuminuria (microalbuminuria) with cardiovascular disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Measurement of the urine albumin-to-creatinine ratio in an untimed urinary sample is the preferred screening strategy for high albuminuria. In order to maximize the reliability of the urine albumin-to-creatinine ratio, patients should refrain from vigorous exercise in the 24 hours prior to the test, since vigorous exercise can cause a transient increase in albumin excretion. In addition, the accuracy of the albumin-to-creatinine ratio will be diminished if creatinine excretion is substantially different from the expected value, such as in a muscular or cachectic individual. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Detection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The mechanism by which high albuminuria is associated with cardiovascular disease is not well understood. However, high albuminuria appears to be a signal that the vasculature, particularly the endothelium, is not functioning normally. Among diabetic patients, the degree of coronary endothelial dysfunction appears to be greater in patients with high albuminuria and may be related to hyperglycemia-induced alterations in extracellular matrix, such as decreased density of heparan sulfate proteoglycans. This abnormality can lead to increased microvascular permeability, resulting in high albuminuria at the glomerulus and perhaps increased lipoprotein deposition in peripheral vessels. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Possible mechanisms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We test for high albuminuria among diabetic patients to screen for cardiovascular risk and to look for changes over time that would indicate the presence of nephropathy. We also screen for high albuminuria among nondiabetic patients at increased risk for chronic kidney disease and cardiovascular disease, such as those with hypertension and the metabolic syndrome. We do",
"      <strong>",
"       NOT",
"      </strong>",
"      screen for high albuminuria in the general population of nondiabetic patients without any such risk factors, since the value of screening in these patients is unclear; the ability of any therapies to provide benefit in this setting is unknown, and it is not cost effective. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Screening'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The KDIGO guidelines suggest that high albuminuria alone that persists for more than three months falls within the definition of chronic kidney disease. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      It is not certain that treatment specifically aimed at lowering albumin excretion in nondiabetics with high albuminuria is beneficial. In the absence of clear data, the following represents our usual approach in",
"      <strong>",
"       nondiabetic",
"      </strong>",
"      patients who have high albuminuria (see",
"      <a class=\"local\" href=\"#H14\">",
"       'Screening'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Testing for high albuminuria should be repeated at least twice to make certain that it is a persistent abnormality. Possible inflammatory causes should be sought, such as periodontal disease. Albumin excretion should be monitored at regular intervals.",
"     </li>",
"     <li>",
"      Among patients with persistent high albuminuria who are hypertensive, we would use an ACE inhibitor or angiotensin II receptor blocker (ARB) because of the greater ability of these drugs to reduce albuminuria compared to other antihypertensive drugs. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42777?source=see_link\">",
"       \"Microalbuminuria in type 1 diabetes mellitus\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41130?source=see_link\">",
"       \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The goal blood pressure is",
"      <span class=\"nowrap\">",
"       &lt;140/&lt;90",
"      </span>",
"      mmHg in the absence of diabetes, renal disease, or cardiovascular disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/40/33417?source=see_link\">",
"       \"What is goal blood pressure in the treatment of hypertension?\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Issues related to blood pressure and LDL-cholesterol goals in patients with atherosclerotic cardiovascular disease are discussed in detail separately. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Recommendations'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/2/29737?source=see_link&amp;anchor=H15#H15\">",
"       \"Blood pressure management in patients with atherosclerotic cardiovascular disease\", section on 'Goal blood pressure'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/59/3002?source=see_link\">",
"       \"Intensity of lipid lowering therapy in secondary prevention of coronary heart disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There are not data to support a conclusion that the increase in risk is sufficient to call high albuminuria alone a coronary equivalent, as is diabetes and chronic kidney disease. We recommend",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      therapy and suggest consideration of a statin in patients who also have other risk factors for cardiovascular disease. The goal LDL-cholesterol concentration is less than 100",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (2.6",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/8/39048?source=see_link\">",
"       \"Estimation of cardiovascular risk in an individual patient without known cardiovascular disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20745/abstract/1\">",
"      Mogensen CE, Vestbo E, Poulsen PL, et al. Microalbuminuria and potential confounders. A review and some observations on variability of urinary albumin excretion. Diabetes Care 1995; 18:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20745/abstract/2\">",
"      Consensus development conference on the diagnosis and management of nephropathy in patients with diabetes mellitus. American Diabetes Association and the National Kidney Foundation. Diabetes Care 1994; 17:1357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20745/abstract/3\">",
"      Comper WD, Osicka TM. Detection of urinary albumin. Adv Chronic Kidney Dis 2005; 12:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20745/abstract/4\">",
"      Schwab SJ, Dunn FL, Feinglos MN. Screening for microalbuminuria. A comparison of single sample methods of collection and techniques of albumin analysis. Diabetes Care 1992; 15:1581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20745/abstract/5\">",
"      K/DOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis 2007; 49(2 Suppl 2):S12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20745/abstract/6\">",
"      Nathan DM, Rosenbaum C, Protasowicki VD. Single-void urine samples can be used to estimate quantitative microalbuminuria. Diabetes Care 1987; 10:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20745/abstract/7\">",
"      Zelmanovitz T, Gross JL, Oliveira JR, et al. The receiver operating characteristics curve in the evaluation of a random urine specimen as a screening test for diabetic nephropathy. Diabetes Care 1997; 20:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20745/abstract/8\">",
"      Jefferson IG, Greene SA, Smith MA, et al. Urine albumin to creatinine ratio-response to exercise in diabetes. Arch Dis Child 1985; 60:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20745/abstract/9\">",
"      Ginsberg JM, Chang BS, Matarese RA, Garella S. Use of single voided urine samples to estimate quantitative proteinuria. N Engl J Med 1983; 309:1543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20745/abstract/10\">",
"      Witte EC, Lambers Heerspink HJ, de Zeeuw D, et al. First morning voids are more reliable than spot urine samples to assess microalbuminuria. J Am Soc Nephrol 2009; 20:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20745/abstract/11\">",
"      Mattix HJ, Hsu CY, Shaykevich S, Curhan G. Use of the albumin/creatinine ratio to detect microalbuminuria: implications of sex and race. J Am Soc Nephrol 2002; 13:1034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20745/abstract/12\">",
"      Eknoyan G, Hostetter T, Bakris GL, et al. Proteinuria and other markers of chronic kidney disease: a position statement of the national kidney foundation (NKF) and the national institute of diabetes and digestive and kidney diseases (NIDDK). Am J Kidney Dis 2003; 42:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20745/abstract/13\">",
"      Gerstein HC, Mann JF, Yi Q, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001; 286:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20745/abstract/14\">",
"      Wachtell K, Ibsen H, Olsen MH, et al. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann Intern Med 2003; 139:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20745/abstract/15\">",
"      Hillege HL, Fidler V, Diercks GF, et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002; 106:1777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20745/abstract/16\">",
"      Roest M, Banga JD, Janssen WM, et al. Excessive urinary albumin levels are associated with future cardiovascular mortality in postmenopausal women. Circulation 2001; 103:3057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20745/abstract/17\">",
"      Klausen K, Borch-Johnsen K, Feldt-Rasmussen B, et al. Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes. Circulation 2004; 110:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20745/abstract/18\">",
"      Wang TJ, Evans JC, Meigs JB, et al. Low-grade albuminuria and the risks of hypertension and blood pressure progression. Circulation 2005; 111:1370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20745/abstract/19\">",
"      Diercks GF, Hillege HL, van Boven AJ, et al. Microalbuminuria modifies the mortality risk associated with electrocardiographic ST-T segment changes. J Am Coll Cardiol 2002; 40:1401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20745/abstract/20\">",
"      Mattock MB, Morrish NJ, Viberti G, et al. Prospective study of microalbuminuria as predictor of mortality in NIDDM. Diabetes 1992; 41:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20745/abstract/21\">",
"      Stehouwer CD, Nauta JJ, Zeldenrust GC, et al. Urinary albumin excretion, cardiovascular disease, and endothelial dysfunction in non-insulin-dependent diabetes mellitus. Lancet 1992; 340:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20745/abstract/22\">",
"      UK Prospective Diabetes Study (UKPDS). X. Urinary albumin excretion over 3 years in diet-treated type 2, (non-insulin-dependent) diabetic patients, and association with hypertension, hyperglycaemia and hypertriglyceridaemia. Diabetologia 1993; 36:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20745/abstract/23\">",
"      Feldt-Rasmussen B, Mathiesen ER, Deckert T. Effect of two years of strict metabolic control on progression of incipient nephropathy in insulin-dependent diabetes. Lancet 1986; 2:1300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20745/abstract/24\">",
"      Valmadrid CT, Klein R, Moss SE, Klein BE. The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus. Arch Intern Med 2000; 160:1093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20745/abstract/25\">",
"      Bianchi S, Bigazzi R, Campese VM. Microalbuminuria in essential hypertension: significance, pathophysiology, and therapeutic implications. Am J Kidney Dis 1999; 34:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20745/abstract/26\">",
"      Calvi&ntilde;o J, Calvo C, Romero R, et al. Atherosclerosis profile and microalbuminuria in essential hypertension. Am J Kidney Dis 1999; 34:996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20745/abstract/27\">",
"      Wachtell K, Olsen MH, Dahl&ouml;f B, et al. Microalbuminuria in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. J Hypertens 2002; 20:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20745/abstract/28\">",
"      Hoehner CM, Greenlund KJ, Rith-Najarian S, et al. Association of the insulin resistance syndrome and microalbuminuria among nondiabetic native Americans. The Inter-Tribal Heart Project. J Am Soc Nephrol 2002; 13:1626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20745/abstract/29\">",
"      De Leeuw PW, Thijs L, Birkenh&auml;ger WH, et al. Prognostic significance of renal function in elderly patients with isolated systolic hypertension: results from the Syst-Eur trial. J Am Soc Nephrol 2002; 13:2213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20745/abstract/30\">",
"      Muntner P, He J, Hamm L, et al. Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. J Am Soc Nephrol 2002; 13:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20745/abstract/31\">",
"      Romundstad S, Holmen J, Kvenild K, et al. Microalbuminuria and all-cause mortality in 2,089 apparently healthy individuals: a 4.4-year follow-up study. The Nord-Tr&oslash;ndelag Health Study (HUNT), Norway. Am J Kidney Dis 2003; 42:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20745/abstract/32\">",
"      Kuusisto J, Mykk&auml;nen L, Py&ouml;r&auml;l&auml; K, Laakso M. Hyperinsulinemic microalbuminuria. A new risk indicator for coronary heart disease. Circulation 1995; 91:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20745/abstract/33\">",
"      Ibsen H, Olsen MH, Wachtell K, et al. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension 2005; 45:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20745/abstract/34\">",
"      McCullough PA, Jurkovitz CT, Pergola PE, et al. Independent components of chronic kidney disease as a cardiovascular risk state: results from the Kidney Early Evaluation Program (KEEP). Arch Intern Med 2007; 167:1122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20745/abstract/35\">",
"      Arnl&ouml;v J, Evans JC, Meigs JB, et al. Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study. Circulation 2005; 112:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20745/abstract/36\">",
"      Kistorp C, Raymond I, Pedersen F, et al. N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. JAMA 2005; 293:1609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20745/abstract/37\">",
"      Klausen KP, Scharling H, Jensen G, Jensen JS. New definition of microalbuminuria in hypertensive subjects: association with incident coronary heart disease and death. Hypertension 2005; 46:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20745/abstract/38\">",
"      McQueen MJ, Gerstein HC, Pogue J, et al. Reevaluation by high-performance liquid chromatography: clinical significance of microalbuminuria in individuals at high risk of cardiovascular disease in the Heart Outcomes Prevention Evaluation (HOPE) Study. Am J Kidney Dis 2006; 48:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20745/abstract/39\">",
"      Clausen P, Jensen JS, Jensen G, et al. Elevated urinary albumin excretion is associated with impaired arterial dilatory capacity in clinically healthy subjects. Circulation 2001; 103:1869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20745/abstract/40\">",
"      Pedrinelli R, Giampietro O, Carmassi F, et al. Microalbuminuria and endothelial dysfunction in essential hypertension. Lancet 1994; 344:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20745/abstract/41\">",
"      Cosson E, Pham I, Valensi P, et al. Impaired coronary endothelium-dependent vasodilation is associated with microalbuminuria in patients with type 2 diabetes and angiographically normal coronary arteries. Diabetes Care 2006; 29:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20745/abstract/42\">",
"      Barzilay JI, Peterson D, Cushman M, et al. The relationship of cardiovascular risk factors to microalbuminuria in older adults with or without diabetes mellitus or hypertension: the cardiovascular health study. Am J Kidney Dis 2004; 44:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20745/abstract/43\">",
"      Knight EL, Kramer HM, Curhan GC. High-normal blood pressure and microalbuminuria. Am J Kidney Dis 2003; 41:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20745/abstract/44\">",
"      Sibley SD, Hokanson JE, Steffes MW, et al. Increased small dense LDL and intermediate-density lipoprotein with albuminuria in type 1 diabetes. Diabetes Care 1999; 22:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20745/abstract/45\">",
"      Freedman BI, Langefeld CD, Lohman KK, et al. Relationship between albuminuria and cardiovascular disease in Type 2 diabetes. J Am Soc Nephrol 2005; 16:2156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20745/abstract/46\">",
"      Mann JF, Gerstein HC, Yi QL, et al. Development of renal disease in people at high cardiovascular risk: results of the HOPE randomized study. J Am Soc Nephrol 2003; 14:641.",
"     </a>",
"    </li>",
"    <li>",
"     K/DOQI Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease. Am J Kidney Dis 2004; 43:5(Suppl 1):S1.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20745/abstract/48\">",
"      Boulware LE, Jaar BG, Tarver-Carr ME, et al. Screening for proteinuria in US adults: a cost-effectiveness analysis. JAMA 2003; 290:3101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20745/abstract/49\">",
"      Asselbergs FW, Diercks GF, Hillege HL, et al. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation 2004; 110:2809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20745/abstract/50\">",
"      Ibsen H, Wachtell K, Olsen MH, et al. Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy. J Hypertens 2004; 22:1805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20745/abstract/51\">",
"      Bakris GL, Ruilope L, Locatelli F, et al. Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: results of the IMPROVE trial. Kidney Int 2007; 72:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20745/abstract/52\">",
"      Tuttle KR. Albuminuria reduction: the holy grail for kidney protection. Kidney Int 2007; 72:785.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1545 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-27EA24A548-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_16_20745=[""].join("\n");
var outline_f20_16_20745=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H220350\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION, TERMINOLOGY, AND DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DETECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Urine albumin concentration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Albumin-to-creatinine ratio",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Limitations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CORRELATION OF HIGH ALBUMINURIA (MICROALBUMINURIA) WITH CARDIOVASCULAR DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Clinical trials",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Population-based studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      High normal albuminuria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      ST and T wave changes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Possible mechanisms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      CORRELATION OF CARDIOVASCULAR DISEASE WITH HIGH ALBUMINURIA (MICROALBUMINURIA)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SCREENING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Antihypertensive drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Statin therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H220350\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41130?source=related_link\">",
"      Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/37/13914?source=related_link\">",
"      Assessment of urinary protein excretion and evaluation of isolated non-nephrotic proteinuria in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/2/29737?source=related_link\">",
"      Blood pressure management in patients with atherosclerotic cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/0/27658?source=related_link\">",
"      C-reactive protein in cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34298?source=related_link\">",
"      Chronic kidney disease and coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/50/19240?source=related_link\">",
"      Clinical trials of cholesterol lowering for primary prevention of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/29/5594?source=related_link\">",
"      Definition and staging of chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/8/39048?source=related_link\">",
"      Estimation of cardiovascular risk in an individual patient without known cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/4/4169?source=related_link\">",
"      Hypertension: Who should be treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/59/3002?source=related_link\">",
"      Intensity of lipid lowering therapy in secondary prevention of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42777?source=related_link\">",
"      Microalbuminuria in type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/33/39449?source=related_link\">",
"      Microalbuminuria in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40906?source=related_link\">",
"      Secondary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32954?source=related_link\">",
"      The metabolic syndrome (insulin resistance syndrome or syndrome X)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/48/40714?source=related_link\">",
"      Treatment of diabetic nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/40/33417?source=related_link\">",
"      What is goal blood pressure in the treatment of hypertension?",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_16_20746="Guidelines for pediatric advanced life support";
var content_f20_16_20746=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Guidelines for pediatric advanced life support",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/16/20746/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/16/20746/contributors\">",
"     Eric Fleegler, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/16/20746/contributors\">",
"     Monica Kleinman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/16/20746/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/16/20746/contributors\">",
"     Susan B Torrey, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/16/20746/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/16/20746/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/16/20746/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 31, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American Heart Association (AHA) Pediatric Advanced Life Support (PALS) program provides a structured approach to the assessment and treatment of the critically ill pediatric patient [",
"    <a class=\"abstract\" href=\"UTD.htm?20/16/20746/abstract/1\">",
"     1",
"    </a>",
"    ]. The AHA guidelines for pediatric resuscitation were updated in 2010 to reflect advances and research in clinical care using new evidence from a variety of sources ranging from large clinical trials to animal models [",
"    <a class=\"abstract\" href=\"UTD.htm?20/16/20746/abstract/2\">",
"     2",
"    </a>",
"    ]. The PALS content includes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Overview of assessment",
"     </li>",
"     <li>",
"      Recognition and management of respiratory distress and failure",
"     </li>",
"     <li>",
"      Recognition and management of shock",
"     </li>",
"     <li>",
"      Recognition and management of cardiac arrhythmias",
"     </li>",
"     <li>",
"      Recognition and management of cardiac arrest",
"     </li>",
"     <li>",
"      Postresuscitation management of patients with pulmonary and cardiac arrest",
"     </li>",
"     <li>",
"      Review of pharmacology",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinician should primarily focus on prevention of cardiopulmonary failure through early recognition and management of respiratory distress, respiratory failure, and shock that can lead to cardiac arrest from hypoxia, acidosis, and ischemia.",
"   </p>",
"   <p>",
"    This topic will discuss the advanced components of recognition and treatment of respiratory failure, shock, cardiopulmonary failure, and cardiac arrhythmias in children. Basic life support in children and guidelines for cardiac resuscitation in adults are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/43/7864?source=see_link\">",
"     \"Basic life support in infants and children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/33/13850?source=see_link\">",
"     \"Advanced cardiac life support (ACLS) in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW OF ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The assessment of respiratory distress and circulatory compromise in children, including the common findings, is covered in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/51/22327?source=see_link\">",
"     \"Initial assessment and stabilization of children with respiratory or circulatory compromise\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    PALS uses an assessment model that facilitates rapid evaluation and intervention for life-threatening conditions. In infants and children, most cardiac arrests result from progressive respiratory failure",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    shock, and one of the aims of this rapid assessment model is to prevent progression to cardiac arrest. The evaluation includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      General assessment via the pediatric assessment triangle (brief visual and auditory observation of child's overall appearance, work of breathing, circulation) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/51/22327?source=see_link\">",
"       \"Initial assessment and stabilization of children with respiratory or circulatory compromise\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Primary assessment (rapid evaluation of cardiopulmonary and neurologic function)",
"     </li>",
"     <li>",
"      Secondary assessment (focused medical history using SAMPLE mnemonic and thorough head to toe physical exam)",
"     </li>",
"     <li>",
"      Tertiary assessment (laboratory, radiographic, and other ancillary studies)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Primary assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinician should in rapid sequence assess:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Airway (patent, patent with",
"      <span class=\"nowrap\">",
"       maneuvers/adjuncts,",
"      </span>",
"      partially or completely obstructed)",
"     </li>",
"     <li>",
"      Breathing (respiratory rate, effort, tidal volume, lung sounds, pulse oximetry)",
"     </li>",
"     <li>",
"      Circulation (skin color and temperature, heart rate and rhythm, blood pressure, peripheral and central pulses, capillary refill time)",
"     </li>",
"     <li>",
"      Disability",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      AVPU pediatric response scale: Alert, Voice, Pain, Unresponsive",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Glasgow Coma Scale: Eye Opening, Verbal Response, Motor Response (",
"      <a class=\"graphic graphic_table graphicRef59662 \" href=\"UTD.htm?2/58/2989\">",
"       table 1",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Pupillary response to light",
"     </li>",
"     <li>",
"      Presence of hypoglycemia (rapid bedside glucose or response to empiric administration of dextrose)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Exposure (fever or hypothermia, skin findings, evidence of trauma)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Secondary assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;This portion of the evaluation includes a thorough head to toe physical examination, as well as a focused medical history that consists of the \"SAMPLE\" history:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      S: Signs and symptoms",
"     </li>",
"     <li>",
"      A: Allergies",
"     </li>",
"     <li>",
"      M: Medications",
"     </li>",
"     <li>",
"      P: Past medical history",
"     </li>",
"     <li>",
"      L: Last meal",
"     </li>",
"     <li>",
"      E: Events leading to current illness",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Tertiary assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Injury and infection are common causes of life-threatening illness in children. Thus, ancillary studies are frequently directed towards identifying the extent of trauma or an infectious focus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29962?source=see_link&amp;anchor=H21#H21\">",
"     \"Trauma management: Approach to the unstable child\", section on 'Adjuncts to the primary survey'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29962?source=see_link&amp;anchor=H37#H37\">",
"     \"Trauma management: Approach to the unstable child\", section on 'Adjuncts to the secondary survey'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/39/17018?source=see_link&amp;anchor=H12#H12\">",
"     \"Approach to the septic-appearing infant\", section on 'Ancillary studies'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/49/14104?source=see_link&amp;anchor=H8#H8\">",
"     \"Initial evaluation of shock in children\", section on 'Evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     RESPIRATORY DISTRESS AND FAILURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;A major goal of PALS is to recognize and treat respiratory conditions amenable to simple measures (eg, supplemental oxygen, inhaled",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/54/39782?source=see_link\">",
"     albuterol",
"    </a>",
"    ). The clinician may also have to treat rapidly progressive conditions and intervene with advanced therapies to avoid cardiopulmonary arrest in patients with respiratory failure. Early detection and treatment improve overall outcome.",
"   </p>",
"   <p>",
"    There are many causes of acute respiratory compromise in children (",
"    <a class=\"graphic graphic_table graphicRef61637 \" href=\"UTD.htm?27/39/28285\">",
"     table 2",
"    </a>",
"    ). The clinician should strive to categorize respiratory distress or failure into one or more of the following (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/61/7130?source=see_link\">",
"     \"Emergent evaluation of acute respiratory compromise in children\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Upper airway obstruction (eg, croup, epiglottitis)",
"     </li>",
"     <li>",
"      Lower airway obstruction (eg, bronchiolitis, status asthmaticus)",
"     </li>",
"     <li>",
"      Lung tissue (parenchymal) disease (eg, bronchopneumonia)",
"     </li>",
"     <li>",
"      Disordered control of breathing (eg, seizure, coma, muscle weakness)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Initial management supports airway, breathing, and circulation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Airway &ndash; Key steps in basic airway management include (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/22/29030?source=see_link\">",
"       \"Basic airway management in children\"",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Provide 100 percent inspired oxygen",
"     </li>",
"     <li>",
"      Allow child to assume position of comfort or manually open airway",
"     </li>",
"     <li>",
"      Clear airway (suction)",
"     </li>",
"     <li>",
"      Insert oropharyngeal airway or nasopharyngeal airway if consciousness impaired",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Breathing &ndash; The clinician should assist ventilation manually in patients not responding to basic airway maneuvers, monitor oxygenation by pulse oximetry, monitor ventilation by end-tidal CO2 if available, and administer medications as needed (",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/54/39782?source=see_link\">",
"       albuterol",
"      </a>",
"      , epinephrine). In preparation for intubation, positive pressure ventilation should be initiated with a bag-valve-mask to preoxygenate and improve ventilation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/22/29030?source=see_link\">",
"       \"Basic airway management in children\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Children who cannot maintain their airway, oxygenation, or ventilatory requirements should undergo placement of an artificial airway, usually via endotracheal intubation and less commonly with a laryngeal mask airway or alternative device. A rapid overview describes the steps in performing rapid sequence intubation (",
"      <a class=\"graphic graphic_table graphicRef51456 \" href=\"UTD.htm?17/26/17837\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/48/29450?source=see_link\">",
"       \"Emergent endotracheal intubation in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/29/24026?source=see_link\">",
"       \"Rapid sequence intubation (RSI) in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Circulation &ndash; Key interventions consist of monitoring heart rate and rhythm and establishing vascular access (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/55/8057?source=see_link\">",
"       \"Vascular (venous) access for pediatric resuscitation and other pediatric emergencies\"",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     SHOCK",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal is to recognize and categorize the type of shock in order to prioritize treatment options (",
"    <a class=\"graphic graphic_algorithm graphicRef81356 \" href=\"UTD.htm?1/61/2000\">",
"     algorithm 1",
"    </a>",
"    ). Early treatment of shock may prevent the progression to cardiopulmonary failure (",
"    <a class=\"graphic graphic_algorithm graphicRef77079 \" href=\"UTD.htm?41/12/42178\">",
"     algorithm 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Shock results from the inadequate delivery of oxygen to the tissues relative to tissue metabolic demand, usually characterized by inadequate perfusion. Shock may occur with normal, increased, or decreased systolic blood pressure. Shock in children is usually related to low cardiac output, but some patients may have high cardiac output, such as with sepsis or severe anemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/49/14104?source=see_link\">",
"     \"Initial evaluation of shock in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Shock severity is usually categorized by its effect on systolic blood pressure:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Compensated shock occurs when compensatory mechanisms (including tachycardia, increased systemic vascular resistance, increased inotropy, and increased venous tone) maintain a systolic blood pressure within a normal range. The calculators provide the percentile of blood pressure by height for boys, age 2 to 17 years (",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?9/15/9463?source=see_link\">",
"       calculator 1",
"      </a>",
"      ) and girls, age 2 to 17 years (",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?9/33/9751?source=see_link\">",
"       calculator 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Hypotensive shock (or decompensated shock) occurs when compensatory mechanisms fail to maintain systolic blood pressure. In children 1 to 10 years of age, hypotension is defined as:",
"      <br/>",
"      <br/>",
"      Systolic pressure (5",
"      <sup>",
"       th",
"      </sup>",
"      percentile) &lt; 70 mmHg + (child's age in years x2)",
"      <br/>",
"      <br/>",
"      For infants 1 to 12 months of age, hypotension is defined by systolic pressure &lt;70 mmHg, and, in term infants 0 to 1 month of age, systolic pressure &lt;60 mmHg [",
"      <a class=\"abstract\" href=\"UTD.htm?20/16/20746/abstract/2\">",
"       2",
"      </a>",
"      ]. Systolic blood pressure &lt;90 mmHg indicates hypotension in children over 10 years of age. Hypotensive shock may rapidly progress to cardiopulmonary failure.",
"     </li>",
"     <li>",
"      <strong>",
"       Shock categorization",
"      </strong>",
"      &ndash; There are four major categories of shock (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/49/14104?source=see_link\">",
"       \"Initial evaluation of shock in children\"",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Hypovolemic shock &ndash; Hypovolemic shock is characterized by inadequate circulating blood volume. Common causes of fluid loss include diarrhea, hemorrhage (internal and external), vomiting, inadequate fluid intake, osmotic diuresis (eg, diabetic ketoacidosis), third-space losses, and burns.",
"     </li>",
"     <li>",
"      Distributive shock &ndash; Distributive shock describes inappropriately distributed blood volume typically associated with decreased systemic vascular resistance. Common causes include septic shock, anaphylactic shock, and neurogenic shock (eg, head injury, spinal injury).",
"     </li>",
"     <li>",
"      Cardiogenic shock &ndash; Cardiogenic shock refers to impairment of heart contractility. Common causes include congenital heart disease, myocarditis, cardiomyopathy, arrhythmias, sepsis, poisoning or drug toxicity, and myocardial injury (trauma).",
"     </li>",
"     <li>",
"      Obstructive shock &ndash; In this form of shock, hypotension arises from obstructed blood flow to the heart. Common causes include cardiac tamponade, tension pneumothorax, ductal dependent congenital heart lesions, and massive pulmonary embolism.",
"      <br/>",
"      <br/>",
"      Any given patient may suffer from more than one type of shock. For example, a child in septic shock may develop hypovolemia during the prodrome phase, distributive shock during the early phase of sepsis, and cardiogenic shock later in the course.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Shock management",
"      </strong>",
"      &ndash; The approach to undifferentiated shock in children requires careful attention to history and physical examination in order to arrive at the type of shock present (",
"      <a class=\"graphic graphic_algorithm graphicRef77079 \" href=\"UTD.htm?41/12/42178\">",
"       algorithm 2",
"      </a>",
"      ). Goal-directed therapy for shock is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/8/26762?source=see_link&amp;anchor=H2#H2\">",
"       \"Initial management of shock in children\", section on 'Early goal-directed therapy'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Early treatment can greatly improve outcome. Goals are to improve oxygen delivery and to reduce oxygen consumption. Specific measures include increasing circulating volume, increasing cardiac contractility, improving distribution of cardiac output, and reducing oxygen demand. Methods include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Administration of high concentration of oxygen",
"     </li>",
"     <li>",
"      Support of respirations to decrease the work of breathing",
"     </li>",
"     <li>",
"      If rapid sequence intubation is necessary, a sedating agent should be chosen so that hemodynamic stability is not worsened (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/8/26762?source=see_link&amp;anchor=H10#H10\">",
"       \"Initial management of shock in children\", section on 'Airway management'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Rapid intravenous administration of fluids (eg, boluses of normal saline 20",
"      <span class=\"nowrap\">",
"       mL/kg)",
"      </span>",
"      up to three times or more as needed for persistent hypotension. For septic shock in children in resource-rich settings, it is optimal to deliver 60",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      within the first 60 minutes of management (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/33/4634?source=see_link&amp;anchor=H19450206#H19450206\">",
"       \"Septic shock: Rapid recognition and initial resuscitation in children\", section on 'Intravenous fluid therapy'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Administration of vasoconstrictors in selected patients",
"     </li>",
"     <li>",
"      Use of inotropic medications in selected patients",
"     </li>",
"     <li>",
"      Transfusion",
"     </li>",
"     <li>",
"      Reversal of identified obstructions",
"     </li>",
"     <li>",
"      Other adjunct methods include treatment of underlying infection, fever, pain and anxiety, and treatment of metabolic derangements (hypoglycemia, hypocalcemia, hyperkalemia, metabolic acidosis)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     CARDIOPULMONARY FAILURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Respiratory failure and hypotensive shock are the most common conditions preceding cardiac arrest.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Causes of respiratory failure include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Upper airway obstruction (choking, infection)",
"     </li>",
"     <li>",
"      Lower airway obstruction (asthma, foreign body aspiration)",
"     </li>",
"     <li>",
"      Parenchymal disease (pneumonia, acute pulmonary edema)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Causes of hypotensive shock include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Hypovolemia (dehydration, hemorrhage)",
"     </li>",
"     <li>",
"      Cardiac disease",
"     </li>",
"     <li>",
"      Distributive shock (septic, neurogenic)",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Metabolic/electrolyte",
"      </span>",
"      disturbances",
"     </li>",
"     <li>",
"      Acute myocardial",
"      <span class=\"nowrap\">",
"       infarction/ischemia",
"      </span>",
"     </li>",
"     <li>",
"      Toxicologic ingestions",
"     </li>",
"     <li>",
"      Pulmonary embolism",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The following physical findings often precede cardiopulmonary failure:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <strong>",
"       Airway",
"      </strong>",
"      &ndash; Possible upper airway obstruction secondary to decreased level of consciousness or anatomic obstruction from foreign body or infection",
"     </li>",
"     <li>",
"      <strong>",
"       Breathing",
"      </strong>",
"      &ndash; Bradypnea, irregular, ineffective respiration, gasping",
"     </li>",
"     <li>",
"      <strong>",
"       Circulation",
"      </strong>",
"      &ndash; Bradycardia, capillary refill &gt;5 seconds, weak central pulses, no peripheral pulses, hypotension, cool extremities,",
"      <span class=\"nowrap\">",
"       mottled/cyanotic",
"      </span>",
"      skin",
"     </li>",
"     <li>",
"      <strong>",
"       Disability",
"      </strong>",
"      &ndash; Diminished level of consciousness",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The patient in cardiopulmonary failure will progress rapidly to cardiac arrest without aggressive intervention. Positive pressure ventilations with 100 percent inspired oxygen, chest compressions for heart rate &lt;60 beats per minute in patients with poor perfusion, and administration of intravenous fluids and medications tailored to treat the underlying cause are indicated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/22/29030?source=see_link\">",
"     \"Basic airway management in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/43/7864?source=see_link\">",
"     \"Basic life support in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     APPROACH TO CARDIAC ARRHYTHMIAS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arrhythmias are classified as bradyarrhythmias, tachyarrhythmias, and pulseless arrest. Evaluation requires knowledge of the child's typical heart rate (",
"    <a class=\"graphic graphic_table graphicRef78097 \" href=\"UTD.htm?27/37/28252\">",
"     table 4",
"    </a>",
"    ) and baseline rhythm as well as level of activity and clinical condition. The approach presented here is based on the consensus 2010 international resuscitation guidelines developed by the American Heart Association (AHA) and the International Liaison Committee on Resuscitation (ILCOR) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/16/20746/abstract/3-5\">",
"     3-5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     BRADYARRHYTHMIAS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Definition &ndash; Bradycardia is defined as a heart rate that is slow compared with normal heart rates for the patient's age (",
"      <a class=\"graphic graphic_table graphicRef78097 \" href=\"UTD.htm?27/37/28252\">",
"       table 4",
"      </a>",
"      ). Primary bradycardia is the result of congenital and acquired heart conditions that directly slow the spontaneous depolarization rate of the heart's pacemaker or slow conduction through the heart's conduction system. Secondary bradycardia is the result of conditions that alter the normal function of the heart, including hypoxia, acidosis, hypotension, hypothermia, and drug effects. Bradyarrhythmias are common prearrest rhythms in children and are often due to hypoxia.",
"     </li>",
"     <li>",
"      Signs and symptoms &ndash; Pathologic bradycardia frequently causes a change in the level of consciousness, lightheadedness, dizziness, syncope, or fatigue. Shock associated with bradycardia can manifest with hypotension, poor end-organ perfusion, altered consciousness,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      sudden collapse. Bradycardia with symptoms of shock (eg, poor systemic perfusion, hypotension, altered consciousness) requires urgent treatment to prevent cardiac arrest. ECG findings associated with bradycardia include (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/24/33161?source=see_link\">",
"       \"Bradycardia in children\"",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Slow heart rate relative to normal rates (",
"      <a class=\"graphic graphic_table graphicRef78097 \" href=\"UTD.htm?27/37/28252\">",
"       table 4",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      P waves that may or may not be visible",
"     </li>",
"     <li>",
"      QRS complex that is narrow (electrical conduction arising from the atrium or high nodal area) or wide (electrical conduction from low nodal or ventricular region)",
"     </li>",
"     <li>",
"      P wave and QRS complex may be unrelated (ie, atrioventricular dissociation) or have an abnormally long period between them (atrioventricular block)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Sinus bradycardia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sinus bradycardia is commonly an incidental finding in healthy children as a normal consequence of reduced metabolic demand (sleep, rest) or increased stroke volume (well-conditioned athlete). Pathologic causes include hypoxia, hypothermia, poisoning, electrolyte disorders, infection, sleep apnea, drug effects, hypoglycemia, hypothyroidism, and increased intracranial pressure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/24/33161?source=see_link&amp;anchor=H17#H17\">",
"     \"Bradycardia in children\", section on 'Sinus bradycardia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Atrioventricular block",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrioventricular (AV) block is defined as a delay or interruption in the transmission of an atrial impulse to the ventricles due to an anatomical or functional impairment in the conduction system. Heart block is categorized into three types:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       First degree",
"      </strong>",
"      &ndash; First degree AV block is characterized by a prolonged PR interval for age caused by slow conduction through the AV node without missed ventricular beats (",
"      <a class=\"graphic graphic_waveform graphicRef67882 \" href=\"UTD.htm?11/45/11989\">",
"       waveform 1",
"      </a>",
"      ). Of note, first degree AV block does not cause bradycardia. In general, the normal PR-intervals are: 70 to 170 msec in newborns, and 80 to 200 msec in young children and adults. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/24/33161?source=see_link&amp;anchor=H25#H25\">",
"       \"Bradycardia in children\", section on 'First-degree AV block'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Second degree",
"      </strong>",
"      &ndash; In second-degree AV block, the organized atrial impulse fails to be conducted to the ventricle in a 1:1 ratio. There are two types of second degree AV block (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/24/33161?source=see_link&amp;anchor=H26#H26\">",
"       \"Bradycardia in children\", section on 'Second-degree AV block'",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Mobitz type I (Wenckebach phenomenon) &ndash; On ECG, there is progressive prolongation of the PR-interval until a P wave fails to be conducted (",
"      <a class=\"graphic graphic_waveform graphicRef73051 \" href=\"UTD.htm?42/35/43573\">",
"       waveform 2",
"      </a>",
"      ). The block is located at the level of the AV node and is usually not associated with other significant conduction system disease or symptoms.",
"     </li>",
"     <li>",
"      Mobitz type II &ndash; This block occurs below the AV node and has consistent inhibition of a specific proportion of atrial impulses, usually with a 2:1 atrial to ventricular rate (",
"      <a class=\"graphic graphic_waveform graphicRef51492 \" href=\"UTD.htm?16/4/16452\">",
"       waveform 3",
"      </a>",
"      ). It has a less predictable course and frequently progresses to complete heart block.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Third degree",
"      </strong>",
"      &ndash; In third-degree AV block, also referred to as complete heart block, there is complete failure of the atrial impulse to be conducted to the ventricles (",
"      <a class=\"graphic graphic_waveform graphicRef65545 \" href=\"UTD.htm?12/50/13095\">",
"       waveform 4",
"      </a>",
"      ). The atrial and ventricular activity is independent of one another. The ventricular escape rhythm that is generated is dictated by the location of the block. It is usually slower than the lower limits of normal for age, resulting in clinically significant bradycardia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/24/33161?source=see_link&amp;anchor=H30#H30\">",
"       \"Bradycardia in children\", section on 'Third-degree AV block'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Bradyarrhythmia management",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of bradycardia focuses on reestablishing or optimizing oxygenation and ventilation, supporting circulation with chest compressions if needed, and using medications to increase heart rate and cardiac output (",
"    <a class=\"graphic graphic_algorithm graphicRef52446 \" href=\"UTD.htm?20/4/20545\">",
"     algorithm 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/22/29030?source=see_link\">",
"     \"Basic airway management in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/43/7864?source=see_link\">",
"     \"Basic life support in infants and children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/23/15738?source=see_link&amp;anchor=H6#H6\">",
"     \"Primary drugs in pediatric resuscitation\", section on 'Epinephrine'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/23/15738?source=see_link&amp;anchor=H14#H14\">",
"     \"Primary drugs in pediatric resuscitation\", section on 'Atropine'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If these measures fail, transcutaneous pacing can be attempted; however, the same factors that are producing refractory bradycardia (eg, hypoxia, hypothermia, electrolyte disturbance, drug overdose) may prevent effective electrical capture. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/24/33161?source=see_link&amp;anchor=H16#H16\">",
"     \"Bradycardia in children\", section on 'Acute management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     TACHYARRHYTHMIAS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Definition",
"      </strong>",
"      &ndash; Tachyarrhythmias are fast abnormal rhythms originating in the atria or the ventricles. Relative tachycardia is a heart rate that is too fast for the child's age, level of activity, and clinical condition (",
"      <a class=\"graphic graphic_table graphicRef78097 \" href=\"UTD.htm?27/37/28252\">",
"       table 4",
"      </a>",
"      ). In children, sinus tachycardia usually represents hypovolemia, fever, physiologic response to stress or fear, or drug effect (such as with beta agonists). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/38/9832?source=see_link\">",
"       \"Approach to the child with tachycardia\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Certain arrhythmias, such as supraventricular tachycardia and ventricular tachycardia, can lead to shock and cardiac arrest. Unstable rhythms lead to poor tissue perfusion with a fall in cardiac output, poor coronary artery perfusion, and increased myocardial oxygen demand, which can all lead to cardiogenic shock.",
"     </li>",
"     <li>",
"      <strong>",
"       Signs and symptoms",
"      </strong>",
"      &ndash; Clinical findings in children with tachycardia are often nonspecific and vary by age. They may include palpitations, lightheadedness, dizziness, fatigue and syncope. In infants, prolonged tachycardia may cause poor feeding, tachypnea, and irritability with signs of heart failure. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/34/22056?source=see_link\">",
"       \"Approach to the child with palpitations\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/10/11432?source=see_link\">",
"       \"Emergent evaluation of syncope in children and adolescents\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Important ECG findings include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Heart rate that is fast compared with normal rates (",
"      <a class=\"graphic graphic_table graphicRef78097 \" href=\"UTD.htm?27/37/28252\">",
"       table 4",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      P waves that may or may not be visible",
"     </li>",
"     <li>",
"      QRS interval that is narrow or wide",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Classification",
"      </strong>",
"      &ndash; Treatment priorities in managing tachycardias rely on differentiating between tachycardia with narrow QRS complex (sinus tachycardia, supraventricular tachycardia, atrial flutter) and wide QRS complex tachycardias (ventricular tachycardia, supraventricular tachycardia with aberrant intraventricular conduction).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Sinus tachycardia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sinus tachycardia is characterized by a rate of sinus node discharge that is faster than normal for the patient's age (",
"    <a class=\"graphic graphic_table graphicRef78097 \" href=\"UTD.htm?27/37/28252\">",
"     table 4",
"    </a>",
"    ). This rhythm usually represents the body's increased need for cardiac output or oxygen delivery. The heart rate is not fixed and varies with other factors, including fever, stress, and level of activity. Causes include tissue hypoxia, hypovolemia, fever, metabolic stress, injury, pain, anxiety,",
"    <span class=\"nowrap\">",
"     toxins/poisons/drugs,",
"    </span>",
"    and anemia. Less common causes include cardiac tamponade, tension pneumothorax, and thromboembolism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/38/9832?source=see_link\">",
"     \"Approach to the child with tachycardia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Typical ECG findings in patients with sinus tachycardia include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Heart rate is usually",
"      <span class=\"nowrap\">",
"       &lt;220/min",
"      </span>",
"      in infants,",
"      <span class=\"nowrap\">",
"       &lt;180/min",
"      </span>",
"      in children, and exhibits beat to beat variability in rate",
"     </li>",
"     <li>",
"      P waves are present with normal appearance",
"     </li>",
"     <li>",
"      PR interval is constant and exhibits a normal duration for age",
"     </li>",
"     <li>",
"      R-R interval is variable",
"     </li>",
"     <li>",
"      QRS complex is narrow",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Supraventricular tachycardia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Supraventricular tachycardia (SVT) can be defined as an abnormally rapid heart rhythm originating above the ventricles, often (but not always) with a narrow QRS complex; it conventionally excludes atrial flutter and atrial fibrillation. The two most common forms of SVT in children are atrioventricular reentrant tachycardia (AVRT), including the Wolff-Parkinson-White (WPW) syndrome (",
"    <a class=\"graphic graphic_waveform graphicRef77867 \" href=\"UTD.htm?32/2/32815\">",
"     waveform 5",
"    </a>",
"    ), and atrioventricular nodal reentrant tachycardia (AVNRT).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Signs and symptoms",
"      </strong>",
"      &ndash; SVT typically has an abrupt onset and intermittent presentation. Signs and symptoms in infants include poor feeding, tachypnea, irritability, increased sleepiness, diaphoresis, pallor,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      vomiting. Older children may have palpitations, shortness of breath, chest",
"      <span class=\"nowrap\">",
"       pain/discomfort,",
"      </span>",
"      dizziness, lightheadedness,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      fainting. Infants and children with prolonged SVT may display clinical findings of heart failure. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/54/31593?source=see_link&amp;anchor=H10#H10\">",
"       \"Supraventricular tachycardia in children: AV reentrant tachycardia (including WPW) and AV nodal reentrant tachycardia\", section on 'Clinical features'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Typical ECG findings in patients with SVT include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Heart rate that is usually",
"      <span class=\"nowrap\">",
"       &gt;220/min",
"      </span>",
"      in infants,",
"      <span class=\"nowrap\">",
"       &gt;180/min",
"      </span>",
"      in children, and has NO beat to beat variability",
"     </li>",
"     <li>",
"      P waves are absent or abnormal",
"     </li>",
"     <li>",
"      PR interval may not be present or short PR interval with ectopic atrial tachycardia",
"     </li>",
"     <li>",
"      R-R interval is usually constant",
"     </li>",
"     <li>",
"      QRS is usually narrow. Conduction delay along the ventricular system may lead to an appearance of wide complex tachycardia, known as SVT with aberrant conduction.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Ventricular tachycardia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ventricular tachycardia (VT) originates from the ventricular myocardium or Purkinje cells below the bifurcation of the bundle of His (",
"    <a class=\"graphic graphic_waveform graphicRef63176 \" href=\"UTD.htm?28/0/28680\">",
"     waveform 6",
"    </a>",
"    ). VT is associated with sudden cardiac death. As a result, patients who develop VT or are at risk for developing VT must be identified, evaluated, and treated if necessary. Some forms of VT found primarily in infants and young children may be benign, but this conclusion is reached only after other more serious causes of VT are excluded. VT may present with or without pulses. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/33/15897?source=see_link&amp;anchor=H3#H3\">",
"     \"Causes of wide QRS complex tachycardia in children\", section on 'Ventricular tachycardia'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H21\">",
"     'Pulseless arrest'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    VT with pulses can vary in rate from near normal to &gt;200 beat per minute. Faster rates can compromise stroke volume and cardiac output leading to pulseless VT or ventricular fibrillation (VF). Causes of VT include underlying heart disease or cardiac surgery, prolonged QT syndrome, or",
"    <span class=\"nowrap\">",
"     myocarditis/cardiomyopathy.",
"    </span>",
"    Other causes include hyperkalemia and toxic ingestions (eg, tricyclic antidepressants, cocaine) (",
"    <a class=\"graphic graphic_table graphicRef66773 \" href=\"UTD.htm?23/11/23742\">",
"     table 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Findings of ventricular tachycardia on ECG include (",
"    <a class=\"graphic graphic_waveform graphicRef63176 \" href=\"UTD.htm?28/0/28680\">",
"     waveform 6",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Ventricular rate is &gt;120 beats per minute and regular",
"     </li>",
"     <li>",
"      P waves are often not identifiable, may have AV dissociation, or may have retrograde depolarization",
"     </li>",
"     <li>",
"      QRS is typically wide (&gt;0.09 sec)",
"     </li>",
"     <li>",
"      T waves are often opposite in polarity from the QRS complex",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Tachyarrhythmia management",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of sinus tachycardia focuses on treatment of the underlying physiologic derangement and is largely supportive. The management of tachyarrhythmias that are not sinus in origin is guided by the appearance of the QRS complex, and by the patient's status, whether compensated or uncompensated (",
"    <a class=\"graphic graphic_algorithm graphicRef67438 \" href=\"UTD.htm?11/37/11860\">",
"     algorithm 4",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with either narrow or wide complex tachycardia who have significantly impaired consciousness and hypotensive shock should be treated with synchronized cardioversion (Initial dose: 0.5 to 1",
"      <span class=\"nowrap\">",
"       J/kg).",
"      </span>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/49/21272?source=see_link&amp;anchor=H21#H21\">",
"       \"Defibrillation and cardioversion in children (including automated external defibrillation)\", section on 'Methods: Manual defibrillator use'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients who are mentating and not hypotensive may receive a trial of anti-arrhythmic therapy, based on whether the arrhythmia is believed to originate from above the AV node (narrow complex) or below the AV node (wide complex). For narrow complex tachycardia, the first recommended medication is adenosine, 0.1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      (maximum dose 6 mg) administered rapidly",
"      <span class=\"nowrap\">",
"       IV/IO",
"      </span>",
"      and followed by a rapid saline flush. &nbsp;Anti-arrhythmic therapy of wide-complex tachycardia involves agents with significant side effects (eg:",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/41/9882?source=see_link\">",
"       amiodarone",
"      </a>",
"      ) and consultation with a pediatric cardiology specialist is recommended. &nbsp;If the wide-complex rhythm is monomorphic and regular, it is acceptable to administer a dose of adenosine to determine if the rhythm is actually supraventricular tachycardia with aberrant conduction. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/9/15514?source=see_link&amp;anchor=H8#H8\">",
"       \"Management of supraventricular tachycardia in children\", section on 'Antiarrhythmic drugs'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/40/22152?source=see_link&amp;anchor=H2#H2\">",
"       \"Management and evaluation of wide QRS complex tachycardia in children\", section on 'Initial management'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/23/15738?source=see_link&amp;anchor=H4895863#H4895863\">",
"       \"Primary drugs in pediatric resuscitation\", section on 'Adenosine'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/23/15738?source=see_link&amp;anchor=H8196866#H8196866\">",
"       \"Primary drugs in pediatric resuscitation\", section on 'Amiodarone'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/23/15738?source=see_link&amp;anchor=H4895234#H4895234\">",
"       \"Primary drugs in pediatric resuscitation\", section on 'Procainamide'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     PULSELESS ARREST",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulseless arrest refers to cessation of blood circulation caused by absent or ineffective cardiac mechanical activity.",
"   </p>",
"   <p>",
"    Most pediatric cardiac arrests are",
"    <span class=\"nowrap\">",
"     hypoxic/asphyxial",
"    </span>",
"    arrests that result from a progression of respiratory distress, respiratory failure, or shock rather than from primary cardiac arrhythmias (\"sudden cardiac arrest\"). Thus, the presenting rhythm is typically pulseless electrical activity or asystole.",
"   </p>",
"   <p>",
"    Children with pulseless arrest appear apneic or display a few agonal gasps. They have no palpable pulses, and are unresponsive. Overall survival from pediatric cardiac arrest is poor, and the incidence of neurologic deficits in survivors is high.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Epidemiology and presenting rhythm",
"    </span>",
"    &nbsp;&mdash;&nbsp;Out-of-hospital arrests in children six months to young adulthood often occur at or near home [",
"    <a class=\"abstract\" href=\"UTD.htm?20/16/20746/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. The most common cause of death is from trauma, leading to respiratory compromise",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    shock. Massive head injury and severe multiple systems trauma are common in nonsurvivors. Sudden infant death syndrome (SIDS) is a leading cause of death in infants &lt;6 months [",
"    <a class=\"abstract\" href=\"UTD.htm?20/16/20746/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sudden cardiac arrest due to ventricular fibrillation (VF) or pulseless ventricular tachycardia (VT) occurs in up to 18 percent of all pediatric prehospital cardiac arrests, but is less commonly the presenting rhythm in younger children between the ages of one and eight years (8 percent) and infants [",
"    <a class=\"abstract\" href=\"UTD.htm?20/16/20746/abstract/8\">",
"     8",
"    </a>",
"    ]. Predisposing conditions or causes of ventricular rhythms in pediatric patients with pulseless arrest include hypertrophic cardiomyopathy, anomalous coronary artery (from the pulmonary artery), long QT syndrome, myocarditis, drug intoxication (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/24/27017?source=see_link\">",
"     digoxin",
"    </a>",
"    , ephedra, cocaine), and commotio cordis (ie, sharp blow to chest). These patients may have intact survival if defibrillation is performed within minutes of arrest.",
"   </p>",
"   <p>",
"    For in-hospital cardiac arrest, shockable rhythms are present at some point during the resuscitation in up to 27 percent of children, with 10 to 15 percent having",
"    <span class=\"nowrap\">",
"     VF/VT",
"    </span>",
"    as the initial arrest rhythm [",
"    <a class=\"abstract\" href=\"UTD.htm?20/16/20746/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. In one observational study of 1005 in-hospital cardiac arrest reported to a multicenter cardiac arrest registry, survival was higher if VF or VT was the presenting arrhythmia (35 percent survival) versus \"non-shockable\" rhythms, such as asystole (11 percent) (",
"    <a class=\"graphic graphic_algorithm graphicRef80003 \" href=\"UTD.htm?41/30/42470\">",
"     algorithm 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/16/20746/abstract/9\">",
"     9",
"    </a>",
"    ]. In another multicenter observational study of 1031 children, risk-adjusted survival for all patients in cardiopulmonary arrest was 43 percent, with significantly improved adjusted survival for those whose initial arrest rhythms were pulseless VT or pulseless electrical activity when compared to asystole (risk ratio 1.6 and 1.2, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/16/20746/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Arrest rhythms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Asystole, pulseless electrical activity (PEA), ventricular fibrillation (VF), and pulseless ventricular tachycardia (VT) comprise the potential arrest rhythms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Asystole",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with asystole have cardiac standstill with no discernible electrical activity (",
"    <a class=\"graphic graphic_waveform graphicRef67777 \" href=\"UTD.htm?26/1/26648\">",
"     waveform 7",
"    </a>",
"    ). The most common cause is respiratory failure progressing to critical hypoxemia, bradycardia, and then cardiac standstill. Underlying conditions include pneumonia, submersion, hypothermia, sepsis, and poisoning (eg, carbon monoxide poisoning, sedative-hypnotics) leading to hypoxia and acidosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Pulseless electrical activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulseless electrical activity (PEA) consists of any organized electrical activity observed on ECG in a patient with no central palpable pulse. Reversible conditions may underlie PEA, including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hypovolemia",
"     </li>",
"     <li>",
"      Hypoxia",
"     </li>",
"     <li>",
"      Hydrogen ion (acidosis)",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Hypo-/hyperkalemia",
"      </span>",
"     </li>",
"     <li>",
"      Hypoglycemia",
"     </li>",
"     <li>",
"      Hypothermia",
"     </li>",
"     <li>",
"      Toxins",
"     </li>",
"     <li>",
"      Tamponade, cardiac",
"     </li>",
"     <li>",
"      Tension pneumothorax",
"     </li>",
"     <li>",
"      Thrombosis (coronary or pulmonary)",
"     </li>",
"     <li>",
"      Trauma",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These can be remembered as the H's and T's of PEA [",
"    <a class=\"abstract\" href=\"UTD.htm?20/16/20746/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Ventricular fibrillation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ventricular fibrillation is characterized by no organized rhythm and no coordinated contractions (",
"    <a class=\"graphic graphic_waveform graphicRef67777 \" href=\"UTD.htm?26/1/26648\">",
"     waveform 7",
"    </a>",
"    ). Electrical activity is chaotic. Causes overlap with etiologies of ventricular tachycardia, including hyperkalemia, congenital or acquired heart disease, toxic exposures, electrical or lightning shocks, and submersion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Pulseless ventricular tachycardia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulseless VT is a cardiac arrest of ventricular origin characterized by organized, wide QRS complexes (",
"    <a class=\"graphic graphic_waveform graphicRef63176 \" href=\"UTD.htm?28/0/28680\">",
"     waveform 6",
"    </a>",
"    ). Any cause of VT with pulses can lead to pulseless VT. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Ventricular tachycardia'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Torsades de pointes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Torsades de pointes or polymorphic VT displays a QRS complex that changes in polarity and amplitude, appearing to rotate around the ECG isoelectric line (translation: \"twisting of the points\") (",
"    <a class=\"graphic graphic_waveform graphicRef53891 \" href=\"UTD.htm?42/23/43380\">",
"     waveform 8",
"    </a>",
"    ). This arrhythmia is associated with markedly prolonged QTc interval from congenital conditions (long QT syndrome), drug toxicity (antiarrhythmic drugs, tricyclic antidepressants, calcium channel blockers, phenothiazine), and electrolyte disturbances (eg, hypomagnesemia arising from anorexia nervosa). Ventricular tachycardia, including torsades de pointes, can deteriorate into ventricular fibrillation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;For highly effective chest compressions, the individual performing the compressions needs to push hard, push fast, allow complete chest recoil, and minimize interruptions in chest compressions. The clinician should only interrupt compressions for ventilation, rhythm check, and shock delivery. While chest-compression only CPR is effective as the initial treatment for adult out-of-hospital cardiac arrest, infants and children should still receive both chest compressions and ventilations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/43/7864?source=see_link&amp;anchor=H8#H8\">",
"     \"Basic life support in infants and children\", section on 'Chest compressions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Advanced management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once basic cardiopulmonary resuscitation is established, treatment of pulseless arrest requires rapid assessment of rhythm, performance of defibrillation as indicated, and pharmacotherapy aimed at increasing coronary artery circulation and restoration of organized cardiac conduction (",
"    <a class=\"graphic graphic_algorithm graphicRef80003 \" href=\"UTD.htm?41/30/42470\">",
"     algorithm 5",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with ventricular fibrillation (VF) or pulseless ventricular tachycardia (pVT) should receive immediate CPR and defibrillation as soon as a device is available. After delivering the shock, perform approximately two minutes of CPR (10 cycles for two person CPR or 5 cycles for one person CPR) before checking the rhythm. If the rhythm has not converted with defibrillation, the patient should receive a repeated defibrillation at a higher dose. Persistent VF or pVT requires the addition of medications such as parenteral epinephrine and antiarrhythmic therapy (eg,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/41/9882?source=see_link\">",
"       amiodarone",
"      </a>",
"      for VF or pVT;",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/29/34262?source=see_link\">",
"       magnesium sulfate",
"      </a>",
"      for torsades de pointes). See the algorithm for drug dosing (",
"      <a class=\"graphic graphic_algorithm graphicRef80003 \" href=\"UTD.htm?41/30/42470\">",
"       algorithm 5",
"      </a>",
"      ). Details of drug dosing and administration are provided separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/23/15738?source=see_link&amp;anchor=H8196866#H8196866\">",
"       \"Primary drugs in pediatric resuscitation\", section on 'Amiodarone'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/23/15738?source=see_link&amp;anchor=H8196901#H8196901\">",
"       \"Primary drugs in pediatric resuscitation\", section on 'Magnesium sulfate'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with asystole or pulseless electrical activity should receive cardiopulmonary resuscitation and epinephrine",
"      <span class=\"nowrap\">",
"       (IV/IO",
"      </span>",
"      administration preferred over endotracheal). See the algorithm for drug dosing (",
"      <a class=\"graphic graphic_algorithm graphicRef80003 \" href=\"UTD.htm?41/30/42470\">",
"       algorithm 5",
"      </a>",
"      ). The dosing and administration of epinephrine in children is discussed in more detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/23/15738?source=see_link&amp;anchor=H6#H6\">",
"       \"Primary drugs in pediatric resuscitation\", section on 'Epinephrine'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      During the course of the resuscitation, the clinician should evaluate for underlying causes (H's and T's) for the pulseless arrest as indicated on the algorithm (",
"      <a class=\"graphic graphic_algorithm graphicRef80003 \" href=\"UTD.htm?41/30/42470\">",
"       algorithm 5",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Vascular access",
"    </span>",
"    &nbsp;&mdash;&nbsp;Establishment of reliable vascular access is a critical step in pediatric resuscitation. During pulseless arrest, intraosseous cannulation and peripheral venous access should be pursued simultaneously. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/55/8057?source=see_link\">",
"     \"Vascular (venous) access for pediatric resuscitation and other pediatric emergencies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/51/40761?source=see_link\">",
"     \"Intraosseous infusion\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Resuscitation medications given through a peripheral IV should be followed with a 5 mL flush of normal saline to move the drug from the peripheral to the central circulation.",
"   </p>",
"   <p>",
"    Many clinicians regard intraosseous cannulation as the preferred initial route of vascular access, especially in young infants with pulseless arrest. Doses of medications administered via an intraosseous line are the same as peripheral IV doses and should be followed by a 5 to 10 mL flush of normal saline. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/51/40761?source=see_link\">",
"     \"Intraosseous infusion\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Intraosseous cannulation becomes progressively more difficult as children age because the cortex of bone becomes thicker and the tibial bone marrow cavity becomes smaller. However, the development of devices, such as spring-loaded single-deployment devices and battery-operated handheld drills, has made intraosseous cannulation feasible for patients of all ages, including adults. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/51/40761?source=see_link&amp;anchor=H5#H5\">",
"     \"Intraosseous infusion\", section on 'Preparation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Attempts at peripheral and central venous access in the head, neck, and chest should NOT interrupt chest compressions. Central lines are more secure than peripheral access and provide more rapid onset and higher peak concentration of medications but are NOT required during initial resuscitation attempts. If central lines are used, the femoral route is preferred by many. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/55/8057?source=see_link&amp;anchor=H17#H17\">",
"     \"Vascular (venous) access for pediatric resuscitation and other pediatric emergencies\", section on 'Femoral vein'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Endotracheal drug administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although lipid soluble drugs, such as",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/57/37776?source=see_link\">",
"     lidocaine",
"    </a>",
"    , epinephrine,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/13/25816?source=see_link\">",
"     atropine",
"    </a>",
"    , and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/4/20551?source=see_link\">",
"     naloxone",
"    </a>",
"    (\"LEAN\"), may be administered via endotracheal tube (ETT), the intravascular route is always preferred. Optimal drug dosing via endotracheal tube is unknown, with unpredictable drug absorption leading to lower blood levels when compared with the same dose given intravascularly. Several key actions are needed when giving drugs via ETT:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Increase the epinephrine dose ten-fold (by using the 1:1000 concentration instead of the 1:10,000 concentration used for IV delivery) and the dose of other medications (",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/13/25816?source=see_link\">",
"       atropine",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/57/37776?source=see_link\">",
"       lidocaine",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/4/20551?source=see_link\">",
"       naloxone",
"      </a>",
"      ) two- to threefold. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/23/15738?source=see_link&amp;anchor=H6#H6\">",
"       \"Primary drugs in pediatric resuscitation\", section on 'Epinephrine'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/23/15738?source=see_link&amp;anchor=H14#H14\">",
"       \"Primary drugs in pediatric resuscitation\", section on 'Atropine'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/21/22874?source=see_link&amp;anchor=H18254225#H18254225\">",
"       \"Opioid intoxication in children and adolescents\", section on 'Dosing and administration'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hold compressions during ETT administration.",
"     </li>",
"     <li>",
"      Follow drug administration with 3 to 5 mL of normal saline.",
"     </li>",
"     <li>",
"      Provide five positive pressure ventilations after instilling the drug.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h3\">",
"     Defibrillation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Defibrillation does not restart the heart; the shock \"stuns\" the heart by depolarizing all of the myocardial cells, hopefully terminating VF and allowing the heart's natural pacemaker cells to resume an organized rhythm. After delivering a shock, the caregivers should perform approximately two minutes of CPR (10 cycles for two person CPR or 5 cycles of one person CPR) before checking the rhythm. CPR may be discontinued when a perfusing rhythm has been established. The dose of energy for pediatric defibrillation is 2",
"    <span class=\"nowrap\">",
"     joules/kg",
"    </span>",
"    for the initial shock, 4",
"    <span class=\"nowrap\">",
"     joules/kg",
"    </span>",
"    for the second shock, and 4",
"    <span class=\"nowrap\">",
"     joules/kg",
"    </span>",
"    or more for subsequent shocks with a maximum of 10",
"    <span class=\"nowrap\">",
"     joules/kg",
"    </span>",
"    or the adult dose (maximum dose differs between defibrillator models). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/49/21272?source=see_link&amp;anchor=H21#H21\">",
"     \"Defibrillation and cardioversion in children (including automated external defibrillation)\", section on 'Methods: Manual defibrillator use'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Biphasic defibrillators have a high first shock efficacy rate for ventricular fibrillation (VF) of short duration in adults. This procedure eliminates VF but may not lead to a perfusing rhythm (often the patient will be in asystole or PEA after the shock) or myocardial ischemia prevents proper cardiac contractility. For this reason, after delivering the shock, chest compressions should resume immediately for approximately two minutes as above. Cardiopulmonary resuscitation is required to maintain blood flow to the heart, coronary circulation, and brain until effective cardiac contractility resumes.",
"   </p>",
"   <p>",
"    Although manual defibrillators or automated external defibrillators with pediatric attenuating devices are preferred for use in infants and children, automated external defibrillators without pediatric attenuating devices may be used if they are the only option available. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/43/7864?source=see_link&amp;anchor=H15#H15\">",
"     \"Basic life support in infants and children\", section on 'Automated external defibrillator'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h3\">",
"     Pharmacologic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A detailed discussion of pediatric resuscitation drugs is provided separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/23/15738?source=see_link\">",
"     \"Primary drugs in pediatric resuscitation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Epinephrine is the most commonly used medication in children with pulseless arrest. It is classified as a catecholamine, vasopressor, and inotrope. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/23/15738?source=see_link&amp;anchor=H6#H6\">",
"     \"Primary drugs in pediatric resuscitation\", section on 'Epinephrine'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For pulseless arrest, the",
"    <span class=\"nowrap\">",
"     IV/IO",
"    </span>",
"    dosing is 0.01",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    (0.1",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    of the 1:10,000 concentration) given every three to five minutes; maximum single dose: 1 mg (10 mL). High dose intravenous epinephrine is no longer recommended. When epinephrine is administered via ET tube, use a 10-fold higher dose or 0.1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    (0.1",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    of the 1:1000 concentration) every three to five minutes. The",
"    <span class=\"nowrap\">",
"     IV/IO",
"    </span>",
"    route is always preferred (",
"    <a class=\"graphic graphic_algorithm graphicRef80003 \" href=\"UTD.htm?41/30/42470\">",
"     algorithm 5",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h1\">",
"     EARLY POSTRESUSCITATION MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The early postresuscitation period involves the time soon after return of spontaneous circulation or recovery from circulatory or respiratory failure. During this time, the clinician must continue to treat the underlying cause of the life-threatening event and monitor for common respiratory or circulatory problems that may cause secondary morbidity or death [",
"    <a class=\"abstract\" href=\"UTD.htm?20/16/20746/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Oxygen administration",
"      </strong>",
"      &ndash; Once return of spontaneous circulation has been achieved, the clinician should titrate inspired oxygen to maintain arterial oxyhemoglobin saturation between 94 to 99 percent to avoid hyperoxemia. In two large, multicenter observational studies hyperoxia has been associated with clinically significant increased risk of death [",
"      <a class=\"abstract\" href=\"UTD.htm?20/16/20746/abstract/11,12\">",
"       11,12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Intubated patients",
"      </strong>",
"      &ndash; All intubated children require continued assessment to ensure proper endotracheal tube positioning, continuous monitoring of oxygenation (pulse oximetry), and ongoing monitoring of ventilation (eg, continuous end-tidal CO2 monitoring, if available,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      intermittent blood gas assessment). Insertion of a gastric tube helps to reduce gastric distension.",
"      <br/>",
"      <br/>",
"      The causes of sudden decompensation in a child who has been successfully intubated with an artificial airway is described by the mnemonic \"DOPE\":",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <strong>",
"       D",
"      </strong>",
"      : Dislodged or displaced endotracheal tube (right mainstem or esophageal location)",
"     </li>",
"     <li>",
"      <strong>",
"       O",
"      </strong>",
"      : Obstructed endotracheal tube (eg, mucous plug, kinked endotracheal tube)",
"     </li>",
"     <li>",
"      <strong>",
"       P",
"      </strong>",
"      : Pneumothorax",
"     </li>",
"     <li>",
"      <strong>",
"       E",
"      </strong>",
"      : Equipment failure (eg, ventilator malfunction, oxygen disconnected or off)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Recurrent shock",
"      </strong>",
"      &ndash; After fluid resuscitation in a child, circulatory instability may recur as the result of ongoing fluid loss, decreased cardiac function,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      harmful alterations in systemic vascular resistance. Goal-directed therapy emphasizes the need to assess clinical findings of perfusion (eg, capillary refill, urine output), measure central venous pressure, and measure central venous oxygen saturation, to determine the best course of action. Vasopressors (eg, epinephrine infusion (",
"      <a class=\"graphic graphic_table graphicRef56049 \" href=\"UTD.htm?2/18/2350\">",
"       table 6",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef66791 \" href=\"UTD.htm?39/39/40573\">",
"       table 7",
"      </a>",
"      )) may be appropriate therapies for children with documented or suspected cardiovascular dysfunction in the post-resuscitation setting. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/8/26762?source=see_link&amp;anchor=H2#H2\">",
"       \"Initial management of shock in children\", section on 'Early goal-directed therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Glucose",
"      </strong>",
"      &ndash; The clinician should monitor blood glucose levels and promptly treat hypoglycemia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/0/8201?source=see_link&amp;anchor=H8#H8\">",
"       \"Approach to hypoglycemia in infants and children\", section on 'Immediate management'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Sustained hyperglycemia (blood glucose greater than 180",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [10",
"      <span class=\"nowrap\">",
"       mmol/L])",
"      </span>",
"      is associated with higher mortality in critically ill children and should be avoided [",
"      <a class=\"abstract\" href=\"UTD.htm?20/16/20746/abstract/13,14\">",
"       13,14",
"      </a>",
"      ]. Evidence indicates that blood glucose should be maintained below this threshold but the role of &ldquo;tight control&rdquo; that uses insulin to achieve a specified blood glucose range is of uncertain value in children after cardiac arrest [",
"      <a class=\"abstract\" href=\"UTD.htm?20/16/20746/abstract/5\">",
"       5",
"      </a>",
"      ]. If performed, tight glucose control requires close monitoring of blood glucose and avoidance of hypoglycemia. Intensive insulin therapy in adults to maintain a blood glucose range of 80 to 110",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (4.4 to 6.1",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      increases the risk of hypoglycemia without demonstrated benefit. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/23/28023?source=see_link&amp;anchor=H15#H15\">",
"       \"Glycemic control and intensive insulin therapy in critical illness\", section on 'General approach'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Therapeutic hypothermia",
"      </strong>",
"      &ndash; Lowering of core body temperature to 32 to 34",
"      <sup>",
"       &deg;",
"      </sup>",
"      C during the first few hours after cardiac arrest is associated with improved neurologic outcomes and decreased mortality in adults with an out-of-hospital cardiac arrest and either ventricular fibrillation or pulseless ventricular tachycardia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/28/35274?source=see_link&amp;anchor=H733778#H733778\">",
"       \"Post-cardiac arrest management in adults\", section on 'Evidence of benefit in ventricular fibrillation and pulseless ventricular tachycardia'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      In children, evidence is very limited [",
"      <a class=\"abstract\" href=\"UTD.htm?20/16/20746/abstract/5\">",
"       5",
"      </a>",
"      ]. The use of therapeutic hypothermia (core body temperature 32 to 34",
"      <sup>",
"       &deg;",
"      </sup>",
"      C) may be appropriate for children with out-of-hospital arrest and persistent coma or those with ventricular fibrillation or pulseless ventricular tachycardia. The timing, duration, and methods for therapeutic hypothermia are discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/28/35274?source=see_link&amp;anchor=H9724176#H9724176\">",
"       \"Post-cardiac arrest management in adults\", section on 'Therapeutic (Induced) hypothermia'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If the child is not being treated in a center with pediatric emergency and critical care expertise, the child should be stabilized and rapidly transferred for definitive care at a regional pediatric center. Critically ill or injured children typically benefit from transport by a team with pediatric expertise and advanced pediatric treatment capability, although in some isolated cases (eg, expanding epidural hematoma) more rapid transport by an immediately available non-pediatric team may be advantageous. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/59/26553?source=see_link&amp;anchor=H10751377#H10751377\">",
"     \"Prehospital pediatrics and emergency medical services (EMS)\", section on 'Inter-facility transport'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Prior to transfer the physician responsible for the child's care at the transferring hospital should speak directly to the physician who will be taking charge of the patient at the receiving hospital. All documentation of care (eg, medical chart, medication administration record, laboratory results, copies of ancillary studies [radiographs, ECGs]) should be sent with the patient. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/59/26553?source=see_link&amp;anchor=H10751377#H10751377\">",
"     \"Prehospital pediatrics and emergency medical services (EMS)\", section on 'Inter-facility transport'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1302189\">",
"    <span class=\"h1\">",
"     RAPID RESPONSE TEAMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A rapid response team (RRT), also known as a medical emergency team, consists of personnel from medical, nursing",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    respiratory therapy who have critical care training and are available 24 hours per day, seven days a week for evaluation and treatment of patients who show signs of clinical deterioration and are located in nonacute care settings (eg, medical or surgical inpatient wards). Implementation of a RRT has been promoted as a major strategy for improving patient safety in hospitals [",
"    <a class=\"abstract\" href=\"UTD.htm?20/16/20746/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The quality and generalizability of the evidence describing the effectiveness of implementing RRTs is limited by features such as before and after observation design, selection of primary and secondary outcome measures, and varied indications for RRT activation. In addition, because the mortality following PICU admission is typically low, its utility as an outcome measure may be limited. Finally, the systems being studied are complex, making it difficult to identify confounding factors such as changes in secular trends or indirect benefits derived from the RRT implementation.",
"   </p>",
"   <p>",
"    We suggest that pediatric tertiary care centers develop and maintain rapid response teams for the prompt assessment and management of hospitalized infants and children who are showing signs of clinical deterioration and are located in nonacute care settings. This recommendation is based in part upon the following information. However, the benefit of an RRT is not consistent across all settings, and it is possible that explanations other than the RRT may be responsible for at least part of the benefit.",
"   </p>",
"   <p>",
"    A meta-analysis of five pediatric prospective observational studies with a total of 347,618 patient admissions found that implementation of a RRT was associated with a significant reduction in deaths from cardiac arrest when compared to historical control periods (0.05 versus 0.17 percent, RR 0.6, 95% CI 0.5-0.8) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/16/20746/abstract/16\">",
"     16",
"    </a>",
"    ]. However, decreased mortality after implementation of a RRT was not found in all studies.",
"   </p>",
"   <p>",
"    A cohort study of 29,294 patient admissions (7257 admissions after institution of a RRT) that was included in the meta-analysis compared hospital-wide mortality rates and rates of respiratory and cardiopulmonary arrests outside of the intensive care unit before and after implementation of an RRT in a 264-bed freestanding children&rsquo;s hospital [",
"    <a class=\"abstract\" href=\"UTD.htm?20/16/20746/abstract/17\">",
"     17",
"    </a>",
"    ]. Major findings included:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The mean monthly mortality rate decreased from 1.0 to 0.8 deaths per 100 discharges (18 percent decrease, 95% CI 5-30 percent).",
"     </li>",
"     <li>",
"      The mean monthly code rate (respiratory or cardiopulmonary arrest) decreased from 2.5 to 0.7 codes per 1000 patient admissions (RR 0.3, 95% CI 0.1-0.7). A possible explanation for this finding is that early activation of the RRT in a critically ill patient might have prevented codes.",
"     </li>",
"     <li>",
"      Over 18 months, the RRT was activated 143 times, most commonly for respiratory distress, hypotension, hypoxemia, altered mental status, and tachycardia. The most common actions by the RRT were respiratory support, fluid resuscitation, airway management, and transfer to the intensive care unit.",
"     </li>",
"     <li>",
"      A multicenter, prospective observational study of the implementation of a physician-led pediatric RRT in four pediatric academic centers found that initiation of an RRT was associated with a significant reduction in pediatric intensive care unit mortality rate after readmission from a medical or surgical unit (0.3 to 0.1 deaths per 1000 hospital admissions) but no significant decline in the rate of cardiopulmonary arrests [",
"      <a class=\"abstract\" href=\"UTD.htm?20/16/20746/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, these observations do not prove that the RRT was responsible for the improvement in outcomes. Support for this concern comes from an observational study in a children&rsquo;s hospital that did",
"    <strong>",
"     not",
"    </strong>",
"    implement an RRT but also found a significant reduction in mortality over the same time period in which other pediatric centers reported decreased mortality in association with RRT implementation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/16/20746/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1302295\">",
"    <span class=\"h1\">",
"     FAMILY PRESENCE DURING RESUSCITATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Observational studies indicate that caretakers should be given the option of being present during the in-hospital resuscitation of their child [",
"    <a class=\"abstract\" href=\"UTD.htm?20/16/20746/abstract/5\">",
"     5",
"    </a>",
"    ]. Key findings include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most parents want the opportunity to remain with their child during resuscitation [",
"      <a class=\"abstract\" href=\"UTD.htm?20/16/20746/abstract/5\">",
"       5",
"      </a>",
"      ] and believe it is their right [",
"      <a class=\"abstract\" href=\"UTD.htm?20/16/20746/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Caretakers present during the resuscitation of a family member frequently reported that their presence during the resuscitation was beneficial to the patient [",
"      <a class=\"abstract\" href=\"UTD.htm?20/16/20746/abstract/20-22\">",
"       20-22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Two-thirds of caretakers present during the resuscitation of a child who died reported that their presence helped with their adjustment to the death and the grieving process [",
"      <a class=\"abstract\" href=\"UTD.htm?20/16/20746/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Studies of hospital personnel suggest that the presence of a family member, in most instances, was not stressful to staff and did not negatively impact staff performance [",
"      <a class=\"abstract\" href=\"UTD.htm?20/16/20746/abstract/20,21,23\">",
"       20,21,23",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When family members are present during a pediatric resuscitation, a staff member with clinical knowledge, empathy, and strong interpersonal skills should be present with them to provide support and answer questions.",
"   </p>",
"   <p>",
"    In the rare instance that family presence is disruptive to team resuscitation efforts, the family members should be respectfully asked to leave.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The principle aim for pediatric advanced life support (PALS) is to prevent cardiopulmonary failure through early recognition and management of respiratory distress, respiratory failure, and shock. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Overview of assessment'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/51/22327?source=see_link\">",
"     \"Initial assessment and stabilization of children with respiratory or circulatory compromise\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Respiratory distress and failure",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A major goal of pediatric advanced life support is to recognize and treat respiratory conditions amenable to simple measures (eg, supplemental oxygen, inhaled",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/54/39782?source=see_link\">",
"       albuterol",
"      </a>",
"      ) (",
"      <a class=\"graphic graphic_table graphicRef61637 \" href=\"UTD.htm?27/39/28285\">",
"       table 2",
"      </a>",
"      ). The clinician may also have to treat rapidly progressive conditions and intervene with advanced therapies to avoid cardiopulmonary arrest in patients with respiratory failure. Early detection and treatment improve overall outcome. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Respiratory distress and failure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Airway &ndash; Key steps in basic airway management include (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/22/29030?source=see_link\">",
"       \"Basic airway management in children\"",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Provide 100 percent inspired oxygen",
"     </li>",
"     <li>",
"      Allow child to assume position of comfort or manually open airway",
"     </li>",
"     <li>",
"      Clear airway (suction)",
"     </li>",
"     <li>",
"      Insert oropharyngeal airway or nasopharyngeal airway if consciousness impaired",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Breathing &ndash; The clinician should assist ventilation manually in patients not responding to basic airway maneuvers, monitor oxygenation by pulse oximetry, monitor ventilation by end-tidal CO2 if available, and administer medications as needed (",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/54/39782?source=see_link\">",
"       albuterol",
"      </a>",
"      , epinephrine). In preparation for intubation, the patient should receive 100 percent oxygen via a high-concentration mask, or if indicated, positive pressure ventilation with a bag-valve-mask to preoxygenate and improve ventilation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/22/29030?source=see_link\">",
"       \"Basic airway management in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/18/44328?source=see_link\">",
"       \"Carbon dioxide monitoring (capnography)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Children who cannot maintain an effective airway, oxygenation, or ventilation should undergo endotracheal intubation. A rapid overview provides the steps in performing rapid sequence intubation (",
"      <a class=\"graphic graphic_table graphicRef51456 \" href=\"UTD.htm?17/26/17837\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/48/29450?source=see_link\">",
"       \"Emergent endotracheal intubation in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/29/24026?source=see_link\">",
"       \"Rapid sequence intubation (RSI) in children\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Shock and cardiac arrhythmias",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Proper treatment of shock in children requires the clinician to recognize and eventually categorize the type of shock in order to prioritize treatment options (",
"      <a class=\"graphic graphic_algorithm graphicRef81356 \" href=\"UTD.htm?1/61/2000\">",
"       algorithm 1",
"      </a>",
"      ). Early treatment of shock may prevent the progression to cardiopulmonary failure (",
"      <a class=\"graphic graphic_algorithm graphicRef77079 \" href=\"UTD.htm?41/12/42178\">",
"       algorithm 2",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/49/14104?source=see_link\">",
"       \"Initial evaluation of shock in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/8/26762?source=see_link\">",
"       \"Initial management of shock in children\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H7\">",
"       'Shock'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Algorithms provide the pediatric advanced life support guidelines for treatment of children with tachyarrhythmias (",
"      <a class=\"graphic graphic_algorithm graphicRef67438 \" href=\"UTD.htm?11/37/11860\">",
"       algorithm 4",
"      </a>",
"      ), pulseless arrest (",
"      <a class=\"graphic graphic_algorithm graphicRef80003 \" href=\"UTD.htm?41/30/42470\">",
"       algorithm 5",
"      </a>",
"      ), and symptomatic bradycardia (",
"      <a class=\"graphic graphic_algorithm graphicRef52446 \" href=\"UTD.htm?20/4/20545\">",
"       algorithm 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Bradyarrhythmias'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'Tachyarrhythmias'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H21\">",
"       'Pulseless arrest'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h2\">",
"     Postresuscitation care",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The early postresuscitation period includes the time soon after return of spontaneous circulation or recovery from circulatory or respiratory failure. During this time, the clinician must continue to treat the underlying cause for the life-threatening event and monitor for common respiratory or circulatory problems that may cause secondary morbidity or death.",
"     </li>",
"     <li>",
"      If the child is not being treated in a center with pediatric emergency and critical care expertise, the child should be stabilized and rapidly transferred for definitive care at a regional pediatric center.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1302202\">",
"    <span class=\"h2\">",
"     Rapid response teams",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest that pediatric tertiary care centers develop and maintain multidisciplinary rapid response teams for the prompt assessment and management of hospitalized infants and children who are showing signs of clinical deterioration and are located in nonacute care units (eg, medical or surgical inpatient wards) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1302189\">",
"       'Rapid response teams'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20746/abstract/1\">",
"      ECC Committee, Subcommittees and Task Forces of the American Heart Association. 2005 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2005; 112:IV1.",
"     </a>",
"    </li>",
"    <li>",
"     Ralston, M, Hazinski, MF, Zaritsky, AL, et al. PALS Provider Manual. American Academy of Pediatrics, American Heart Association, Dallas, Texas, 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20746/abstract/3\">",
"      Kleinman ME, de Caen AR, Chameides L, et al. Pediatric basic and advanced life support: 2010 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science with Treatment Recommendations. Pediatrics 2010; 126:e1261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20746/abstract/4\">",
"      Kleinman ME, de Caen AR, Chameides L, et al. Part 10: Pediatric basic and advanced life support: 2010 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. Circulation 2010; 122:S466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20746/abstract/5\">",
"      Kleinman ME, Chameides L, Schexnayder SM, et al. Part 14: pediatric advanced life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2010; 122:S876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20746/abstract/6\">",
"      Atkins DL, Everson-Stewart S, Sears GK, et al. Epidemiology and outcomes from out-of-hospital cardiac arrest in children: the Resuscitation Outcomes Consortium Epistry-Cardiac Arrest. Circulation 2009; 119:1484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20746/abstract/7\">",
"      Gerein RB, Osmond MH, Stiell IG, et al. What are the etiology and epidemiology of out-of-hospital pediatric cardiopulmonary arrest in Ontario, Canada? Acad Emerg Med 2006; 13:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20746/abstract/8\">",
"      Smith BT, Rea TD, Eisenberg MS. Ventricular fibrillation in pediatric cardiac arrest. Acad Emerg Med 2006; 13:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20746/abstract/9\">",
"      Samson RA, Nadkarni VM, Meaney PA, et al. Outcomes of in-hospital ventricular fibrillation in children. N Engl J Med 2006; 354:2328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20746/abstract/10\">",
"      Girotra S, Spertus JA, Li Y, et al. Survival trends in pediatric in-hospital cardiac arrests: an analysis from get with the guidelines-resuscitation. Circ Cardiovasc Qual Outcomes 2013; 6:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20746/abstract/11\">",
"      Kilgannon JH, Jones AE, Parrillo JE, et al. Relationship between supranormal oxygen tension and outcome after resuscitation from cardiac arrest. Circulation 2011; 123:2717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20746/abstract/12\">",
"      Ferguson LP, Durward A, Tibby SM. Relationship between arterial partial oxygen pressure after resuscitation from cardiac arrest and mortality in children. Circulation 2012; 126:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20746/abstract/13\">",
"      Srinivasan V, Spinella PC, Drott HR, et al. Association of timing, duration, and intensity of hyperglycemia with intensive care unit mortality in critically ill children. Pediatr Crit Care Med 2004; 5:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20746/abstract/14\">",
"      Kong MY, Alten J, Tofil N. Is hyperglycemia really harmful? A critical appraisal of \"Persistent hyperglycemia in critically ill children\" by Faustino and Apkon (J Pediatr 2005; 146:30-34). Pediatr Crit Care Med 2007; 8:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20746/abstract/15\">",
"      Berwick DM, Calkins DR, McCannon CJ, Hackbarth AD. The 100,000 lives campaign: setting a goal and a deadline for improving health care quality. JAMA 2006; 295:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20746/abstract/16\">",
"      Chan PS, Jain R, Nallmothu BK, et al. Rapid Response Teams: A Systematic Review and Meta-analysis. Arch Intern Med 2010; 170:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20746/abstract/17\">",
"      Sharek PJ, Parast LM, Leong K, et al. Effect of a rapid response team on hospital-wide mortality and code rates outside the ICU in a Children's Hospital. JAMA 2007; 298:2267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20746/abstract/18\">",
"      Kotsakis A, Lobos AT, Parshuram C, et al. Implementation of a multicenter rapid response system in pediatric academic hospitals is effective. Pediatrics 2011; 128:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20746/abstract/19\">",
"      Joffe AR, Anton NR, Burkholder SC. Reduction in hospital mortality over time in a hospital without a pediatric medical emergency team: limitations of before-and-after study designs. Arch Pediatr Adolesc Med 2011; 165:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20746/abstract/20\">",
"      Mangurten J, Scott SH, Guzzetta CE, et al. Effects of family presence during resuscitation and invasive procedures in a pediatric emergency department. J Emerg Nurs 2006; 32:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20746/abstract/21\">",
"      Dudley NC, Hansen KW, Furnival RA, et al. The effect of family presence on the efficiency of pediatric trauma resuscitations. Ann Emerg Med 2009; 53:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20746/abstract/22\">",
"      Tinsley C, Hill JB, Shah J, et al. Experience of families during cardiopulmonary resuscitation in a pediatric intensive care unit. Pediatrics 2008; 122:e799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/16/20746/abstract/23\">",
"      Curley MA, Meyer EC, Scoppettuolo LA, et al. Parent presence during invasive procedures and resuscitation: evaluating a clinical practice change. Am J Respir Crit Care Med 2012; 186:1133.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6392 Version 19.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.243-684EC2BD62-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_16_20746=[""].join("\n");
var outline_f20_16_20746=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H36\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW OF ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Primary assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Secondary assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Tertiary assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      RESPIRATORY DISTRESS AND FAILURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      SHOCK",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      CARDIOPULMONARY FAILURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      APPROACH TO CARDIAC ARRHYTHMIAS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      BRADYARRHYTHMIAS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Sinus bradycardia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Atrioventricular block",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Bradyarrhythmia management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      TACHYARRHYTHMIAS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Sinus tachycardia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Supraventricular tachycardia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Ventricular tachycardia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Tachyarrhythmia management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      PULSELESS ARREST",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Epidemiology and presenting rhythm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Arrest rhythms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Asystole",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Pulseless electrical activity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Ventricular fibrillation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Pulseless ventricular tachycardia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Torsades de pointes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Advanced management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Vascular access",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Endotracheal drug administration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      - Defibrillation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      - Pharmacologic therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      EARLY POSTRESUSCITATION MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1302189\">",
"      RAPID RESPONSE TEAMS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1302295\">",
"      FAMILY PRESENCE DURING RESUSCITATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Respiratory distress and failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Shock and cardiac arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      Postresuscitation care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1302202\">",
"      Rapid response teams",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6392\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6392|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?1/61/2000\" title=\"algorithm 1\">",
"      Undifferentiated pediatric shock algorithm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?41/12/42178\" title=\"algorithm 2\">",
"      Initial management of shock in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?20/4/20545\" title=\"algorithm 3\">",
"      Pediatric bradycardia algorithm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?11/37/11860\" title=\"algorithm 4\">",
"      Pediatric tachycardia algorithm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?41/30/42470\" title=\"algorithm 5\">",
"      Pediatric cardiac arrest algorithm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6392|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/58/2989\" title=\"table 1\">",
"      Glasgow and pediatric coma scales",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/39/28285\" title=\"table 2\">",
"      Causes acute respiratory distress in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/26/17837\" title=\"table 3\">",
"      Rapid overview of rapid sequence intubation in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/37/28252\" title=\"table 4\">",
"      Normal respiratory rate and heart rate in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/11/23742\" title=\"table 5\">",
"      Drug and toxin induced ECG abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/18/2350\" title=\"table 6\">",
"      Example of epinephrine infusion - pediatric 10 kg",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/39/40573\" title=\"table 7\">",
"      Example of epinephrine infusion - pediatric 20 kg",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6392|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?11/45/11989\" title=\"waveform 1\">",
"      ECG first degree AV block I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?42/35/43573\" title=\"waveform 2\">",
"      ECG Mobitz type I AV block",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?16/4/16452\" title=\"waveform 3\">",
"      ECG Mobitz II heart block",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?12/50/13095\" title=\"waveform 4\">",
"      Third degree or complete AV block with narrow QRS escape",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?32/2/32815\" title=\"waveform 5\">",
"      AV reentrant tachycardia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?28/0/28680\" title=\"waveform 6\">",
"      ECG Monomorphic VT tutorial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?26/1/26648\" title=\"waveform 7\">",
"      ECG showing changes in VF over time",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?42/23/43380\" title=\"waveform 8\">",
"      ECG Torsades de pointes tutorial",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?9/15/9463?source=related_link\" title=\"calculator 1\">",
"      Calculator: Blood pressure percentiles for boys (2 to 17 years)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?9/33/9751?source=related_link\" title=\"calculator 2\">",
"      Calculator: Blood pressure percentiles for girls (2 to 17 years)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/33/13850?source=related_link\">",
"      Advanced cardiac life support (ACLS) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/0/8201?source=related_link\">",
"      Approach to hypoglycemia in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/34/22056?source=related_link\">",
"      Approach to the child with palpitations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/38/9832?source=related_link\">",
"      Approach to the child with tachycardia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/39/17018?source=related_link\">",
"      Approach to the septic-appearing infant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/22/29030?source=related_link\">",
"      Basic airway management in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/43/7864?source=related_link\">",
"      Basic life support in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/24/33161?source=related_link\">",
"      Bradycardia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/18/44328?source=related_link\">",
"      Carbon dioxide monitoring (capnography)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/33/15897?source=related_link\">",
"      Causes of wide QRS complex tachycardia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/49/21272?source=related_link\">",
"      Defibrillation and cardioversion in children (including automated external defibrillation)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/48/29450?source=related_link\">",
"      Emergent endotracheal intubation in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/61/7130?source=related_link\">",
"      Emergent evaluation of acute respiratory compromise in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/10/11432?source=related_link\">",
"      Emergent evaluation of syncope in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/23/28023?source=related_link\">",
"      Glycemic control and intensive insulin therapy in critical illness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/51/22327?source=related_link\">",
"      Initial assessment and stabilization of children with respiratory or circulatory compromise",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/49/14104?source=related_link\">",
"      Initial evaluation of shock in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/8/26762?source=related_link\">",
"      Initial management of shock in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/51/40761?source=related_link\">",
"      Intraosseous infusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/40/22152?source=related_link\">",
"      Management and evaluation of wide QRS complex tachycardia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/9/15514?source=related_link\">",
"      Management of supraventricular tachycardia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/21/22874?source=related_link\">",
"      Opioid intoxication in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/28/35274?source=related_link\">",
"      Post-cardiac arrest management in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/59/26553?source=related_link\">",
"      Prehospital pediatrics and emergency medical services (EMS)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/23/15738?source=related_link\">",
"      Primary drugs in pediatric resuscitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/29/24026?source=related_link\">",
"      Rapid sequence intubation (RSI) in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/33/4634?source=related_link\">",
"      Septic shock: Rapid recognition and initial resuscitation in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/54/31593?source=related_link\">",
"      Supraventricular tachycardia in children: AV reentrant tachycardia (including WPW) and AV nodal reentrant tachycardia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29962?source=related_link\">",
"      Trauma management: Approach to the unstable child",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/55/8057?source=related_link\">",
"      Vascular (venous) access for pediatric resuscitation and other pediatric emergencies",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_16_20747="HAT species characteristics";
var content_f20_16_20747=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F85846&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F85846&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Characteristics of African trypanosomiasis species",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"3\" width=\"33%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Trypanosoma brucei gambiense",
"       </td>",
"       <td class=\"subtitle1\">",
"        Trypanosoma brucei rhodesiense",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Geographic distribution",
"        </strong>",
"       </td>",
"       <td>",
"        West, Central Africa",
"       </td>",
"       <td>",
"        East Africa",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Fly species",
"        </strong>",
"       </td>",
"       <td>",
"        Glossina palpalis",
"       </td>",
"       <td>",
"        Glossina morsitans",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Fly habitat",
"        </strong>",
"       </td>",
"       <td>",
"        Humid; river habitat",
"       </td>",
"       <td>",
"        Dry; savannah and woodland habitat",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Primary host",
"        </strong>",
"       </td>",
"       <td>",
"        Humans",
"       </td>",
"       <td>",
"        Animals",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Nature of clinical infection",
"        </strong>",
"       </td>",
"       <td>",
"        Chronic",
"       </td>",
"       <td>",
"        Acute",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_16_20747=[""].join("\n");
var outline_f20_16_20747=null;
var title_f20_16_20748="Causes of ophthalmoplegia children";
var content_f20_16_20748=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F76783&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F76783&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of chronic progressive external ophthalmoplegia in children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Myasthenia gravis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Myasthenia-like syndromes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Lambert-Eaton myasthenic syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Drug-induced (penicillamine, gold)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Inflammatory and infectious myopathies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Orbital cellulitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Dural sinus thrombosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thyroid eye disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Idiopathic orbital myositis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Infiltrative myopathy (eg, amyloidosis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Abetalipoproteinemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Organophosphate poisoning",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Botulism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hereditary ataxia syndromes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Encephalomyopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Leigh syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Mitochondrial neurogoastrointestinal encephalopathy syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Canavan disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Primary metabolic diseases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Cytochrome C oxidase deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Carnitine deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Vitamin E deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Primary and metastatic muscle tumors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Episodic ophthalmoplegic syndromes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Familial periodic paralysis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Muscle trauma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Ischemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Vasculitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Ophthalmopolegic migraine",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_16_20748=[""].join("\n");
var outline_f20_16_20748=null;
var title_f20_16_20749="IPSS-R in MDS";
var content_f20_16_20749=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F85832&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F85832&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Revised international prognostic scoring system (IPSS-R) in myelodysplastic syndrome",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"8\" width=\"12%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Prognostic variable",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"7\">",
"        Score",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        0",
"       </td>",
"       <td class=\"subtitle2\">",
"        0.5",
"       </td>",
"       <td class=\"subtitle2\">",
"        1.0",
"       </td>",
"       <td class=\"subtitle2\">",
"        1.5",
"       </td>",
"       <td class=\"subtitle2\">",
"        2.0",
"       </td>",
"       <td class=\"subtitle2\">",
"        3.0",
"       </td>",
"       <td class=\"subtitle2\">",
"        4.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cytogenetics*",
"       </td>",
"       <td>",
"        Very good",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Good",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Intermediate",
"       </td>",
"       <td>",
"        Poor",
"       </td>",
"       <td>",
"        Very poor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bone marrow blast (percent)",
"       </td>",
"       <td>",
"        &le;2",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &gt;2 to &lt;5",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        5 to 10",
"       </td>",
"       <td>",
"        &gt;10",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hemoglobin (g/dL)",
"       </td>",
"       <td>",
"        &ge;10",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        8 to &lt;10",
"       </td>",
"       <td>",
"        &lt;8",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Platelets (cells/microL)",
"       </td>",
"       <td>",
"        &ge;100",
"       </td>",
"       <td>",
"        50 to 100",
"       </td>",
"       <td>",
"        &lt;50",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Absolute neutrophil count (cells/microL)",
"       </td>",
"       <td>",
"        &ge;0.8",
"       </td>",
"       <td>",
"        &lt;0.8",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td colspan=\"8\">",
"        This scoring system was applied to an initial group of 7012 patients with primary MDS by the French-American-British classification who had at least two months of stable blood counts, &le;30 percent bone marrow blasts and &le;19 percent peripheral blood blasts, and who were observed until progression to AML transformation or death (did not receive disease-modifying agents for MDS). Patients could be stratified into five groups with the following estimated overall survival and progression to AML.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\" colspan=\"2\">",
"        Risk group",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"2\">",
"        IPSS-R score",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"2\">",
"        Median overall survival (years)",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"2\">",
"        Median time to 25 percent AML evolution (years)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        Very low",
"       </td>",
"       <td colspan=\"2\">",
"        &le;1.5",
"       </td>",
"       <td colspan=\"2\">",
"        8.8",
"       </td>",
"       <td colspan=\"2\">",
"        &gt;14.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        Low",
"       </td>",
"       <td colspan=\"2\">",
"        &gt;1.5 to 3.0",
"       </td>",
"       <td colspan=\"2\">",
"        5.3",
"       </td>",
"       <td colspan=\"2\">",
"        10.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        Intermediate",
"       </td>",
"       <td colspan=\"2\">",
"        &gt;3 to 4.5",
"       </td>",
"       <td colspan=\"2\">",
"        3.0",
"       </td>",
"       <td colspan=\"2\">",
"        3.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        High",
"       </td>",
"       <td colspan=\"2\">",
"        &gt;4.5 to 6",
"       </td>",
"       <td colspan=\"2\">",
"        1.6",
"       </td>",
"       <td colspan=\"2\">",
"        1.4",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td colspan=\"2\">",
"        Very high",
"       </td>",
"       <td colspan=\"2\">",
"        &gt;6",
"       </td>",
"       <td colspan=\"2\">",
"        0.8",
"       </td>",
"       <td colspan=\"2\">",
"        0.7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"8\">",
"        The prognostic value of the IPSS-R was validated in an external cohort of 200 patients with MDS",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     AML: acute myeloid leukemia; MDS: myelodysplastic syndrome.",
"     <br/>",
"     * Cytogenetic definitions:",
"     <br/>",
"     Very good: -Y, del(11q).",
"     <br/>",
"     Good: Normal, del(5q), del(12p), del(20q), double including del(5q).",
"     <br/>",
"     Intermediate: del(7q), +8, +19, i(17q), any other single or double independent clones.",
"     <br/>",
"     Poor: -7, inv(3)/t(3q)/del(3q), double including -7/del(7q), complex: 3 abnormalities.",
"     <br/>",
"     Very poor: Complex: &gt;3 abnormalities.",
"    </div>",
"    <div class=\"reference\">",
"     This research was originally published in Blood. Greenberg PL, Tuechler H, Schanz J, et al. Revised International Prognostic Scoring System (IPSS-R) for myelodysplastic syndromes. Blood 2012. Copyright &copy; 2012 the American Society of Hematology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_16_20749=[""].join("\n");
var outline_f20_16_20749=null;
var title_f20_16_20750="Tibial and fibular fracture ORIF";
var content_f20_16_20750=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F50245&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F50245&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Tibial and fibular fracture ORIF",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 172px; height: 396px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This antero-posterior radiograph shows the result following open reduction and internal fixation (ORIF) of an unstable lower leg fracture using an intramedullary rod in the tibia and plate and screws on the distal fibula.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Karl B Fields, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_16_20750=[""].join("\n");
var outline_f20_16_20750=null;
var title_f20_16_20751="Nasal mask for ventilation";
var content_f20_16_20751=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F58072&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F58072&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nasal mask for intermittent positive pressure ventilation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 308px; height: 158px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The nasal mask, developed in the 1980s for administration of continuous positive airway pressure (CPAP) in patients with obstructive sleep apnea, is used to provide nocturnal assisted ventilation for a variety of disorders.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Peter C Gay, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_16_20751=[""].join("\n");
var outline_f20_16_20751=null;
